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Neuroimmune Signaling and Microglia in Chronic Ethanol 
Consumption 
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Alcohol use disorder (AUD) is a pervasive and debilitating condition characterized 
by the inability to stop consuming alcohol. Studies suggest that chronic alcohol use 
damages the prefrontal cortex (PFC), the brain region important for executive control, 
further driving alcohol consumption.  Recent work has revealed that alcohol use alters 
immune signaling in the PFC, perturbing cortical function and increasing consumption. 
Although it is known that chronic alcohol use leads to neuroimmune changes in the brain, 
it remains unclear which specific innate immune signaling pathways are responsible. In 
addition, it is unknown how microglia, the immune cells of the brain, contribute to the 
ethanol-induced immune response in vivo.  Thus, I sought to elucidate the specific immune 
pathways and microglial changes that occur in response to chronic voluntary ethanol. 
Using a voluntary chronic drinking paradigm in mice, I evaluated gene expression 
changes in the Toll-like receptor (TLR) signaling pathways immediately following 
consumption and 24-hours after ethanol removal. I discovered that the primary TLR 
signaling pathway (the MyD88-dependent pathway) remained relatively unchanged, while 
 vii 
Tlr3 and components of its pathway (the TRIF-dependent pathway) were increased 24-
hours after ethanol consumption in the PFC. I also looked at the nucleus accumbens (NAc) 
and amygdala (AMY) and found that the NAc showed similar changes to the PFC but 
weaker, while the AMY showed changes in the opposite direction. Furthermore, 
administration of a TRIF-pathway inhibitor decreased ethanol consumption, suggesting a 
role for this pathway in regulating drinking behavior.  
Then, using isolated glial cells, I sought to determine which cell types TLR genes 
were localized in and which cell types showed changes following immune induction. I 
discovered that most TLR pathway genes are enriched and changed in microglia, however 
Tlr3 is enriched and increased in astrocytes. These results suggest a potential role for TRIF-
dependent signaling in astrocytes. 
To further investigate the microglial changes in response to ethanol, I isolated the 
total homogenate and microglia from the PFC of mice that had undergone chronic 
voluntary ethanol consumption. I discovered that microglial changes were mostly 
undetected in the total homogenate and that microglial changes were associated with 
endosomal TLR signaling and TGF-b signaling. In addition, I investigated the microglial 
response to ethanol to the response to lipopolysaccharide (LPS), a TLR ligand that 
produces an immune response often compared to ethanol. Surprisingly, I found that 
microglia from the two treatments showed very different gene expression changes.  
Together, these data suggest a role for endosomal TLR signaling, the TRIF-
dependent pathway, and TGF-b in the ethanol-neuroimmune response. Future studies will 
aim to elucidate the mechanisms by which these signaling pathways change drinking, as 
well as the roles of the different cell types.  
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Chapter 1: General Introduction and Significance 
 
Despite many advances in science and medicine over the last century, brain-related 
pathologies remain poorly understood and therefore difficult to treat. Drug and alcohol 
addiction is one of these brain pathologies with a complex etiology, including genetic, 
psychological and environmental components. To develop improved treatments for 
addiction, there needs to be a more complete understanding of the biological processes 
that mediate the transition from use to dependence.  
Recently, there has been an appreciation for the importance of immune signaling 
in the brain and how this signaling can contribute to many brain pathologies, including 
alcohol addiction. While it is known that neuroimmune signaling changes with chronic 
ethanol use and that this signaling can regulate consumption, it is unclear which signaling 
pathways mediate these changes and how different cell types in the brain contribute to 
this process.  
1.I.  ALCOHOL USE DISORDER 
 
Alcohol use disorder (AUD), characterized by heavy alcohol use and abuse, is a 
widespread societal problem. Affecting 6.2% of the adult population in the United States, 
AUDs contribute to an estimated 88,000 deaths per year making it the third leading cause 
of death (Center for Behavioral Health Statistics and Quality et al. n.d.; Centers for 
Disease Control and Prevention (CDC) n.d.). In addition to having devastating 
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consequences for the affected individual, AUDs also have detrimental effects on the rest 
of society. Every year in the US, alcohol-use is responsible for approximately 10,000 
impaired-driving fatalities, 696,000 college sexual assaults, Fetal Alcohol Syndrome 
(FAS) in 2-7 births/1000, and more than 10% of children living with a parent with 
alcohol problems (National Center for Statistics and Analysis 2015; Substance Abuse  
and Mental Health Services Administration 2012; Hingson et al. 2005; May et al. 2009). 
AUDs also have a large economic impact costing the U.S. $249 billion per year 
(Bouchery et al. 2011).  
Despite the prevalence and impact of AUDs, there are only three FDA-approved 
drugs and these treatments show limited success, particularly in reducing alcohol craving 
and relapse (Edwards et al. 2011). To develop more successful treatments, we need to 
better understand the genomic and molecular changes that contribute to the development 
of AUDs.  
1.I.a. The Prefrontal Cortex and AUDs 
 
Described in the Diagnostic and Statistical Manual of Mental Disorders 5, AUDs 
are characterized by tolerance, withdrawal, loss of control over consumption, and 
continued use despite negative consequences (American Psychiatric Association 2013). 
There are three main stages of alcohol use that contribute to the development of AUDs: 
the initiation of alcohol use driven by the rewarding properties, the continued use due to 
withdrawal symptoms and negative reinforcement, and the craving for alcohol that often 
drives relapse (Koob et al. 2014). Chronic alcohol use impacts many organs in the body, 
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however, the changes in the brain are most likely responsible for the transition from 
alcohol use to abuse and dependence. One brain region that is particularly sensitive to the 
effects of alcohol and important to the development of dependence is the prefrontal 
cortex (PFC).  
The PFC is a region of the frontal cortex that is divided into three sub-regions: the 
medial PFC, the dorsolateral PFC, and the orbitofrontal cortex (Siddiqui et al. 2008). The 
PFC is responsible for executive function and has connections with sensory cortices, 
motor structures, and limbic regions that control memory and reward (E. K. Miller et al. 
2002). There is controversy over how preserved the PFC is across mammalian species. 
While the PFC is different in size and structurally diverse across species, there is strong 
support from anatomical and functional data that rodents have a PFC, although less 
differentiated than in humans and non-human primates (Uylings et al. 2003).  
Although the PFC is primarily involved in the craving of alcohol, it also 
contributes to the rewarding effects. The rewarding properties of alcohol that reinforce 
continued use come from activation of the mesocorticolimbic dopaminergic pathway, 
which includes the ventral tegmental area (VTA), the nucleus accumbens (NAc) and the 
PFC (Vengeliene et al. 2009). The PFC not only receives and integrates information from 
brain regions important for reward, but is responsible for key executive functions such as 
decision-making, planning, working memory, and impulse control (E. K. Miller et al. 
2002). Many of these executive functions become impaired with chronic alcohol use and 
thus contribute to the loss of control and relapse associated with AUDs (Abernathy et al. 
2010).  
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Alcohol-dependent human subjects show several structural changes in the PFC, 
including decreased neuronal density, reduced white matter volume and integrity, and 
reduced glial cell number (Oscar-Berman & Marinković 2007). In addition, fMRI scans 
have revealed many functional changes in the PFC of alcoholics, including reduced blood 
flow, event-related action potentials, and glucose metabolism (Oscar-Berman & 
Marinković 2007). Alcohol-dependent subjects also show decreased performance on 
behavioral tests, suggesting that these biological changes are driving the changes in 
executive control (Abernathy et al. 2010). For example, alcoholics show impairment on 
tests of memory, reversal learning, attention, decision making, and impulsivity.  Many of 
these behavioral impairments seen in alcoholics are also seen in those with PFC lesions, 
further supporting the fact that the PFC regulates these behaviors (Bechara 2005).  In 
addition, because the PFC interacts with limbic regions (e.g. amygdala and 
hippocampus), frontal cortical damage also causes changes in emotion and social 
behavior (Bechara 2005) (Oscar-Berman & Marinković 2007). Consistent with that idea, 
alcoholics display deficits in emotional perception and social function (Oscar-Berman & 
Marinković 2007).  
Although it is difficult to causally show how cognitive dysfunction promotes 
continued alcohol use, impulse inhibition is thought to play an important role. While 
decision making is a complex process that requires attention, impulsivity requires little 
attention and focuses only on reward value without considering consequences (Crews & 
Boettiger 2009a). Alcoholics show deficits in inhibition response, and inhibition is 
further perturbed in response to alcohol cues (Noël et al. 2007). In addition, reduced 
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cortical activity in alcoholics during decision making correlates with choice of immediate 
over delayed rewards, while naltrexone (FDA approved drug for AUDs), increases 
activity and improves decision making (Boettiger et al. 2007; Boettiger et al. 2009). 
Furthermore, disinhibition and antisocial personality are highly correlated with early-
onset alcoholism and chronic alcohol use and dependence (Oscar-Berman & Marinković 
2007). Consistent with the idea that cortical dysfunction promotes consumption, the 
degree of cortical dysfunction in abstinent alcoholics is predictive of the probability of 
relapse {Burnett:2016ka}. There is also evidence that frontal cortical dysfunction is 
genetic, and thus not only promotes consumption in dependent subjects, but is a factor in 
the initiation of alcohol use and abuse.  
Although there is some understanding of how alcohol changes the PFC and 
therefore drives addiction, a better understanding of the molecular processes that cause 
cortical dysfunction is needed to develop drugs that prevent relapse.  
1.I.b. Mouse models of AUD 
 
Although human alcoholic data is informative and necessary, to better study 
alcohol in a controlled setting, several rodent paradigms have been developed to model 
different aspects of AUDs. Although human studies of alcoholics have provided insight 
into structural and molecular abnormalities in the PFC, they make it impossible to 
determine whether these aberrations predisposed the individual to alcohol use or were the 
consequence of it. Voluntary ethanol consumption models are advantageous because they 
can be used to study both cause and effect. With a voluntary consumption paradigm, 
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genetically identical mice can be allowed to drink ethanol and changes can be measured 
compared to a control group. Once molecular changes are identified, the same strain of 
mice can be manipulated to determine how a particular molecular change can alter 
ethanol consumption.  
There are several types of rodent voluntary ethanol consumption paradigms which 
differ in ethanol percentage, access to water, and frequency and duration of ethanol 
access. In C57BL/6J mice, 24-hour intermittent access to both alcohol and water leads to 
an escalation in ethanol consumption and higher levels of consumption than continuous 
access (Crabbe et al. 2012). Every-other-day ethanol access is thought to model human 
consumption better than continuous access because of the escalation in drinking, which is 
seen in individuals with AUDs. This escalation is attributed to increases in binge like 
drinking and anticipation of the reinstatement of alcohol (Melendez 2011). Consequently, 
voluntary every-other-day 2-bottle choice (EOD-2BC) paradigms are used to measure 
changes that result from continuous bouts of ethanol consumption and are useful in 
determining how any biological or environmental manipulations may alter consumption.  
1.II. ALCOHOL AND NEUROIMMUNE SIGNALING 
The transition from initial alcohol use to dependence involves several genomic and 
molecular changes. Recent studies suggest that neuroimmune signaling is an important 
mediator of this shift, particularly in the PFC. It is hypothesized that chronic ethanol 
consumption leads to neuroimmune changes that impair cortical function and promote 
dependence. 
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1.II.i. Defining “neuroinflammation”  
I would like the preface this section with the issue of defining “neuroinflammation”. 
Neuroinflammation is simply defined as inflammation of the nervous tissue, while 
inflammation is defined as the reaction of living tissues to injury, although neither of these 
definitions are particularly informative (Streit et al. 2004). Other definitions of 
neuroinflammation include processes such as: the release of proinflammatory mediators, 
activation of glial cells, damage to the blood brain barrier, leukocyte infiltration, and 
contribution to neurodegeneration (O'Callaghan et al. 2008; Streit et al. 2004). The exact 
definition of neuroinflammation remains controversial, as do the criteria for how 
pronounced the neuroimmune response must be to qualify as “neuroinflammation”.  
Although it remains controversial whether the neuroimmune changes produced by stimuli 
such as alcohol meet the criteria of neuroinflammation, for lack of a better noun, I will use 
term inflammation/neuroinflammation to describe the impact of perturbed neuroimmune 
signaling throughout this dissertation.  
 
1.II.a. Neuroimmune signaling in the brain 
It was previously thought that due to the blood-brain barrier the brain was an 
immune privileged organ. It is now widely accepted that the brain has its own specialized 
immune response, often referred to as neuroimmune signaling (Dantzer et al. 2008). Recent 
work suggests that neuroimmune signaling plays an important role in brain pathologies, 
including alcohol addiction (Ransohoff 2016b; Vetreno & Crews 2014; Cherry et al. 2014; 
Hayley 2014). Neuroimmune signaling encompasses both innate and adaptive immunity, 
however, the focus in alcohol research is largely the innate immune response (Vetreno & 
Crews 2014). Innate immunity is a nonspecific response to pathogens that involves the 
recruitment of immune cells and the production of cytokines, small immunomodulatory 
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agents involved in autocrine, paracrine, and endocrine signaling. Immune cells in the body 
identify pathogens and endogenous ligands through pattern recognition receptors (PRRs) 
that detect pathogen-associated molecular patterns (PAMPs) or damage-associate 
molecular patterns (DAMPs). In response to PAMPs or DAMPs, immune cells activate 
immune related signaling pathways and transcription factors. These responses lead to the 
release of cytokines and reactive oxygen species, which then act on surrounding cells and 
amplify the immune response (Mogensen 2009).  
The peripheral immune response can activate the neuroimmune response through 
cytokine-activation of afferent nerves, cytokine diffusion from the blood to the brain, and 
cytokine transport across the blood-brain barrier (Dantzer et al. 2008). Peripheral immune 
signaling then leads to activation of the resident immune cell of the CNS, microglia. 
Activated microglia secrete cytokines that serve to amplify the immune response by 
signaling to other microglia as well as astrocytes and neurons (Vetreno & Crews 2014). In 
addition to microglia, other CNS cells, including astrocytes and neurons, also participate 
in the immune response and amplification (discussed in more detail in 1.III.a.iii. Microglial 
interaction with other cell types, 1.IV.c. Localization of TLR signaling). The immune 
response can be both pro- and anti-inflammatory and can be beneficial by killing pathogens 
or repairing damage. However, the pro- and anti- inflammatory balance is important and 
the immune response can also cause damage in response to chronic inflammation, such as 
the inflammation resulting from long-term alcohol abuse (Vetreno & Crews 2014).  
 
1.II.b. Alcohol’s impact on immune signaling  
Alcohol’s effects on immune signaling throughout the body and peripheral immune 
system work in concert with neuroimmune signaling. Alcohol alters peripheral immune 
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signaling by increasing intestinal permeability (more detail in 1.V.a.i. Indirect effects via 
peripheral immune signaling). Because the intestines are colonized by large amounts of 
bacteria, increased intestinal permeability can cause bacteria to leak out of the intestines 
into the blood stream. Components of bacterial molecules, such as the endotoxin 
lipopolysaccharide (LPS), can act as PAMPs and lead to immune activation and cytokine 
production. Peripheral immune activation then causes an immune response in other 
peripheral organs (e.g. liver) and in the CNS (Leclercq et al. 2017). The peripheral and 
CNS immune response differ in latency and duration as the neuroimmune response takes 
longer to occur but is sustained longer (Qin et al. 2008). In addition, acute and chronic 
ethanol consumption differ in their effects on the immune system. Acute alcohol exposure 
suppresses the peripheral immune response while chronic ethanol exposure increases 
neuroinflammation (Vetreno & Crews 2014).  
Although immune signaling in response to ethanol has been studied in the periphery 
for many years, particularly with regards to alcoholic liver disease, there is a growing 
appreciation for alcohol’s effects on neuroimmune signaling. The link between alcohol and 
immune signaling in the brain was originally discovered in gene expression studies in the 
human alcohol cortex (Lewohl, L. Wang, Miles, Zhang, Dodd & Harris 2000a). Since then, 
several in vitro culture, rodent, and human postmortem alcoholic studies provide evidence 
for ethanol-induced neuroimmune signaling.  
In vitro ethanol exposure causes increased cytokine expression in macrophage 
cultures, as well as primary cultures from the CNS immune cells microglia and astrocytes. 
These cytokines include tumor necrosis factor alpha (TNF-a) and interleukin-1 beta (IL-
1b), which are typically pro-inflammatory and amplify the immune response (Fernandez-
Lizarbe et al. 2009; Alfonso-Loeches et al. 2010; Fernandez-Lizarbe et al. 2008). 
Additionally, ethanol-exposed cultures show increased expression of enzymes involved in 
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the inflammatory response, inducible nitrous oxide synthase (iNOS) and cyclooxygenase 
2 (COX-2), and the immune transcription factor nuclear factor kappa-light-chain-enhancer 
of activated B-cells (NF-kB) (Fernandez-Lizarbe et al. 2009; Blanco et al. 2008). Rat brain 
slice cultures also show several immune changes in response to ethanol, including 
increased NF-kB DNA binding and expression of cytokines, endogenous DAMPS, and 
iNOS (Zou & Crews 2010; Crews et al. 2013).  
Binge ethanol exposure in rodent models leads to increased expression of the Toll-
like receptors (TLRs), a category of PPR, and their endogenous DAMP high mobility group 
box 1 (HMGB1) (Crews et al. 2013). Binge ethanol also leads to increased cytokine 
expression (MCP-1/CCL2, IL-6) (Kane et al. 2013), increased COX-2 expression, 
increased NF-kB binding, and glial cell activation (Crews et al. 2006; Crews et al. 2013). 
Similarly, chronic ethanol exposure in rodents leads to increased TLR and endogenous 
ligand expression, increased cytokine expression (MCP-1, IL-1b, TNF-a), increased COX-
2 and iNOS expression, and glial activation (Whitman et al. 2013; Lippai et al. 2013; 
Alfonso-Loeches et al. 2010). Many of these immune changes were found in the cortex, 
highlighting the importance of immune signaling in this brain region.  
Consistent with evidence in vitro and in rodent models of alcohol consumption, 
several immune changes are found in post-mortem alcoholic brains. These changes include 
microglial activation, increased expression of TLRs and HMGB1, and increased cytokine 
expression (Vetreno et al. 2013; He & Crews 2008; Crews et al. 2013). Together these 
studies suggest that alcohol impacts neuroimmune signaling with respect to 
PAMPs/DAMPs, PRRs, cytokine production, and glial activation.  
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1.II.c. Immune signaling and ethanol-induced damage 
One of the consequences of ethanol-induced immune signaling is cell or organ 
damage and dysfunction. This ethanol-induced inflammatory damage is well established 
in the liver where it contributes to the development of alcoholic liver disease (Szabo et al. 
2011; Szabo & Lippai 2014). Neuroimmune signaling is also involved in the ethanol-
induced brain damage observed in alcoholics. Human alcoholic brains show damage, 
including reduced gray and white-matter volumes, neuronal loss, and decreased glial 
counts and size, and this damage is particularly apparent in the frontal cortex (Abernathy 
et al. 2010; Vetreno & Crews 2014). Recent studies suggest that ethanol-induced 
neuroinflammation contributes to neuronal damage and neurodegeneration (M. A. Pascual 
et al. 2011; Zou & Crews 2010; Qin et al. 2008).  
Chronic alcohol induces microglial and astroglial activation, production of 
cytokines and reactive oxygen species, cell death, and cognitive dysfunction in mice 
(Alfonso-Loeches et al. 2010; Blanco et al. 2005; Fernandez-Lizarbe et al. 2009; M. A. 
Pascual et al. 2011). Studies reveal that the PPR TLR4 is essential for these ethanol-
induced neurotoxic and behavioral deficits, further supporting the idea that neuroimmune 
signaling contributes to the brain damage caused by alcohol consumption (M. A. Pascual 
et al. 2011; Alfonso-Loeches et al. 2010). There are several mechanisms by which 
inflammation leads to damage. Studies suggest that ethanol causes a shift in transcription, 
decreasing binding of cyclic AMP response element-binding protein (CREB) transcription 
factors which promote neuronal survival, while increasing NF-kB binding, which 
transcribes cytokines and promotes oxidative stress (Crews & Kim Nixon 2009). The 
cytokine TNFa, in conjunction with reactive oxygen species, can cause apoptosis (Hsu et 
al. 1996; Kamata et al. 2005). Neuroimmune signaling also causes a decrease in astrocytic 
glutamate transport causing hyperexcitability, and increased extracellular glutamate, 
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leading to neurotoxicity (Zou & Crews 2005a; Vetreno & Crews 2014). In addition, ethanol 
reduces cortical and hippocampal neurogenesis (formation of new neurons) by inhibiting 
neural stem cell proliferation and survival, and this reduction is reversed by blocking the 
PPR interleukin 1 beta (Il1b) receptor or inhibiting NF-kB (Zou & Crews 2010; Crews et 
al. 2006; Zou & Crews 2012; Kimberly Nixon & Crews 2002; Crews & Kim Nixon 2009).  
Pharmacological studies further support the idea that neuroimmune signaling 
potentiates ethanol-induced damage. Adolescent rats undergoing binge drinking show 
increased COX-2 and iNOS, cell death, and behavioral deficits, which are prevented by the 
COX-2 inhibitor Indomethacin (M. Pascual et al. 2007). Supporting the hypothesis that 
NF-kB induced oxidative stress promotes damage, the anti-oxidant butylated 
hydroxytoluene also blocked COX-2 induction, neuronal death, and increased 
neurogenesis (Crews et al. 2006). In addition, Rolipram, which increases CREB-DNA 
binding, reduced ethanol- induced neurodegeneration (Crews & Kim Nixon 2009). 
Minocycline and naltrexone, drugs that are known to block microglial activation, also 
reduced neuroinflammation and cell death in response to ethanol (Qin & Crews 2012). 
These studies highlight the effects of neuroimmune signaling on CNS damage and suggest 
that drugs targeting inflammation may be beneficial to alcoholics.  
 
1.II.d. Immune signaling regulates ethanol consumption  
 In addition to contributing to neuronal damage, neuroimmune signaling can 
regulate ethanol consumption. The first hint of a correlation between immune genes and 
ethanol came from human post-mortem genomic studies, however, those data don’t show 
whether consumption increased gene expression or gene expression increased consumption 
(Jianwen Liu et al. 2006).  Consequently, genomic studies using abstinent animals from 
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rodent lines that are known to consume high or low amounts of alcohol, revealed 
differences in immune gene expression (Mulligan et al. 2006). These data then suggested 
a causal role for immune genes in regulating ethanol intake. Consistent with differences in 
rodent lines, polymorphisms for immune genes are associated with risk of developing 
AUDs (Cui et al. 2014).  
Several studies have shown that systemic increases in immune signaling promote 
ethanol consumption while deletion of immune genes reduce consumption. Injection of the 
bacterial endotoxin LPS leads to persistent increases in ethanol consumption (Blednov, 
Benavidez, et al. 2011), while knockout mice for immune genes show decreased ethanol 
consumption. Chemokines are a family of small cytokines that induce chemotaxis, and 
transgenic mice with deletions of C-C motif chemokine ligands 2/3 (Ccl2, Ccl3) and the 
C-C motif chemokine receptor 2 (Ccr2) genes show reduced ethanol preference and 
consumption (BLEDNOV et al. 2005). Several immune-related genes previously linked to 
alcohol consumption in gene expression studies were also validated in vivo. Knockout mice 
for several other immune genes, beta-2 microglobulin (B2m), cluster of differentiation 14 
(Cd14), interleukin-1 receptor antagonist (Il1rn), interleukin 6 (Il6), cathepsin S (Ctss), and 
cathepsin F (Ctsf), all showed decreased ethanol consumption and preference in a 24-hour 
2-bottle choice test (Blednov, Ponomarev, et al. 2011).  
Additionally, CNS specific manipulations of immune genes can alter ethanol 
consumption, highlighting the role of immune signaling in the brain. Knockdown of IKKb, 
a kinase involved in activation of NF-kB, in the nucleus accumbens or central amygdala, 
reduced voluntary ethanol consumption in mice (Truitt et al. 2016). In addition, knockdown 
of the PPR TLR4 in the amygdala of alcohol-preferring rats reduces binge drinking (Juan 
Liu et al. 2011). Global knockout of TLR4 or knockdown in the ventral pallidum did not 
change ethanol consumption, highlighting the complexity of neuroimmune signaling and 
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the importance of studying the response in specific brain regions (Juan Liu et al. 2011; 
Harris et al. 2017).  
Pharmacological studies also provide evidence for immune regulation of ethanol 
consumption. Minocycline, an antibiotic with immune-modulatory properties, significantly 
reduced voluntary ethanol consumption in mice (Agrawal, Hewetson, C. M. George, 
Syapin & Bergeson 2011a).  In addition, two inhibitors of IKKb, TPCA-1 and 
sulfasalazine, decrease ethanol intake and preference in mice (Truitt et al. 2016). These 
results not only support the involvement of neuroimmune signaling in the regulation of 
consumption, but suggest that drugs targeting immune signaling may be promising for the 
treatment of AUDs.  
 
1.III. MICROGLIA 
In the adult brain microglia are confined to the CNS and make up approximately 5-
10% of cells, however, microglia have a distinct lineage compared to other brain cell types 
(Lawson et al. 1990). While neurons, astrocytes and oligodendrocytes are derived from 
neural stem cells, microglia are derived from yolk-sac hematopoietic stem cells (Ransohoff 
& Cardona 2010). Myeloid progenitor cells enter the neural tube at E8.5 in rodents and 
differentiate into microglia (Salter & Beggs 2014). The microglial population in the adult 
CNS is a finely tuned balance of proliferation and apoptosis, and microglia are mostly 
maintained through local self-renewal instead of repopulation from bone marrow 
macrophages (Askew et al. 2017). Compared to other tissue macrophages, microglia are 
uniquely regulated and have a distinct genomic signature (Salter & Beggs 2014). 
Consequently, microglia are specialized cells that have important immune and CNS 
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functions which vary depending on whether the brain is in a healthy or pathological state 
(Fig. 1.1).   
 
1.III.a. Microglial Function 
1.III.a.i Microglial Function under physiological conditions 
Under physiological conditions, microglia are in a “ramified state” during which 
they have a small cell body with long processes and are continuously surveying the entire 
brain. Although this surveillance is in part to detect any disease or damage, it is also to 
interact with other CNS cells, including neural stem cells and differentiated neurons (Salter 
& Beggs 2014).  
During postnatal development, microglia are responsible for regulating the number 
of neuronal precursors and neurons. Microglia regulate neuron number by inducing 
apoptosis and phagocytosing dispensable neurons, controlling differentiation of precursor 
cells, and providing trophic support to necessary neurons (Salter & Beggs 2014). 
Additionally, microglia play an important role in synaptic pruning during development, a 
process important for refining neuronal connectivity. Synaptic pruning is dependent on 
synaptic activity and microglia respond to neuronal activity and signals, eliminating 
inactive synapses (Salter & Beggs 2014). Microglia are also involved in maturation of the 
excitatory synapses by altering the composition of NMDA receptor subunits and the ratio 
of AMPA to NMDA receptors (Salter & Beggs 2014).  
Aside from their role in development, microglia also play an important role in the 
healthy adult brain. Learning and memory involve activity-dependent synaptic plasticity, 
through the process of long-term potentiation (LTP) or long-term depression (LTD). 
Microglia are critical for activity-dependent synaptic plasticity, as evidenced by deficits in 
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LTP and glutamate recycling in mice with dysfunction microglia (CNS-TGFb1-deficient 
mice) (Koeglsperger, Li, Brenneis, Saulnier, Mayo, Carrier, Selkoe & Weiner 2013a). 
Microglia show increased contact with highly active neurons, and this contact seems to 
lead to a reduction in spontaneous and evoked calcium activity (Y. Li et al. 2012). Thus, it 
appears that microglia monitor the synaptic function of neurons they are in contact with, 
and can alter neuronal activity in response. Additionally, microglial depletion in adult mice 
results in altered spine dynamics and deficits in motor learning (Parkhurst et al. 2013).  
In addition, microglia continue to regulate neurogenesis in the adult CNS (Luo & 
S.-D. Chen 2012). Microglia not only participate in the “pruning process” by removing 
apoptotic cells, but can also influence proliferation, differentiation and survival or 
progenitor cells (Gemma & Bachstetter 2013). Progenitor cells grown in conditioned 
microglial media show a higher proportion of neuronal cells, while neurons grown in 
conditioned media have increased survival. Studies suggest that microglia secrete growth 
factors, including insulin-like growth factor (IGF) and brain-derived neurotrophic factor 
(BDNF), that promote neurogenesis and survival. Additional studies support the idea that 
microglia beneficially impact neurogenesis, suggesting that microglial dysfunction may be 
involved in the decreased neurogenesis seen in aged mice (Luo & S.-D. Chen 2012).  
Together, new data support an important role for microglia in normal brain 
development and synaptic plasticity and future studies will further elucidate these 
processes. These results highlight how alterations in microglial activity can impact brain 
function, even in the absence of inflammation.  
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1.III.a.ii Microglial Function under pathological conditions 
Despite their important roles in the healthy brain, microglia are primarily known 
for being the resident immune cells of the brain. Microglia are constantly surveying the 
brain and if they encounter PAMPS or DAMPs, they become ‘activated’. Activated 
microglia change their morphology from elongated processes to a more amoeboid shape 
with a larger cell body and shorter processes and can become phagocytic (Ransohoff & 
Cardona 2010). Activated microglia adopt different phenotypes, but microglial immune 
response usually results in a shift from homeostatic function to immune-related functions.  
 Although controversial, it is believed that activated microglia can enter either a 
classical-activation state (M1-like), an alternative activation state (M2-like), or acquired 
deactivation state (M0) (Fig. 1.2) (Luo & S.-D. Chen 2012; Ransohoff 2016a). The M1 
and M2 states are based on differences in gene expression originally identified in peripheral 
macrophages, but have some support in CNS studies (Ransohoff & Cardona 2010). The 
M0 or acquired deactivation state is recently identified and is like the M2 state. The 
phenotypic distinction between M0 and M2 is still being elucidated and the M0 state often 
has different names, is considered part of M2 (M2c), or is defined as the homeostatic state. 
It is worth noting that many studies investigating microglial activation states use in vitro 
cultures, which differ substantially from microglia in vivo (Schmid et al. 2009; Ransohoff 
2016a). New techniques are emerging to better capture the in vivo microglial response and 
help to further characterize microglial states. It is mostly agreed upon that microglia can 
exhibit pro-inflammatory or anti-inflammatory properties, but that these properties exist in 
a continuum as opposed to distinct states and that these responses may be different than 
those observed in macrophages or in vitro microglia.  
Classically activated microglia are characterized by the inducing agent IFN-g or 
LPS and the production of pro-inflammatory cytokines, reactive oxygen and nitrogen 
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species, and antigen-presenting molecules (Cherry et al. 2014; Colton 2009). Specific 
markers of M1 activation include IL-1b, IL-6, TNF-a, CCL2, ROS, and NO. The purpose 
of classical activation is to mount an inflammatory response within the CNS and defend 
against bacterial and viral infections (Nakagawa & Chiba 2014). However, the pro-
inflammatory response mounted to destroy pathogens, can also be neurotoxic (Y. Tang & 
Le 2016). Furthermore, the PRRs responsible for recognizing pathogens are also capable 
of detecting endogenous molecules (e.g. miRNAs, misfolded proteins, damaged cells and 
organelles), leading to an unnecessary pro-inflammatory response (Sochocka et al. 2016). 
Chronic activation of microglia in a pro-inflammatory/M1-like state can lead to 
mitochondrial dysfunction, impaired neuronal function, apoptosis, and impairment of the 
blood brain barrier (Sochocka et al. 2016).   
Conversely, alternatively activated or acquired deactivated microglia release anti-
inflammatory cytokines and serve to suppress inflammation and promote repair (Luo & S.-
D. Chen 2012). The major difference between the M2 and M0 states is the ligand that 
stimulates them, with M2 being induced in response to IL-4 and IL-13 and M0 being 
induced in response to TGF-b, IL-10, or apoptosis (Luo & S.-D. Chen 2012; Colton 2009; 
Y. Tang & Le 2016). IL-4, IL-13, and IL-10 are well known anti-inflammatory cytokines, 
while transforming growth factor beta (TGF-b) is an anti-inflammatory cytokine and 
growth factor that has many functions. In addition to influencing the immune response, 
TGF-b has important roles in development, cell-cycle, apoptosis, migration, angiogenesis, 
and extracellular matrix (ECM) remodeling (X. Guo & X.-F. Wang 2009).  
Markers of M0/M2 activation include the surface markers Arg-1, Ym1, CD36, 
CD163, and IL-10. (Nakagawa & Chiba 2014). M2 activation can lead to the production 
of TGF-b and promote M0 activity, while M0 microglia can upregulate markers that 
enhance M2 activity (Y. Tang & Le 2016). Production of anti-inflammatory cytokines by 
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M2 microglia can also downregulate the pro-inflammatory response in M1 microglia. 
Interestingly, there is also evidence that pro-inflammatory cytokines (CCL2, IL-6) 
produced by M1 microglia may induce M2 polarization to begin the repair process 
(Nakagawa & Chiba 2014). M2 microglial activation increases expression of genes 
involved in tissue and ECM repair, promotes phagocytosis of cell debris, and releases 
neurotrophic factors to support neuronal survival  (Y. Tang & Le 2016).  
Despite the discrete classifications, activation states exist as a spectrum and it is 
unclear whether different activation states can exist simultaneously (Nakagawa & Chiba 
2014; Y. Tang & Le 2016). For the CNS to function correctly, a balance between pro- and 
anti-inflammatory responses is important. Disruption of this balance is what leads to 
chronic neuroinflammation and damage (Luo & S.-D. Chen 2012; Carniglia et al. 2017; 
Cherry et al. 2014). Although an M1-response seems detrimental, while an M2-response 
seems beneficial, the impact of these responses in CNS pathology is context dependent. 
For example, an overactive pro-inflammatory response (attributed to M1-microglia) is 
thought to contribute to Schizophrenia and depression (Nakagawa & Chiba 2014). In 
contrast,  dysfunctional M2 response and TGF-b signaling is implicated in aging and 
Alzheimer’s disease (Bernhardi et al. 2015). Furthermore, timing of microglial responses 
are important, and there is evidence that in certain diseases (e.g. experimental allergic 
encephalomyelitis) a specific response might be beneficial at one time point but detrimental 
at another (Luo & S.-D. Chen 2012).  
 
1.III.a.iii. Microglial interaction with other cell types 
Microglia not only regulate neuronal processes, but are also strongly regulated by 
neurons. When healthy, neurons send inhibitory signals to microglia preventing activation 
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(Luo & S.-D. Chen 2012). Interactions between neurons and microglia are often mediated 
by interactions between ligands that are expressed on neurons and their receptors expressed 
on microglia, such as CD200-CD200R, CD22-CD45, and CX3CL1-CX3CR1(Ransohoff & 
Cardona 2010). In addition to direct interactions, neurons also regulate microglia through 
electrical activity and soluble factors. In response to neuronal damage, these inhibitory 
signals get disrupted, leading to microglial activation.   
Microglia also continuously interact with astrocytes within the CNS. Although 
microglia-astrocyte interactions during homeostasis remain unclear, the two cell types have 
many interactions during inflammation. Activated microglia induce A1 (neurotoxic) 
astrocytes by secreting Il-1a, TNF, and C1q (Liddelow et al. 2017). Activated astrocytes, 
in turn, reduce glutamate transport, leading to increased levels of extracellular glutamate 
and ultimately excitoxicity (Bal-Price & Brown 2001). In response to activation, astrocytes 
can secrete cytokines and further activate microglia through calcium waves or they can 
suppress cytokine production and decrease microglial toxicity (Luo & S.-D. Chen 2012). 
Microglial signals can also alter astrocyte proliferation, glutamate activity, and survival 
(Luo & S.-D. Chen 2012).   
Oligodendrocytes have a less appreciated role in the neuroimmune response, but 
they regulate myelination which is impacted in neuroinflammatory conditions like Multiple 
Sclerosis (MS). Microglia are known to regulate survival, differentiation, and proliferation 
of oligodendrocyte progenitor cells (OPCs) during development (Miron 2017). Microglia 
also play an important role in re-myelination, by phagocytosing myelin debris to make way 
for OPCs (Miron 2017). In addition, activated microglia directly promote OPC 
proliferation, differentiation, and remyelination.  
Although microglial interactions are confined to the CNS in healthy brain, 
disruption of the blood-brain barrier leads to infiltration of other immune cell types that 
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can interact with microglia. Activated microglia can function as antigen presenting cells 
that recruit T-cells from the periphery. Recruited T-cells, in turn, can directly or indirectly 
modulate the microglial response (Luo & S.-D. Chen 2012).  
 
1.III.b. Microglial changes with ethanol consumption 
1.III.b.i. Changes in morphology and marker expression 
Microglial under normal conditions are considered “ramified” and have a small cell 
body and several long processes that are continuously monitoring the parenchyma (Kovács 
2017). However, in response to danger or damage, microglia become activated and begin 
to mount an immune response, characterized by a bushy morphology with a larger cell 
body and smaller processes. Fully activated and phagocytic microglia take on an amoeboid 
appearance (He & Crews 2008). In addition, expression of microglial markers is 
upregulated in response to microglial activation (Imai & Kohsaka 2002).   
Studies have shown that both LPS and ethanol can change expression of microglial 
markers and microglial morphology in several models. In cultured primary microglia, 
ethanol treatment led to a more activated morphology, characterized by a more bushy and 
amoeboid appearance (Fernandez-Lizarbe et al. 2009). In ethanol pre-treated mice injected 
with LPS, microglia showed increased size and changes in morphology consistent with 
microglial activation (Qin et al. 2008).  Chronic ethanol consumption in mice leads to 
increased levels of microglial markers (Cd11b and Iba1) in the cortex and cerebellum while 
binge ethanol results in microglial activation indicated by an amoeboid morphology and 
thicker processes (Alfonso-Loeches et al. 2010; Lippai et al. 2013; Crews et al. 2006). 
Human postmortem data also supports the idea that alcohol exposure leads to microglial 
activation. In human alcoholic postmortem brains, the cingulate cortex shows increased 
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microglial marker (Iba-1 and GluT5) immunoreactivity compared to control brains (He & 
Crews 2008).  
Interestingly, imaging studies using the microglial activation marker 18-kDa 
translocator protein (TSPO) show decreases with chronic alcohol. Positron emission 
tomography revealed 10% lower TSPO levels in the striatum and hippocampus of alcohol-
dependent subjects compared to healthy controls (Hillmer et al. 2017). An additional study 
found that hippocampal TSPO levels correlated with verbal memory performance in 
healthy controls but not in recently abstinent alcohol dependent subjects (Kalk et al. 2017). 
These results highlight the complexity of the neuroimmune response to ethanol. Although 
TSPO is primarily expressed in microglia and reactive astrocytes, it is also found in some 
neurons and has high expression in endothelial cells (Rupprecht et al. 2010; Y. Zhang et 
al. 2014). Furthermore, decreased TSPO expression in neurons regulates ethanol-
responsive behaviors in Drosophila (Lin et al. 2015). It is possible that TSPO is changing 
differently in different cell types. In addition, it is possible that TSPO function is changing 
despite microglial activation or that it is labeling a different subtype of microglia than other 
markers. Consistent with the complexity of these measurements, a recent study fund that 
down-regulation of TSPO does not change cytokine induction in a microglial cell line (Dou 
et al. 2014). Future work elucidating the role of TSPO in microglia will be necessary to 
reconcile contrasting results about microglial activation.  
. 
1.III.b.ii. Microglial changes in function 
Alcohol also leads to functional changes in microglia. Cultured primary microglia 
exposed to ethanol show increased phagocytic activity as measured by ingestion of labeled 
beads (Fernandez-Lizarbe et al. 2009). Additionally, these cultured microglia showed 
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increased activation of NF-kB, expression of COX-2 and iNOS, and release of TNF-a, IL-
1b and nitric oxide, which are also released in response to LPS. Neurons cultured in the 
ethanol-treated microglia conditioned media undergo increased apoptosis, suggesting that 
the molecules secreted by microglia in response to ethanol can cause neuronal cell death 
(Fernandez-Lizarbe et al. 2009). Although it is hard to attribute in vivo changes to only 
microglia, LPS and ethanol exposure in rodents and mice leads to increased expression of 
pro-inflammatory molecules known to be released by microglia (TNF-a, IL-1b, iNOS, Il-
6, CCL2) as well as increased expression of inflammatory molecules often found in 
microglia (TLRs, NF-kB, NLRP3 inflammasome) (Lippai et al. 2013; Alfonso-Loeches et 
al. 2010; Crews et al. 2013; Kane et al. 2013; Whitman et al. 2013). In mice exposed to 
chronic ethanol, increased expression of COX-2 is co-localized to microglia, although it is 
seen in neurons and astrocytes as well (Alfonso-Loeches et al. 2010). Increases in cytokines 
and immune signaling molecules common to microglia are also seen in human post-
mortem brains, although the data do not show specific microglial localization (He & Crews 
2008; Crews et al. 2013).  
 
1.III.b.iii. Microglial changes in gene expression 
 Although changes in gene expression have been observed in response to ethanol 
in cultured microglia (Fernandez-Lizarbe et al. 2009; Fernandez-Lizarbe et al. 2013), 
none of these experiments have been unbiased gene expression screens and it has recently 
been acknowledged that cultured microglia have a different gene expression signature 
than microglia in vivo (Butovsky et al. 2013). Additionally, gene expression studies have 
looked at the transcriptome response to ethanol and identified immune changes (often 
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attributed to microglia) (Osterndorff-Kahanek et al. 2015; Osterndorff-Kahanek et al. 
2013; Most et al. 2015; Lewohl, L. Wang, Miles, Zhang, Dodd & Harris 2000b; Jianwen 
Liu et al. 2006), but none of these studies have been performed using isolated microglia. 
Thus, there is a need for further identification of microglia-specific changes in response 
to ethanol in vivo to further characterize the role of microglia in ethanol-induced 
neuroimmune signaling.  
1.III.c. Microglial heterogeneity 
Once microglia were determined to be from a macrophage lineage, researchers 
began to apply knowledge based on macrophages to microglia. However, recent studies 
have highlighted the differences between macrophages and microglia, as well as the 
differences between types of microglia used in experiments. Butovsky et al. compared 
microglia with several immune cells and tissue-specific macrophages and found that all 
cell types differed, but microglia were most closely related to splenic red-pulp 
macrophages, followed by other tissue-specific macrophages, then dendritic cells, and 
furthest from B and T cells (Butovsky et al. 2013). In addition, they discovered that 
microglial cell lines used in vitro (primary microglia, BV2 and N9 microglial cell lines, 
embryonic stem cell microglia, and RAW264.7 macrophages) do not express the same 
microglial signature observed in isolated adult microglia. These results highlight the 
importance of being cautious in our assumptions about microglia moving forward, 
particularly given the differences in the CNS compared to other tissues (Ransohoff 2016a). 
This is further evidenced by the recent discovery of important non-immune functions of 
microglia (1.III.a.i Microglial Function under physiological conditions).  
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In addition to differences between macrophage sub-types and differences between 
microglia in vitro and in vivo, microglia display temporal and spatial heterogeneity. In 
mice, microglia have different gene expression patterns throughout development, with 
lower expression of microglial genes during embryonic and postnatal stages and higher 
expression of microglial genes during late adolescence-young adulthood (P21- 2 months) 
(Butovsky et al. 2013). Additionally, microglia from aged mice show different 
morphologies, distribution, function, and gene expression signatures (Orre et al. 2014; 
Hickman et al. 2013). (Harry 2013). These microglial changes are thought to be unrelated 
to activation state, but attributed microglial dysregulation that contributes to 
neurodegeneration (Harry 2013).  
It has been known for a while that microglia have different densities and 
morphologies throughout the brain (Lawson et al. 1990). Given the structural and 
functional differences in brain regions, it is unlikely that microglia are behaving in the same 
way across the CNS. Consistent with this notion, a recent gene expression study found that 
microglia from the cerebellum, cerebral cortex, hippocampus, and striatum exhibited 
distinct gene expression patterns that change during aging (Grabert et al. 2016). These 
findings highlight the importance of considering age and brain region when collecting and 
interpreting microglial data.  
Although results from rodent studies are informative in our understanding of 
microglia, data from human microglia will be important for complete understanding. 
Technologies are advancing to be able to gather this data and should further elucidate how 
microglia function during homeostasis and respond to different disease states (Mizee et al. 
2017).   
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1.IV. TOLL-LIKE RECEPTORS 
PRRs are the molecules responsible for recognizing PAMPs and DAMPS and 
initiating an innate immune response. There are several classes of PPRs, including Toll-
like receptors (TLRs), which were the first class discovered and are the best characterized 
(Kawasaki & Kawai 2014). There are 10 identified TLRs in humans, and 12 in mice. TLRs 
are located either on the cell surface (TLR1, TLR2, TLR4, TLR5, TLR6, and TLR10) or 
on intracellular endosomes (TLR3, TLR7, TLR8, TLR9, TLR11, TLR12, TLR13). Cell 
surface TLRs recognize a variety of PAMPs, most of which are lipids or proteins found on 
bacteria (peptidoglycans, lipoproteins). In contrast, endosomal TLRs primarily recognize 
viral nucleic acids, although some do recognize bacterial nucleic acids as well. 
Additionally, TLRs recognize endogenous ligands including high-mobility group box 1 
(HMGB1), heat shock proteins, extracellular matrix components, and micro RNAs (Yu et 
al. 2010; Coleman et al. 2017). Due to their importance in immune signaling, TLRs and 
their signaling components have been a focus of the neuroimmune response to ethanol.  
 
1.IV.a. TLR Signaling pathways 
TLRs form homodimers or heterodimers and upon recognition of PAMPs or 
DAMPs, recruit adapter molecules to the intracellular Toll/IL-1 receptor (TIR) domain 
(Kawasaki & Kawai 2014). The TIR domain is highly conserved across TLRs and is 
responsible for downstream signaling. There are five different TIR-domain-containing 
adaptor molecules that can be recruited to TLRs: Myeloid differentiation primary response 
protein 88 (MyD88), MyD88-adaptor-like (MAL/TIRAP), TIR-domain containing adaptor 
protein inducing IFNb (TRIF/TICAM1), TRIF-related adaptor molecule 
(TRAM/TICAM2), and sterile a- and armadillo-motif-containing protein (SARM) 
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(O'Neill & Bowie 2007). Each TLR signals through one or multiple of the adaptor proteins 
MyD88, MAL, TRIF, and TRAM; while SARM acts as an inhibitor of TRIF signaling.  
MyD88 is the primary adaptor molecule and is recruited by all TLRs except TLR3 
and signals through the MyD88-dependent pathway (Fig. 1.3). In addition to MyD88, 
MAL is required for TLR2 and TLR4 signaling (O'Neill & Bowie 2007). Once recruited, 
MyD88 signals through a series of molecules collectively referred to as the MyD88-
dependent pathway. Bound MyD88 recruits Interleukin 1 receptor associated kinase 4 
(IRAK4) and IRAK1 to form the Myddosome complex (Kawasaki & Kawai 2014). IRAK4 
phosphorylates and activates IRAK1 leading to its release from the complex. IRAK1 then 
recruits and binds TNF receptor associated factor 6 (TRAF6) and the two molecules bind 
TGF-b-activated kinase 1 (TAK1), TAK1-binding proteins TAB1, and TAB2 (Kawasaki 
& Kawai 2014). TRAF6, TAK1, and ubiquitin-conjugating enzymes form a complex 
which undergoes poly-ubiquitination leading to TAK1 activation. TAK1 can then activate 
two separate pathways, the NF-kB pathway and the MAPK pathway (Kawasaki & Kawai 
2014).  
Activation of the NF-kB pathway results from TAK1 binding to the inhibitor of 
nuclear factor Kappa B Kinase (IKK) complex, containing IKKa, IKKb, and IKKg 
(NEMO). The binding of TAK1 to the complex leads to phosphorylation and activation of 
IKKb, which in turn phosphorylates inhibitor of NF-kB (IkB) leading to its ubiquitination 
(Kawasaki & Kawai 2014). Ubiquitination of IkB leads to the release of NF-kB and its 
translocation to nucleus, where it binds DNA and leads to the transcription of pro-
inflammatory cytokines (e.g. IL-1b, TNFa, IL-6, ROS) (Mogensen 2009). TAK1 is also 
able to activate members of MAPK family, leading to activation of the transcription factor 
activator protein 1 (AP-1). AP-1 is primarily composed of the Fos and Jun proteins, which 
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regulate many processes including differentiation, cell-cycle progression, and apoptosis 
(Hess et al. 2004).  
TLR3 and TLR4 signaling can occur via the TRIF-dependent pathway (MyD88-
independent pathway) (O'Neill & Bowie 2007). TLR3 signals exclusively through the 
TRIF-pathway, while TLR4 recruits MyD88-MAL as well as TRIF-TRAM (O'Neill & 
Bowie 2007). Once recruited, TRIF binds to TRAF6 and TRAF3. TRAF6 then recruits 
RIP-1, which can activate TAK1 leading to IKK/ NF-kB signaling (Kawasaki & Kawai 
2014). Alternatively, TRAF3 can bind to TBK1 and IKKi, leading to phosphorylation and 
activation of Interferon regulatory factor 3 (IRF3). Activated IRF3 dimerizes and 
translocates to the nucleus where it binds DNA (Kawasaki & Kawai 2014). IRF3 is a 
transcription factor that induces expression of type 1 interferon genes (IFN-a, IFN-b). 
Interferons, in turn, can activate JAK/STAT signaling leading to the transcription of 
interferon-inducible genes (Takeda & Akira 2004).    
Despite signaling through the MyD88-dependent pathway and activating NF-kB, 
TLR7 and TLR9 are also able to produce type 1 interferons in plasma dendritic cells. This 
signaling involves IRAK1, IRAK4, TRAF6, TRAF3, and IKKa (Mogensen 2009). In this 
pathway, IRAK1 phosphorylates and activates IRF7, which can transcribe type 1 
interferons.  
The TLR signaling pathways are further complicated by negative and positive 
regulation. The adaptor molecule SARM is produced in response to TRIF-pathway 
signaling and subsequently acts as a negative regulator of TRIF (O'Neill & Bowie 2007). 
In the MyD88-dependent pathway, the splice variant MyD88s is non-functional and 
competes with MyD88 binding, leading to negative regulation of the pathway (O'Neill & 
Bowie 2007). Additionally, there are several other molecules that inhibit MyD88, TRIF, 
TRAF6, NF-kB, and IRF3 (Kawasaki & Kawai 2014). Conversely, many cytokine receptor 
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signaling pathways result in the production of more cytokines, leading to positive feedback 
and exacerbation of the inflammatory response. One example is IL-1b, a transcriptional 
product of MyD88-signaling, that also activates the MyD88-dependent pathway itself, 
leading to positive regulation. 
Studies elucidating the TLR signaling pathways have come from the periphery, not 
the brain. It is assumed that signaling occurs in the same way in the brain, however, that 
has yet to be proven. There is evidence that TLR signaling can differ in cell types, 
evidenced by TLR2 induced production of type 1 interferons in plasmacytoid dendritic 
cells (Kawai & Akira 2010). Future work will be necessary to understand how CNS-
specific TLR signaling occurs. 
 
1.IV.b. TLR signaling and ethanol 
In addition to increasing immune signaling and microglial activation, ethanol 
influences TLR signaling, which is unsurprising given the importance of TLRs in the 
immune response. Within the TLR family, TLR4 has been studied the most in relation to 
alcohol. Not only have several studies shown that TLR4 expression and signaling is 
increased in response to ethanol, but there is also substantial evidence that many of the 
ethanol-induced neuroimmune changes are TLR4 dependent. Recently, studies have 
investigated the effects of alcohol on other TLRs as well, including TLR2, TLR3, TLR7, 
and TLR9.  
Consuelo Guerri and her group have performed several in vitro studies showing 
how ethanol impacts TLRs. TLR4 and its associated pathways are upregulated in response 
to ethanol in macrophages, astrocytes, and microglia and this ethanol response involves the 
clustering of TLR molecules in lipid rafts (Fernandez-Lizarbe et al. 2008; Blanco et al. 
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2005; Pascual-Lucas et al. 2014; Fernandez-Lizarbe et al. 2009; Alfonso-Loeches et al. 
2010). Furthermore, the immune response to ethanol in vitro is TLR4 dependent, and is 
potentiated by TLR2 (Fernandez-Lizarbe et al. 2009; Blanco et al. 2005; Fernandez-
Lizarbe et al. 2013). Rodent models of chronic or binge ethanol exposure also show 
changes in TLRs. Chronic ethanol feeding leads to increased expression and activation of 
the endogenous ligand HMGB1, increased expression of TLR2, TLR4, TLR9 as well as 
increased cytokine expression (Lippai et al. 2013; Whitman et al. 2013). Another chronic 
ethanol study shows increased expression of the co-receptor CD14, activation of NF-kB, 
and expression of pro-inflammatory mediators that are observed in wild type (WT) mice 
but not TLR4 knockout mice (Alfonso-Loeches et al. 2010). Furthermore, TLR4 knockout 
mice don’t display the behavior and cognitive defects observed in ethanol-exposed WT 
mice (M. A. Pascual et al. 2011). Binge ethanol exposure also leads to increased TLR2, 
TLR3, TLR4, and HMGB1 expression, cytokine expression, and NF-kB activation (Crews 
et al. 2013; Kane et al. 2013; Crews et al. 2006). It is important to note that TLR changes 
in vitro are dose and time dependent (Fernandez-Lizarbe et al. 2009; Fernandez-Lizarbe et 
al. 2008; Blanco et al. 2008) while changes in vivo are dependent on ethanol exposure 
(acute vs. chronic), time following exposure (collection when alcohol is on board vs. 
withdrawal), sex, age, species, and brain region (Alfonso-Loeches et al. 2013; Whitman et 
al. 2013; Kane et al. 2013; Agrawal et al. 2013). Studies in human post-mortem tissue have 
reaffirmed the relevance of TLR signaling in alcohol use disorders. Although brain region 
specific, increases in TLR2, TLR3, TLR4, TLR7 and HMGB1 are seen in post-mortem 
alcoholic brains (Crews et al. 2013; Coleman et al. 2017). 
Functional studies have also been performed to determine if TLR signaling 
regulates ethanol consumption. Surprisingly, TLR4 knockout mice do not show changes in 
ethanol consumption, even though the TLR4 ligand LPS increases consumption (Blednov, 
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Benavidez, et al. 2011; Blednov et al. 2017). However, CD14 (co-receptor for TLR4, 
TLR2, TLR3, TLR7, TLR9) knockout mice show decreased ethanol consumption in both 
males and females while TLR2 knockout mice showed decreased consumption in males or 
females depending on the test (Kawasaki & Kawai 2014; Janot et al. 2008; Blednov et al. 
2017). Interestingly, male MyD88 knockout mice showed increased ethanol consumption, 
possibly due to compensatory activation of the TRIF-dependent pathway.  
It is worth noting that knockout mice are effected in all tissues and throughout 
development, making it hard to differentiate peripheral and CNS effects. Studies using viral 
injections have shown that knockdown of TLR4 and IKKb can decrease drinking when 
delivered in certain brain regions, but not in others  
(Harris et al. 2017; Truitt et al. 2016; June et al. 2015; Juan Liu et al. 2011). Future 
studies with brain-region specific manipulations are necessary to further elucidate how 
TLR signaling in the CNS regulates ethanol consumption.   
 
1.IV.c. Localization of TLR signaling 
TLRs are mainly expressed on antigen-presenting cells, leading to the assumption 
that they are exclusively in microglia in the CNS (Kawai & Akira 2010). However, this 
notion has become controversial. There are other glial cell types in the brain that participate 
in the immune response and studies have shown evidence for TLR expression on 
astrocytes, oligodendrocytes, and endothelial cells. Recently, there has been evidence of 
TLR expression on neurons, which further complicates our understanding of how these 
molecules are working in the brain.  
There is widespread support for microglial expression of many TLRs at the mRNA 
level. In primary human glial cultures expression of Tlr1-9 was observed in microglia, and 
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Tlr2 and Tlr3 expression was also observed in astrocytes and oligodendrocytes (Bsibsi et 
al. 2002). As previously mentioned, mouse primary microglial and astrocyte cultures 
express Tlr4, and these cells show altered immune activation when derived from Tlr4 
knockout mice (Fernandez-Lizarbe et al. 2009; Fernandez-Lizarbe et al. 2013). Recent 
gene expression studies on the CNS have further elucidated the localization of Tlrs in the 
brain. A comparison of isolated mouse CNS cell types shows that Tlrs are expressed 
primarily in microglia, with a few exceptions (Y. Zhang et al. 2014). Tlr3 is primarily 
expressed in astrocytes, but also expressed in microglia and endothelial cells. This is 
consistent with several studies that have demonstrated astrocytic expression of Tlr3 (Park 
et al. 2005; Borysiewicz et al. 2013; Scumpia et al. 2005; Jack et al. 2005). Tlr4 and Tlr12 
are expressed mostly in microglia, but also in endothelial cells. Tlr1, Tlr4, Tlr5, Tlr6, Tlr8, 
and Tlr12 show low expression in astrocytes, while Tlr2, Tlr7, Tlr9, and Tlr13 show no 
astrocyte expression. Investigation of TLR expression in human microglia and astrocytes 
also revealed that microglia expressed TLR 1-9, and astrocytes have high levels of TLR3 
(Jack et al. 2005). However, this study detected low levels of TLR1, 4, 5, and 9 in astrocytes 
while TLR2, 6, 7, and 8 were undetectable, suggesting possible differences in expression 
across species.  
The lack of Tlr2 expression in astrocytes is inconsistent with several studies, which 
is possibly due to species differences or changes that occur during culturing (Kielian 2006). 
Furthermore, the RNA-sequencing is from the mouse cortex and the cell types are collected 
at different ages using different methods (Y. Zhang et al. 2014). It is surprising that Tlr4 
expression was found to be so low in astrocytes, given the numerous experiments that have 
studied Tlr4 in astrocyte cultures (Gorina et al. 2010; Blanco et al. 2005; Pascual-Lucas et 
al. 2014). It is possible that the act of culturing the cells alters the expression profile or that 
the low expression of Tlr4 in astrocytes is sufficient to cause functional changes (Kielian 
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2006). Further complicating things, the cell type expression of the downstream signaling 
molecules differs markedly. For example Trif and Myd88 are mostly expressed in 
microglia, while Irf3, Irak1, and Traf6 are expressed relatively evenly across cell types 
including neurons (Y. Zhang et al. 2014). This begs the question of how molecules within 
the same pathway could be expressed in different cell types, and at very different levels. It 
is possible that these molecules are involved in other signaling pathways in the brain that 
differ in cell-type specificity.  
Despite some discrepancies, localization of Tlr mRNA is agreed upon far more than 
localization of TLR protein. One study looking at mouse primary cultures found that TLR2 
was expressed in microglia, astrocytes, and oligodendrocytes but not neurons (Lehnardt 
2009). Conversely, other studies have found TLR2, TLR3, and TLR4 protein to be highly 
neuronal (Crews et al. 2013; S.-C. Tang et al. 2007; Préhaud et al. 2005; Aurelian et al. 
2016; Peltier et al. 2010). Additionally, functional studies have provide mixed results about 
localization of TLR signaling. Several studies provide functional evidence for TLR 
signaling in microglia (Jack et al. 2005; Olson & S. D. Miller 2004; Fernandez-Lizarbe et 
al. 2009; Lehnardt et al. 2002). In addition, functional studies support the role of TLR 
signaling in astrocytes (Borysiewicz et al. 2013; Jack et al. 2005; Park et al. 2005), 
oligodendrocytes , and endothelial cells (Grace et al. 2014). One study found that NF-kB 
activity, the output of TLR signaling, is nearly absent from neurons under basal conditions 
and in response to immune stimuli (Listwak et al. 2013). In contrast, other studies have 
shown that manipulating TLR signaling in neurons leads to changes in immune response  
(Leow-Dyke et al. 2012; June et al. 2015; Truitt et al. 2016; Xing-Jun Liu et al. 
2016; P. Mukherjee et al. 2015).  Understanding the localization of TLR signaling is a 
major gap in our understanding of innate immunity in the CNS. In addition, it is difficult 
to plan future experiments manipulating signaling without a full understanding of cell-type 
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expression. There is a need for research reconciling these discrepancies in TLR cell-type 
localization.  
1.V. MECHANISMS OF REGULATION 
1.V.a. How ethanol regulates immune signaling 
Based on recent studies, it is accepted that ethanol can modulate immune signaling, 
both in the periphery and in the CNS. Although it is not completely clear how ethanol does 
this, there are some proposed mechanisms, including indirect and direct effects (Fig. 1.4).  
 
1.V.a.i. Indirect effects via peripheral immune signaling 
Ingested alcohol goes through the digestive system into the intestines where it is 
converted into acetaldehyde by gut bacteria. In turn, acetaldehyde leads to activation of 
mast cells, a type of white blood cells that regulate intestinal epithelium physiology and 
secrete cytokines (Ferrier et al. 2006). Together through multiple mechanisms, alcohol, 
acetaldehyde and activated mast cells compromise the integrity of the intestinal epithelium, 
leading to increased intestinal permeability or “leaky gut” (Ferrier et al. 2006). “Leaky gut” 
causes intestinal bacteria and LPS to enter the blood stream which leads to activation of 
peripheral blood mononuclear cells (PBMCs) and the secretion of cytokines (Leclercq, De 
Saeger, et al. 2014). Increased LPS and cytokines in the blood stream leads to an innate 
immune response in the peripheral organs, particularly in the liver (Leclercq et al. 2012). 
However, LPS is a large molecule that rarely crosses the blood-brain barrier and no 
endotoxin is detected in the brain following chronic ethanol exposure (Zou & Crews 2012; 
Banks & S. M. Robinson 2010). It is instead hypothesized that the peripheral immune 
activation leads to CNS immune activation, through several different mechanisms.  
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One mechanism is through the circumventricular organs, which are brain structures 
with a normal blood brain barrier and include the pineal gland and parts of the pituitary 
gland. Circumventricular organs can respond to PAMPs in the blood stream and produce 
pro-inflammatory cytokines, which can then enter the brain by diffusion  (Dantzer et al. 
2008). In another mechanism, cytokines can activate the vagal nerves, which signal to the 
brain and cause changes in cytokine production, electrical activity, and parasympathetic 
activity (Olofsson et al. 2012).  A third mechanism involves active transport of cytokines 
across the blood-brain barrier, initiating a CNS immune response (Mayfield et al. 2013; 
Dantzer et al. 2008). Specifically, release of TNFa in the periphery triggers an immune 
response in the brain, leading to activation of NF-kB and AP-1 and increased cytokine 
production (Qin et al. 2007). A final mechanism of immune signaling from the periphery 
to the CNS involves perivascular macrophages and endothelial cells that line the blood 
brain barrier, which express PRRs and secrete inflammatory mediators like prostaglandins 
(Dantzer et al. 2008; Leclercq et al. 2017).  
 
1.V.a.ii. Direct effects of ethanol on CNS immune signaling 
However, there are neuroimmune effects of ethanol that differ from those of LPS, 
suggesting a periphery-independent mechanism of regulation as well. Because ethanol can 
get in the brain, it is plausible that ethanol is directly causing an inflammatory response 
within the CNS. One theory is that ethanol leads to the recruitment of TLRs into lipid rafts, 
leading to their activation (Fernandez-Lizarbe et al. 2008). Although this has been shown 
in vitro, TLR signaling would still require a ligand to induce this signaling. To this end, 
work by Fulton Crews and colleagues demonstrated that alcohol increases expression of 
high mobility group box 1 (HMGB1) within the brain, while LPS does not (Whitman et al. 
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2013). HMGB1, an endogenous ligand for several TLRs, is released by damaged neurons 
and leads to the induction of pro-inflammatory cytokines (Faraco et al. 2007). Furthermore, 
HMGB1 antagonism reduced ethanol-induced cytokine induction and neurotoxicity in 
brain slice cultures (Whitman et al. 2013; Coleman et al. 2017). Recent data also suggest a 
role for miRNAs in mediating the effects of ethanol in immune signaling. For example, 
ethanol increased the binding of the miRNA let-7b to HMGB1 and increased their release 
from microglial microvesicles (Coleman et al. 2017). Ethanol-induced release of let-7b (a 
TLR7 ligand) increases TLR7 expression, NF-kB activation, and neurodegeneration 
(Coleman et al. 2017). Together, these data are increasing our understanding of how 
ethanol activates immune signaling in the brain.  
 
1.V.b. How immune signaling regulates consumption 
Ethanol-induced immune signaling is hypothesized to increase consumption 
leading to more inflammation in a feed forward loop (Fig. 1.5). This hypothesis is 
supported by evidence that alcohol increases immune signaling (1.II.b. Alcohol’s impact 
on immune signaling), and that immune signaling alters consumption (1.II.d. Immune 
signaling regulates ethanol consumption). Immune signaling in the brain, particularly the 
PFC, is believed to regulate ethanol consumption by altering cortical function. Although 
not completely understood, there are several proposed mechanisms by which signaling 
alters cortical function and therefore regulates drinking. These mechanisms include 
changes in neurotransmitter release and synaptic activity, altered synaptic plasticity, 
perturbed neuroendocrine function, decreased neurogenesis, and neuronal damage and 
death. 
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1.V.b.i. Changes in neurotransmitter release and synaptic activity 
Increased neuroimmune signaling leads to the secretion of pro-inflammatory 
mediators, including cytokines and chemokines. Cytokines and chemokines can modulate 
the release of several neurotransmitters that contribute to addiction, including glutamate, 
GABA, dopamine, and serotonin (Cui et al. 2014). In addition, it is well established that 
pro-inflammatory signaling can alter mood and cause depression (Dantzer et al. 2008). 
Given the co-morbidity between depression and AUDs and the contribution of negative 
affect to addiction, mood changes are thought to be an important mediator of immune-
induced alcohol consumption (Koob & Volkow 2010; Crews et al. 2011).  
A leading hypothesis about how immune signaling regulates alcohol consumption 
involves increases in cortical hyperexcitability (Crews et al. 2011). The neurotransmitter 
glutamate regulates excitatory synaptic transmission between the cortex and limbic brain 
regions (Vetreno & Crews 2014). Studies suggest that chronic alcohol leads to a hyper-
glutamatergic state that results in loss of cortical flexibility and increased addiction-like 
behavior (Gruber et al. 2010), and that immune signaling could mediate this response 
(Crews 2012; Vetreno & Crews 2014). The cytokine TNFa is released in response to 
immune activation and reduces the activity of glutamate transporters in astrocytes, while 
activation of chemokine receptors increases astrocyte glutamate release (Zou & Crews 
2005b; Cui et al. 2014).  Astrocytes are responsible for glutamate uptake from the 
extracellular space, thus, reduced glutamate transporter activity and increased glutamate 
release leads to increased extracellular glutamate (Murphy-Royal et al. 2017). In addition, 
microglia can produce quinolinic acid, which also promotes glutamate release (Kovács 
2017). Increases in glutamate accumulation in the synapse cause increased neuronal 
excitation, which increases cortical excitability and interferes with the ability to 
differentiate real signal from noise (Crews et al. 2006).  
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Activity of GABA, the primary inhibitory neurotransmitter, is increased during 
acute ethanol exposure but decreased with chronic ethanol (Most, Ferguson, et al. 2014). 
Although ethanol can directly bind the GABA receptor and modulate activity, studies 
suggest that immune signaling can also influence GABAergic activity. In mouse central 
amygdala, ethanol increased presynaptic and postsynaptic GABA transmission, and this 
was diminished in CD14 knockout mice, suggesting immune regulation (Bajo et al. 2014). 
The amygdala signals to the cortex and is important for the motivation effects of alcohol 
use, thus altered amygdalar GABAergic activity could influence decision making and 
drinking behavior. Furthermore, chemokines (CCL2, CXCL-12) and cytokines (TNFa, IL-
1b) regulate release of GABA and trafficking of GABA receptors (Cui et al. 2014; Galic 
et al. 2012). IL-1b, for example, has been shown to decrease or increase GABAergic 
activity depending on the conditions (Galic et al. 2012). In turn, GABA can regulate the 
release of inflammatory cytokines, so decreased GABA activity can further exacerbate 
inflammation (A. H. Miller et al. 2013).  
Dopamine is neurotransmitter that mediates reward and is highly implicated in 
addiction. There is evidence that neuroimmune signaling regulates dopamine synthesis, re-
uptake, and release. MAPK signaling, which is activated in response to immune signaling, 
increases dopamine reuptake, reducing levels of extracellular dopamine (A. H. Miller et al. 
2013). In addition, immune activation decreases release of the dopamine precursor dopa 
(A. H. Miller et al. 2013).  
Serotonin is a monoamine neurotransmitter that is implicated in anxiety, 
depression, and addition. Inflammatory cytokines activate the enzyme IDO (Indoleamine-
2,3-dioxygenase) that converts tryptophan (the primary amino acid component of 
serotonin) into kynurenine, reducing serotonin levels (A. H. Miller et al. 2013). Cytokines 
can also impair activity of BH4, a co-factor involved in the synthesis of serotonin and 
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dopamine. In addition to altering serotonin synthesis, MAPK signaling and cytokines can 
also increase activity of the serotonin transporter (SERT), decreasing the level of 
extracellular serotonin.  
 
1.V.b.ii. Changes in synaptic plasticity: LTD and LTP 
Another hypothesis about how immune signaling promotes addition is that 
neuroimmune signaling causes changes in LTP and LTD, leading to altered learning and 
memory. Because microglia are now known to influence LTP and LTD during 
homeostasis, their shift to an inflammatory state could lead to neglect of their homeostatic 
roles and impaired learning and memory (Vetreno & Crews 2014). Supporting this 
hypothesis, peripheral injections of LPS produce transient deficits in LTP, while long-term 
LPS exposure causes persistent deficits in LTP (Maggio et al. 2013). Specific immune 
molecules have been shown to influence LTP and LTD, including IL-1b, MHCI, TNFa 
(Shatz 2009; Cui et al. 2014). Therefore, the neuroimmune response could be have a role 
in the changes in synaptic plasticity seen following chronic alcohol use (McCool 2011). 
Impaired learning and memory, in turn, can further promote consumption. 
 
1.V.b.iii. Altered neuroendocrine function 
In addition to modulating neurotransmitter activity, increased immune signaling 
also perturbs neuroendocrine signaling via the hypothalamic-pituitary-adrenal (HPA) axis. 
The HPA axis is often dysregulated with AUDs and stress is a major trigger for relapse 
(Koob & Volkow 2010). Cytokines and chemokines can regulate the release of stress 
hormones like cortisol, while stress-induced glucocorticoids can in turn regulate cytokine 
expression (Cui et al. 2014). Interestingly, many of the immune changes seen in response 
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to ethanol are also seen in response to stress (Crews 2012; Knapp et al. 2016). Studies have 
demonstrated that injection of immune activators into the brain increases ethanol 
withdrawal-induced anxiety-like behavior (Breese et al. 2008). Furthermore, ethanol-
withdrawal induced cytokine expression is blocked by a CRF1 receptor antagonist 
(Whitman et al. 2013). Therefore, perturbation of immune signaling by ethanol could alter 
the stress and anxiety response and drive further use.  
 
1.V.b.iv. Decreases in neurogenesis 
There is evidence that innate immune signaling leads to inhibition of neurogenesis 
(also covered in 1.II.c. Immune signaling and ethanol-induced damage), which is linked 
to drug induced negative-affect and depression-like behavior (Crews et al. 2011). 
Supporting the idea that TLR activation reduces neurogenesis, activation of TLR2 or TLR3 
signaling in embryonic cortical neural stem cells inhibits progenitor cell proliferation 
(Lathia et al. 2008; Okun et al. 2010). There is evidence for this action in the adult mouse 
as well, where TLR4 activation also inhibits progenitor cell proliferation in the 
hippocampus (Rolls et al. 2007). Furthermore, increased extracellular glutamate leads to 
NMDAR activation, decreasing brain derived neurotrophic factor (BDNF), a regulator of 
neurogenesis (A. H. Miller et al. 2013). Interestingly, some cytokines promote 
neurogenesis (IL-1b, CXCL-12), while others inhibit it (TNFa, IL-6) (Cui et al. 2014). 
Reduced neurogenesis is associated with impaired learning, memory, and mood regulation 
(Vetreno & Crews 2014; Kovács 2017). Furthermore, reduced neurogenesis means a 
reduction in neuronal turnover which could contribute to more pervasive drug-associated 
memories (Kovács 2017). Recovery from AUDs is accompanied by increased 
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neurogenesis and improved mood and cognition, suggesting that altered neurogenesis 
could contribute to cognitive deficits seen in alcoholics (Crews et al. 2011).  
 
1.V.b.v. Neuronal damage and death 
As previously covered in 1.II.c., ethanol-induced immune signaling can cause 
neuronal damage and neurodegeneration (Alfonso-Loeches et al. 2010). It is hypothesized 
that this damage contributes to cortical dysfunction and addictive behavior. Increased 
cytokine production in astrocytes results in a hyper-glutamatergic state (see 1.V.b.i. 
Changes in neurotransmitter release and synaptic activity). Not only does 
hyperexcitability increase neuronal excitation, but it also causes excitotoxicity: neuronal 
damage or death due to over activation of glutamate receptors (Crews et al. 2011).  
Another mechanism for neuronal death involves reactive oxygen species (ROS), 
which are a byproduct of alcohol metabolism and a product of immune signaling. ROS are 
secreted by activated microglia and lead to oxidative stress and neuronal death (Crews et 
al. 2015). NADPH oxidase, the enzyme that is responsible for the formation of reactive 
oxygen species, is also induced by ethanol and LPS (Crews et al. 2015). Increased NADPH 
activity leads to oxidative stress, neurodegeneration, and increased NF-kB transcription 
(Qin et al. 2013). Alcohol exposure also decreases antioxidant levels and activity, reducing 
the body’s ability to combat oxidative stress (Crews et al. 2015). Dopaminergic neurons 
are particularly sensitive to increases in oxidative stress (O'Callaghan et al. 2008) and play 
and important role in addictive behaviors, suggesting that damage in these neurons could 
influence consumption (Qin et al. 2007).   
Additional work suggests that the cytokine TGF-b could also be a mediator of 
neuronal apoptosis. TGF-b1 plays an important role in alcohol-induced liver injury 
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(Dooley & Dijke 2012) and levels are increased in the blood of alcohol dependent subjects 
(Kim et al. 2009). Ethanol-induced TGF-b1 has been shown to cause neuronal cell death 
by elevating pro-apoptotic proteins, lowering levels of anti-apoptotic proteins, and 
increasing production of caspase 3 (Crews et al. 2015). Although implicated as an anti-
inflammatory cytokine, studies show that NF-kB activity mediates TGF-b stimulation, 
highlighting the its potential role in pro-inflammatory cell responses (Tobar et al. 2010).   
Additionally, ethanol-induced immune signaling leads to increased NF-kB binding 
and decreased CREB-DNA binding. CREB targets many genes that are responsible for 
responsible for promoting neuronal survival and preventing excitotoxicity and apoptosis 
(Vetreno & Crews 2014). While alcohol decreases CREB activity, activated glial cells 
cause activation of NF-kB and increases in extracellular glutamate. The shift in the CREB/ 
NF-kB balance results in hyperexcitability, cytokine induced-neuronal damage and cell 
death, and altered neuronal function, which can all contribute to addiction (Vetreno & 
Crews 2014; Kovács 2017).  
 
1.V.b.vi. Consequences of altered cortical function 
In summary, there are several potential mechanisms by which ethanol-induced 
immune signaling regulates brain activity and thus addictive behavior. It is likely that these 
processes are occurring in parallel and that modulating immune signaling upstream could 
improve many functions at once. Although immune signaling is altered in many brain 
regions, the sensitivity of the PFC to these changes is thought to be an important 
mechanism by which immune signaling facilitates addictive behavior. The importance of 
the PFC in addiction is discussed in detail in section 1.I.a. The Prefrontal Cortex and 
AUDs. In addition to mediating critical behaviors like impulse inhibition, decision making, 
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and reversal learning, the PFC integrates information from other brain regions that regulate 
reward (nucleus accumbens, ventral tegmental area), negative affect (amygdala), and 
learning and memory (hippocampus).  
 
1.VI. GOALS OF DISSERTATION 
The main goal of my dissertation was to elucidate the neuroimmune response to 
chronic voluntary ethanol in a mouse model. In short, I found that voluntary ethanol has 
several important effects on neuroimmune signaling in the PFC, many of which are novel 
or unexpected.  
First, I found that chronic ethanol induces expression and signaling of the TRIF-
dependent pathway in vivo in a time- and brain-region specific manner. TRIF-dependent 
immune changes were increased in the PFC and nucleus accumbens, while they were 
decreased in the amygdala. I then demonstrated that inhibition of TRIF-dependent 
signaling using an IKKe/TBK1 inhibitor can decrease ethanol consumption.  
Then, to determine which cell types are responsible for neuroimmune changes, I 
profiled the cell-type localization of components and outputs of the TLR signaling 
pathways. I discovered that most the neuroimmune mRNAs are localized in microglia and 
increase in microglia in response to LPS. I also discovered that many of the microglial gene 
expression changes were missed using a typical preparation. Although unable to reliably 
determine the protein localization for the same molecules, I did reveal some potential 
reasons why this is disagreed upon  
Based on my revelation that most immune genes were microglial, but missed in a 
typical preparation, I aimed to profile the microglial response to ethanol. To determine the 
microglia-specific response to ethanol, I used isolated microglia and compared the 
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transcriptome changes to those observed in the total homogenate. I found that microglia 
have distinct gene co-expression networks and that many of the changes detected in 
microglia are not observed in the total homogenate. Specifically, microglia showed many 
genes related to endosomal TLR signaling and TGF-b signaling, validating our interest in 
TRIF-dependent signaling and suggesting a role for growth factor signaling in ethanol-
induced neuroimmune signaling.   
I then attempted to profile the microglial response 1-week after peripheral LPS 
treatment, a time point that previously showed high gene expression overlap with ethanol 
consumption in the total homogenate. I found that LPS not only increased expected 
cytokine genes in microglia, but also increased several many ribosomal genes and genes 
related to misfolded proteins. I further compared the microglial response to LPS and 
ethanol and found that while both treatments modulated immune signaling, the genomic 
responses were very different.  
Together, the data I present provide new targets to investigate in the ethanol-
neuroimmune response. Future studies in the lab will build on these experiments.  
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1.VII. FIGURES 
 
Figure 1.1: Microglial function in homeostasis and inflammation 
Under homeostatic conditions, microglia are ramified with small cell bodies and long 
processes that survey the brain for damage signals. In addition, microglia regulate 
neurogenesis and interact with neurons influencing synaptic activity. In turn, neurons 
send inhibitory signals to microglia preventing activation. In response to activation, 
microglia change morphology and have a larger cell body and smaller processes. 
Although microglial activation is heterogeneous, some effects include release of 
cytokines and reactive oxygen species (ROS), proliferation, and phagocytosis. Cytokines, 
in turn, can activate astrocytes, which further modulate the microglial response. In 
addition, astrocyte activation leads to decreased glutamate uptake and increased 
extracellular glutamate, which can alter neuronal activity and cause excitotoxicity. 
Cytokines and ROS can cause neurotoxicity, while activated microglia neglect their 
functions in neurogenesis and synaptic plasticity. 
Figure created using http://servier.com/Powerpoint-image-bank 
Homeostatic	Conditions Inflammatory	Conditions
Microglial	
Activation
N
eu
ro
tr
an
sm
is
si
on
Microglia
Immune	
surveillance
Astrocyte
Neuron
M
et
ab
ol
ic
	su
pp
or
t
Debris	
phagocytosis
Glutamate	
uptake
Cytokine	
Release
Neuronal	
activity
ROS	release
Increased	
Extracellular
Glutamate
Astrocyte
Neuron
Microglia
Neuronal	
damage/death
Altered	activity
Decreased	
glutamate	
uptake
Cytokine	
Release
Activation	
Amplification
Phagocytosis
Proliferation
 46 
 
 
Figure 1.2: Microglial activation states 
Although controversial, it is believed that microglia have a classical pro-inflammatory 
(M1-like) and alternative anti-inflammatory (M0/M2-like) response. Classical activation 
occurs in response to IFN-g/LPS in vitro and leads to activation of TLRs and NF-kB. A 
classical M1-like response leads to increases in antigen presenting molecules and secretion 
of pro-inflammatory cytokines and reactive oxygen species. The function of an M1-like 
response is to kill pathogens, but it can also lead to neurotoxicity. In vitro, alternative 
activation (M2-like) occurs in response to IL-4/IL-13 while acquired deactivation occurs 
in response to TGF-b/IL-10. Both sets of inducers lead to the production of anti-
inflammatory cytokines, neurotrophic factors, and extracellular matrix proteins. This 
response is usually reparative and includes phagocytosis of debris and resolution of 
inflammation.  
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Figure 1.3: TLR signaling pathways 
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Figure 1.3: continued 
 
Schematic of TLR signaling in response to their respective ligands or DAMPS (such as 
HMGB1 or heat shot proteins). All TLRs except TLR3 signal through the canonical 
MyD88-dependent pathway. In this pathway, MyD88 recruits IRAK4 and IRAK1, leading 
to the phosphorylation and activation of IRAK1. Phosphorylated IRAK1 then dissociates 
and binds TRAF6 and ubiquitin conjugating enzymes, leading to polyubiquitination of 
TRAF6. The polyubiquitin chains then bind TAB2 and TAB3, leading to activation of 
TAK1. Activated TAK1 signals through either IKKs or MAPKs. TAK1 can phosphorylate 
IKKs which in turn phosphorylate IkB leading to its ubiquitination and the release of NF-
kB. NF-kB then translocates to the nucleus where it transcribes proinflammatory genes. 
Alternatively, TAK1 can induce MAPK kinases and activate p38 and JNK leading to 
activation of the transcription factor AP-2. Instead of the MyD88-dependent pathway, 
TLR3 signals through the TRIF-dependent pathway, while TLR4 signals through both 
pathways. The TRIF-dependent pathway utilizes the adaptor molecule TRIF which binds 
to TRAF3 and TRAF6. TRAF6 can then activate TAK1 activation through RIP1. In 
contrast, TRAF3 binds TBK1 and IKKe leading to phosphorylation and activation of IRF3. 
IRF3 then translocates to the nucleus where it leads to transcription of type I interferons 
and interferon inducible genes. TLR7/8/9 can also drive transcription of interferon 
inducible genes by signaling through the MyD88-dependent pathway. This signaling 
involves the recruitment of IRAK1, IRAK4, TRAF6, TRAF3 and IKKa. This complex 
leads to the phosphorylation and activation of IRF7 which translocates to the nucleus and 
transcribes type I interferons.  
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Figure 1.4: Alcohol effects on gut-liver-brain immune signaling 
Alcohol can affect immune signaling in the brain both directly and indirectly. Ingested 
alcohol reaches the intestines where it can cause increased intestinal permeability, bacterial 
leakage, and cytokine secretion. Bacteria and cytokines then enter the blood stream, where 
the inflammatory response is amplified by peripheral blood mononuclear cell (PBMC) 
activation and cytokine secretion. Inflammatory cells and cytokines then reach the liver 
where Kupffer cells become activated and liver damage can occur over time. Increased 
cytokine secretion from the liver re-enters the blood stream and cytokines can enter the 
brain by crossing the blood brain barrier. In addition, alcohol can directly enter the brain 
and cause the release of endogenous TLR ligands and promote TLR binding in lipid rafts.  
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Figure 1.5: Hypothesized alcohol-immune feed forward loop  
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Figure 1.5: continued 
 
It is hypothesized that chronic alcohol consumption leads to neuroimmune gene 
induction, resulting in a pro-inflammatory environment, altered brain activity and 
ultimately cortical dysfunction, which leads to increased consumption. This figure 
displays this hypothesized loop with specific examples and references for each stage, as 
well as evidence that each stage causes the next one (boxes by arrows).  
 
References: 1: (Whitman et al. 2013), 2: (Kane et al. 2013), 3: (Lippai et al. 2013), 4: 
(Zou & Crews 2010), 5: (Alfonso-Loeches et al. 2010), 6: (Fernandez-Lizarbe et al. 
2009), 7: (He & Crews 2008), 8: (Crews et al. 2006), 9: (Crews & Boettiger 2009b), 10: 
(Kimberly Nixon & Crews 2002), 11: (Abernathy et al. 2010), 12: (Oscar-Berman & 
Marinković 2007), 13: (Noël et al. 2007), 14: (Boettiger et al. 2007), 15: (Boettiger et al. 
2009), 16: (Blanco et al. 2008), 17: (Hsu et al. 1996), 18: (Kamata et al. 2005), 19: (Zou 
& Crews 2005b), 20: (M. A. Pascual et al. 2011) 21: (Blednov, Benavidez, et al. 2011), 
22: (BLEDNOV et al. 2005), 23: (Blednov, Ponomarev, et al. 2011), 24: (Agrawal, 
Hewetson, C. M. George, Syapin & Bergeson 2011b), 25: (Truitt et al. 2016), 26: (Crews 
et al. 2013) 27: (Dantzer et al. 2008) 28: (Cui et al. 2014) 29: (Vetreno & Crews 2014) 
30: (M. Pascual et al. 2007) 31: (Ming et al. 2015) 
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Chapter 2: Chronic Ethanol Consumption: Role of TLR3/TRIF-
dependent signaling 
 
Gizelle M. McCarthy B.S., Anna S. Warden B.S., Courtney R. Bridges B.S., Yuri A. 
Blednov, PhD, R. Adron Harris, PhD 
 
2.I. ABSTRACT 
 
Chronic ethanol consumption stimulates neuroimmune signaling in the brain, and 
toll-like receptor (TLR) activation plays a key role in ethanol-induced inflammation.  
However, it is unknown which of the TLR signaling pathways, the MyD88 (myeloid 
differentiation primary response gene 88) dependent or the TRIF (TIR-domain-
containing adapter-inducing interferon-β) dependent, is activated in response to chronic 
ethanol. We used voluntary (every-other-day) chronic ethanol consumption in adult 
C57BL/6J mice and measured expression of TLRs and their signaling molecules 
immediately following consumption and 24 hours after removing alcohol. We focused on 
the prefrontal cortex (PFC) where neuroimmune changes are the most robust, but also 
investigated the nucleus accumbens (NAc) and amygdala (AMY). Tlr mRNA and 
components of the TRIF-dependent pathway (mRNA and protein) were increased in the 
PFC 24 hours after ethanol and Cxcl10 expression increased 0 hours after ethanol. 
Expression of Tlr3 and TRIF-related components increased in the NAc, but slightly 
decreased in the AMY. In addition, we demonstrate that the IKKe/TBK1 inhibitor 
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Amlexanox decreases immune activation of TRIF-dependent pathway in brain and 
reduces ethanol consumption, suggesting the TRIF-dependent pathway regulates 
drinking. Our results support the importance of TLR3 and the TRIF-dependent pathway 
in ethanol-induced neuroimmune signaling and suggest that this pathway could be a 
target in the treatment of alcohol use disorders.  
2.II. INTRODUCTION 
 
Chronic alcohol consumption leads to adaptive changes in the central nervous 
system (CNS) that contribute to dependence and the development of alcohol use 
disorders (AUDs) (Harper 2009; Diamond & Gordon 1997). The prefrontal cortex (PFC), 
a brain region central to cognitive behavior, is important in the development of AUDs (S. 
Mukherjee et al. 2008; Abernathy et al. 2010). Chronic alcohol use produces molecular 
adaptations in the innate immune system and the PFC is particularly sensitive to these 
changes (NIAAA 2012; Goral et al. 2008; Stolyarova et al. 2015). Although the PFC 
shows the strongest immune response to ethanol, the nucleus accumbens (NAc) and 
amygdala (AMY) are also affected (He & Crews 2008; Osterndorff-Kahanek et al. 2015; 
Bajo et al. 2014). There is evidence that neuroimmune mechanisms cause CNS damage 
and also promote alcohol dependence, suggesting that these pathways are potential 
therapeutic targets for the deleterious effects of alcohol (Blednov, Benavidez, et al. 2011; 
Zou & Crews 2010; Alfonso-Loeches et al. 2010; Blednov, Ponomarev, et al. 2011).  
Toll-like receptors (TLRs) are innate immune proteins and key components of the 
neuroimmune response to ethanol, particularly TLR2, TLR3, and TLR4 (Alfonso-
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Loeches et al. 2010; Crews et al. 2013). TLRs are pattern recognition receptors and their 
signaling is triggered through a variety of pathogen-derived ligands. TLR2 and TLR4 are 
found on the cell surface and respond to bacterial ligands while TLR3 and TLR7 are in 
endosomes and respond to viral ligands (Lehnardt 2009).  In addition, TLRs can respond 
to endogenous ligands like high mobility group box 1 (HMGB1) (Anggayasti et al. 2017; 
Crews et al. 2013). TLRs signal through two pathways, the myeloid differentiation 
primary response (MyD88) and the TIR-domain-containing adapter protein 
(TRIF/TICAM-1) pathway. In the MyD88-dependent pathway, the adapter protein 
MYD88 binds to the Toll/IL-1 receptor (TIR) domain and recruits interleukin-1 (IL-1) 
receptor associated kinase 4 (IRAK4), IRAK1, and TNF receptor-associated factor 6 
(TRAF6). IRAK4 then phosphorylates IRAK1, which leads to the release of TRAF6 and 
the formation of the TRAF6 complex. Members of the TRAF6 complex phosphorylate 
the inhibitor of nuclear factor kappa-B kinase (IKK) complex, allowing release and 
activation of nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) 
(Takeda & Akira 2005). NF-κB activation leads to the transcription of proinflammatory 
cytokines, such as IL-1β, tumor necrosis factor alpha (TNF-α), and interleukin 6 (IL-6).  
The TRIF-dependent pathway uses the adapter protein TRIF, which signals through IKKε 
(also referred to as IKKi) and TANK-binding kinase 1 (TBK1), leading to the 
phosphorylation of interferon regulator factor 3 (IRF3) and the transcription of type I 
interferons. Activation of the TRIF-dependent pathway also leads to increased 
transcription of interferon inducible genes like C-X-C motif chemokine 10 (Cxcl10/IP-
10) and Chemokine (C-C motif) ligand 5 (Ccl5/RANTES) (Hirotani et al. 2005; 
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Weighardt et al. 2004). All TLRs (except TLR3) signal through the MyD88-dependent 
pathway while TLR3, TLR4, and possibly TLR2 signal through the TRIF-dependent 
pathway (Nilsen et al. 2015; Takeda & Akira 2005).  
Although studies have shown increased TLR mRNA and protein levels with high 
dose ethanol exposure, few have examined the effects of voluntary ethanol consumption 
on the MyD88 vs. TRIF pathway components in the brain (Whitman et al. 2013; Lippai 
et al. 2013; Crews et al. 2013). It is important to understand the downstream signaling 
events that mediate ethanol-induced changes in order to target the relevant pathways and 
simultaneously alter the activity of multiple TLRs. The goal of this study was to examine 
TLR signaling components after voluntary chronic ethanol consumption. 
Because TLRs are involved in many immunological conditions, there is an effort 
to find drugs that modulate their signaling. Most drugs targeting the TRIF-dependent 
pathway work by inhibiting IKKe, TBK1, or both (Hasan & Yan 2016). Amlexanox, an 
FDA-approved treatment for the treatment of aphthous ulcers in the US and is used to 
treat a variety of inflammatory diseases in Japan. Amlexanox is a dual TBK1 and IKKe 
inhibitor that has reduced inflammation and hepatic steatosis in obese mice, suggesting 
that it could have therapeutic uses for other inflammatory conditions that promote TRIF-
pathway signaling (Reilly et al. 2013).   
We investigated both mRNA and protein changes in TLRs and components of the 
MyD88- and TRIF-dependent pathways using C57BL/6J mice undergoing an every-other-
day 2-bottle choice (EOD-2BC) paradigm, which is a voluntary drinking test that leads to 
escalation in drinking and changes in gene expression (Osterndorff-Kahanek et al. 2013; 
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Crabbe et al. 2012). We examined three different brain regions and two different time 
points to compare changes that occur immediately after consumption, while alcohol is still 
present in low levels, with those that occur when the mice are anticipating reinstatement of 
alcohol. We present novel evidence for TRIF- and brain region-dependent signaling during 
alcohol withdrawal that may influence craving. To determine the functional importance of 
TRIF-signaling in regulating ethanol consumption, we show that Amlexanox inhibits the 
inflammatory response in brain and reduces ethanol consumption. Our results suggest that 
TRIF-dependent may have a role in the development of AUDs and is a potential therapeutic 
target.   
2.III. MATERIALS AND METHODS 
2.III.a. Ethics Statement 
 
All procedures were approved by the University of Texas at Austin Institutional 
Animal Care and Use Committee (animal protocol number AUP-2013-00061) and 
adhered to the NIH Guidelines. The University of Texas at Austin animal facility is 
accredited by the Association for Assessment and Accreditation of Laboratory Animal 
Care.  
2.III.b. Animals and voluntary ethanol consumption 
 
Studies were conducted in adult (6-8 weeks old) drug-naïve C57BL/J (B6) male 
mice (Jackson Laboratories, Bar Harbor, ME). Mice were individually housed and 
allowed to acclimate to upright bottles one week before the start of the experiment. The 
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experimental rooms were maintained at an ambient temperature of 21±1°C, 40-60% 
humidity, and a regular light/dark schedule (7 AM-7 PM). Food and water were available 
ad libitum.  
An EOD-2BC paradigm was used (Osterndorff-Kahanek et al. 2013; Crabbe et al. 
2012), and mice were randomly assigned to the control or treatment group. Treatment 
and control groups each contained 15 mice per time point (60 total). Control groups had 
access to water every day. Treatment groups had EOD access to water and a 15% (v/v) 
ethanol solution, and water only on off days. On days that ethanol was available, bottle 
positions were alternated to control for potential side preferences. Ethanol and water 
bottles were weighed after drinking days and animals were weighed once per week to 
calculate consumption (Fig. 2.6). The study concluded after 60 days (30 drinking days).  
2.III.c. Blood Alcohol Measurements and Tissue Harvest 
 
 Mice were sacrificed either immediately after ethanol was removed (0-hour 
group) or 24 hours after ethanol was removed (24-hour group). For the 0-hour group, 
retro-orbital bleeds were performed before sacrifice to determine blood alcohol 
concentration (BAC). BAC values, expressed as mg ethanol per deciliter of blood (Table 
2.1), were determined spectrophotometrically by an enzyme assay (LUNDQUIST et al. 
1959).  
 Five mice per group were used for immunohistochemistry. These mice were 
anaesthetized using isofluorane and given intraperitoneal injections of Euthanasia III 
Solution (TW Medical, Lago Vista, TX). Once death was confirmed, transcardial 
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perfusion was begun with PBS and followed by 4% paraformaldehyde (PFA). The whole 
brain was removed and post-fixed in 4% PFA. The remaining 10 mice per group were 
used for RNA and protein isolation. Following rapid cervical dislocation, brains were 
removed and placed on ice. The PFC was dissected as previously described (Osterndorff-
Kahanek et al. 2013), cut in half, and flash frozen in liquid nitrogen. The remainder of the 
brain was flash frozen separately. 
2.III.d. Tissue Punches 
 
 Frozen brains were mounted in optimum cutting temperature compound (OCT, 
VWR) and placed in isopentane on dry ice. Micropunches of the NAc and AMY were 
taken as previously described (Osterndorff-Kahanek et al. 2015). The following 
coordinates, anterior-posterior distance from bregma, were utilized: NAc (+1.8 mm to 
+0.6 mm); AMY (-0.9 mm to -1.8 mm).  
2.III.e. RNA Isolation and Quantitative RT-PCR 
 
 Half of each frozen PFC and the tissue punches were used for RNA isolation 
using the MagMax-96 Total RNA Isolation Kit (Thermo Fisher Scientific Inc., Rockford, 
IL). The RNA yield was quantified on a NanoDrop 1000 spectrophotometer and assessed 
for quality on an Agilent 2200 TapeStation (Agilent Technologies, Santa Clara, CA). 
RNA was reverse transcribed into cDNA using the Applied Biosystems High-Capacity 
cDNA Reverse Transcription Kit (Thermo Fisher Scientific Inc.). cDNA was tested for 
genomic DNA contamination and showed at least a 10 Cq difference between the +RT 
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(reverse transcription) and –RT samples (Bustin et al. 2009).  Applied Biosystems 
TaqMan® Gene Expression Assay (Thermo Fisher Scientific Inc.) primers were used 
(specific assay IDs are shown in Table 2.2). Quantitative PCR reactions were performed 
using SsoAdvanced™ Universal Probes Supermix (BioRad, Hercules, CA) in 10-μL 
reactions containing 18 ng of cDNA. All reactions were performed in triplicate and 
included a negative control. qPCR reactions were carried out using the CFX384 Real-
Time System (Thermo Fisher Scientific Inc.). For the PFC, three reference genes (Gusb, 
Gapdh, and Hprt) were tested for each time point and the best two genes were selected 
based on normalization factors in the qbase+ software (Biogazelle, Gent, Belgium). The 
0-hour samples were normalized to Gapdh and Hprt; the 24-hour samples were 
normalized to Gapdh and Gusb. The NAc and AMY micropunches were normalized only 
to Gapdh due to smaller quantities of cDNA. Relative quantification of mRNA levels was 
determined using the qbase+ software.  
2.III.f. Protein Isolation and Western Blot Analysis 
 
 Half of each PFC was used for protein isolation. Tissue was homogenized in 200 
μL of lysis buffer (150 mM NaCl, 50 mM Tris-HCl pH 7.4, 1 mM EDTA, 1% Triton-X-
100, 1% sodium deoxycholic acid, 0.1% SDS, 1X Halt Protease and Phosphatase 
Inhibitor Cocktail (Thermo Fisher Scientific Inc.), centrifuged for 10 minutes at 10,000 x 
g, aliquotted, and frozen at -80°C. Protein concentrations were determined using the DC 
Protein Assay (Bio-Rad). Cell lysates (40 μg) were boiled for 5 minutes, run on 10% 
Mini-Protean TGX Precast Gels (Bio-Rad), and transferred to PVDF membranes using 
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semi-dry transfer. Membranes were blocked with 5% dried milk in TBST (Tris-buffered 
saline with 0.5% Tween-20) and incubated overnight at 4°C with primary antibody 
(Table 2.3). Membranes were washed with TBST and incubated with HRP-conjugated 
secondary antibodies in 5% dried milk in TBST. Bands were visualized using ECL 
(Pierce) and imaged on film and using G:BOX Chemi XX6 (Syngene, Cambridge, UK). 
Bands were quantified using ImageJ and normalized to GAPDH and β-actin. All blots 
were repeated at least once.  
2.III.g. Immunohistochemistry 
 
 Brains were post-fixed for 24 hours in 4% PFA at 4°C, cryoprotected for 24 hours 
in 20% sucrose, and mounted in molds with optimal temperature compound (OTC). 
Frozen brains were sectioned coronally (20 μm thick) and placed free floating into PBS.  
Sections were permeabilized in optimized detergent (0.1% Triton-X-100 or 0.1% SDS) 
and blocked in 10% goat or donkey serum for 1 hour at room temperature. Sections were 
incubated with primary antibody overnight at 4°C (Table 2.3). The following day, 
sections were washed with PBS and incubated with secondary antibody for 2 hours at 
room temperature. Appropriate quality control staining was performed for labeling and 
secondary antibodies (Fig. 2.7). Sections were mounted on slides using Vectashield 
containing DAPI (Vector Labs, Burlingame, CA).  
2.III.h. Microscopy 
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Quantification of immunopositive cells was performed using a Zeiss Axiovert 
200M fluorescent light microscope (Zeiss, Thornwood, NY) equipped with an Axiocam 
b/w camera. Brain regions were identified using a mouse brain atlas as previously 
described (Zuloaga et al. 2014). Bilateral images of the PFC (distance from bregma: +2.8 
mm to +2.24 mm), NAc (+1.10 mm to +0.8 mm), and AMY (-1.20 mm to -1.60 mm) 
were captured using a 20x objective. IRF3 and IKKε immunopositive cells were 
quantified bilaterally within fixed area frames: PFC (box, 645 am x 645 μm), NAc 
(circle, 575 μm diameter), and AMY (circle, 675 μm diameter), using the ImageJ plug-in 
ITCN (http://rsb.info.nih.gov/ij/plugins/itcn.html). Areas used for quantification are 
shown in Figure 2.8. We quantified immunoreactivity as the number of immunopositive 
cells per section divided by total cell count (i.e. DAPI). For all cell quantifications, cells 
were counted in both hemispheres for a given region and summed. Total cell counts for 
each animal were then averaged and are presented as % immunopositive cells per section. 
2.III.i. Amlexanox Treatment 
 
Mice consumed 15% ethanol for at least 8 weeks using the EOD-2BC paradigm 
described above. After this period ethanol consumption was measure for at least 4 days to 
ensure stable consumption. Ethanol intake was then measured after saline administration 
for 2 days and mice were grouped to provide similar levels of ethanol intake and 
preference based on the consumption during these 2 days. On day 4, mice were 
administered saline or Amlexanox once daily and results are presented as the average 
from 2-day periods of consecutive drinking using different bottle positions. Amlexanox 
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(100 mg/kg) was administered orally by gavage (p.o.). Amlexanox was purchased from 
Abcam (ab142825). Drug was prepared as suspensions in saline with 5-4 drops of 
Tween-80 and administered once daily in a volume of 0.05 ml/10g of body weight 30 
minutes before drinking experiments. Saline containing 4-5 drops of Tween-80 was 
administered to control groups.  
2.III.j. Amlexanox-Poly I:C Treatment 
 
Mice were divided into four groups (n=10 per group) and were given an oral 
treatment (saline or Amlexanox 100 mg/kg) followed by an I.P. injection 30 minutes later 
(saline or Poly I:C 5mg/kg). Mice were sacrificed 3 hours after the I.P. injection and the 
PFC was fresh harvested as described above. RNA isolations and qPCR analysis were 
performed as described above.  
2.III.k. Statistical Analysis 
 
Results are reported as the mean ± SEM. Data were analyzed using GraphPad 
software (San Diego, CA) and 2-tailed Student’s t-tests unless otherwise noted (unpaired 
parametric test, assumes populations have the same SD). Statistical outliers were 
identified using Grubb’s test and removed from analysis. Consumption following 
Amlexanox or Saline treatment was analyzed using a 2- way analysis of variance 
(ANOVA) and Tukey’s multiple comparisons test. Gene expression changes following 
Poly I:C and Amlexanox treatments were analyzed using a 1-way ANOVA and Tukey’s 
multiple comparisons test. 
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2.IV. RESULTS 
2.IV.a. Chronic ethanol consumption increases expression of Tlrs  
 
To determine whether chronic ethanol consumption changes mRNA levels in the 
TLR signaling pathways in the PFC, qPCR analysis was performed 0 and 24 hours after 
ethanol removal (Fig. 2.1). Several TLRs are altered in other studies using different 
alcohol paradigms (Alfonso-Loeches et al. 2010; Crews et al. 2013; Whitman et al. 2013; 
Lippai et al. 2013). Consistent with previous studies, qPCR analysis confirmed that Tlr2, 
Tlr3, Tlr4, and Cd14 (TLR co-receptor) are increased following voluntary ethanol 
consumption at the 24-hour time point (Fig. 2.1a). Although Tlr2 and Tlr4 have been 
implicated in alcohol action in more studies than Tlr3 (G. Robinson et al. 2014), the 
largest fold-change (2.12) was observed for Tlr3. Like Tlr3, Tlr7 is another endocytic 
TLR that recognizes viral RNA and leads to the production of Type I interferons, despite 
signaling through the MyD88-dependent pathway. Tlr7 has been implicated in alcohol 
liver disease (Cha et al. 2012) and in the suppression of cytokines by acute ethanol 
exposure (Pruett et al. 2004). To determine whether Tlr7 expression changed with 
chronic ethanol consumption, qPCR was performed at both time points. In contrast to the 
other TLRS, Tlr7 expression increased 0 hours after ethanol removal.  
2.IV.b. Chronic ethanol consumption increases MyD88 and TRIF-related mRNA 
levels in a time dependent manner 
 
qPCR was then used to evaluate changes in components of the MyD88-dependent 
pathway, which is common to all TLRs except TLR3, and hypothesized to be affected by 
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chronic drinking. Only modest increases were observed for Myd88 and Irak4 at 0 hours, 
and all MyD88 pathway components were unchanged at 24 hours (Fig. 2.1b). 
Investigation of the TRIF-dependent pathway revealed an increase in Ikke at 0 hours and 
an increase in Trif and Irf3 24 hours after ethanol removal (Fig. 2.1c). Tbk1 mRNA 
expression was unchanged. These results suggest that chronic ethanol consumption 
mainly changes expression of TRIF-dependent pathway mRNA. There are also molecules 
that are common to both the MyD88 and TRIF-dependent pathways. Traf3 and Irf7 are 
involved in both TRIF-dependent signaling and TLR7 signaling through the MyD88-
dependent pathway while Traf6 is involved in all MyD88- and TRIF-dependent 
signaling. Measurement of these mRNAs using qPCR revealed that Traf3 and Traf6 were 
unchanged at both time points, but Irf7 expression increased at 0 hours (Fig. 2.1d).   
2.IV.c. Chronic ethanol consumption increases Il1b and Cxcl10 mRNA immediately 
after ethanol removal and Il6 24 hours after ethanol removal 
 
TLR pathway activation leads to transcription of cytokines, chemokines, and 
interferons and several cytokine mRNAs have been previously linked to alcohol exposure 
(Il1b, Tnfa, and Il6) (Zou & Crews 2010; Alfonso-Loeches et al. 2010; Whitman et al. 
2013; Lippai et al. 2013). Expression of these cytokines were measured to evaluate 
activation of the MyD88-dependent pathway. In addition, transcriptional outputs of the 
TRIF-dependent pathway (Ifnb, Ccl5, and Cxcl10) were measured, however, only Cxcl10 
was expressed at high enough levels to be quantified. Expression of Il1b and Cxcl10 
mRNA increased at 0 hours while Il6 expression increased 24 hours after ethanol 
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removal (Fig. 2.1e). Il1b transcription is primarily induced by MyD88-dependent 
signaling, while Cxcl10 is mostly induced by TRIF-dependent signaling and Il6 requires 
both pathways (Hirotani et al. 2005). These data suggest that both pathways may be 
activated in response to chronic ethanol exposure.  
2.IV.d. Chronic ethanol consumption increases a microglial, but not an astrocyte, 
marker at 24 hours 
 
Several studies have shown that glial activation is an important component of 
ethanol-induced neuroimmune signaling (He & Crews 2008; Lippai et al. 2013; 
Fernandez-Lizarbe et al. 2009). Microglia and astrocytes respond to pathogens and 
danger signals (i.e. HMGB1) by releasing cytokines, which can then further activate glia 
(Crews & Vetreno 2016). To determine the impact of chronic voluntary ethanol 
consumption on glial activation, we measured the astrocyte marker Gfap, the microglial 
marker Cd11b, and the activated microglial marker Cd68. Cd68 expression decreased at 0 
hours while Cd11b mRNA increased 24 hours after ethanol removal (Fig. 2.1f). No 
additional changes in glial expression were observed.  
2.IV.e. Chronic ethanol consumption did not change protein levels in the PFC 
 
After gene expression changes were observed for TLRs and TRIF-dependent 
pathway transcripts, protein levels were measured from the same PFC tissue using 
western blots. No significant differences were seen in any of the proteins measured (Fig. 
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2.9). Due to the small fold-changes it is possible that western blots are not sensitive 
enough to detect protein level changes.  
2.IV.f. Chronic ethanol consumption leads to increased IKKε and IRF3 
immunopositive cells in the PFC and NAc  
 
Immunohistochemistry, which may be a more sensitive measurement compared to 
western blots, was used to determine the number of IKKε and IRF3 immunopositive cells 
(Fig. 2.2). In the PFC, there was a significant increase in the percentage of IKKε 
immunopositive cells at 0 hours and a significant increase in the percentage of both IKKε 
and IRF3 immunopositive cells 24 hours after ethanol removal (Fig. 2.2a). The increases 
were larger at the 24-hour time point, which is consistent with the qPCR data. It is 
interesting to note that changes in both mRNA and IKKε protein are seen at 0 hours. In 
addition to the PFC, immunopositive cells were measured in the NAc and AMY.  The 
NAc showed similar changes to the PFC, with a small increase in IKKε and IRF3 at 0 
hours and larger increases in both IKKε and IRF3 at 24 hours (Fig. 2.2b). No changes 
were found in the AMY at 0 hours, but there was a decrease in IKKε and an increase in 
IRF3 at 24 hours (Fig. 2.2c). These results suggest that components of the TRIF signaling 
pathway are increased on the protein level by chronic ethanol in a brain region-specific 
manner.  
2.IV.g. Chronic ethanol consumption leads to increased Tlr3 mRNA in the NAc and 
decreased Tlr mRNA in the AMY 
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Because changes in the percentage of immunopositive cells in the NAc and AMY 
were observed, mRNA levels in these brain regions were measured from micropunch 
samples (Fig. 2.3). Due to limited sample, only transcripts that changed in the PFC were 
measured. In the NAc, there was an increase in Tlr3 mRNA at the 24-hour time point 
while there was a decrease in Tlr3 and Tlr4 at 24 hours in the AMY (Fig. 2.3a). Despite 
changes in immunopositive cells, there were no changes in expression in the TRIF-
dependent pathway components at either time point in either brain region (Fig. 2.3b). The 
AMY showed a decrease in Cxcl10 at the 24-hour time point, consistent with the 
decreased expression of Tlr3/4 and IKKe immunopositive cells seen in that brain region 
(Fig. 2.3c). Like the PFC, both the NAc and AMY showed an increase in Il1b expression 
at the 0-hour time point (Fig. 2.3c). This early increase in Il1b has also been observed in 
the hippocampus and VTA (data not shown), suggesting a brain-wide increase in Il1b 
immediately after ethanol removal.  
2.IV.h. Inhibitor of TRIF-dependent pathway decreases ethanol consumption  
 
To evaluate whether changes in TRIF-dependent signaling may regulate ethanol 
consumption, mice were treated with the dual IKKe/TBK1 inhibitor Amlexanox. 
Amlexanox decreases kinase activity of IKKe and TBK1 as well as phosphorylation of 
IRF3 in response to the TLR3 ligand polyinosinic:polycytidylic acid (Poly I:C) (Reilly et 
al. 2013).  At a dose of 100 mg/kg, Amlexanox reduced ethanol consumption and 
preference in mice undergoing a chronic EOD-2BC paradigm but did not significantly 
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change total consumption (Fig. 2.4). These data suggest a role for activation of the TRIF-
dependent pathway in the regulation of ethanol consumption.  
2.IV.i. Amlexanox reduces Poly I:C induced increase in Cxcl10 expression 
 
Amlexanox decreases the Poly I:C response in vitro and decreases high-fat diet 
induced expression of Cxcl10 in liver, but there is no evidence that it inhibits the TRIF-
dependent pathway in brain. To address this, we measured Cxcl10 expression in the PFC 
of mice that were treated with saline only, Amlexanox only, the TLR3 ligand Poly I:C, 
and both Poly I:C and Amlexanox. Administration of Poly I:C resulted in a ~2,000-fold 
increase in Cxcl10 expression, however administration of Poly I:C with Amlexanox 
reduces the Poly I:C-induced increase by 40% (Fig. 2.11).  
2.V. DISCUSSION 
 
Emerging evidence supports the role of neuroinflammatory mechanisms in 
alcohol dependence and alcohol-induced brain damage. Our group and others have shown 
that ethanol upregulates inflammatory mediators in the brain, which activate 
neuroimmune pathways (Blednov, Ponomarev, et al. 2011; Crews et al. 2013). Studies 
have focused on TLR4 because of its role in producing proinflammatory cytokines that 
can promote neuroinflammatory-dependent brain damage (Alfonso-Loeches et al. 2010; 
G. Robinson et al. 2014). Given that MyD88 is the adapter protein for TLR4 (and all 
other TLRs except TLR3), we hypothesized that chronic ethanol drinking would lead to 
increased expression of the MyD88-dependent pathway. However, our findings indicate 
 69 
that EOD ethanol consumption primarily increases expression of Tlr3 and components of 
the TRIF-dependent pathway (Table 2.4). We observed upregulation of TRIF signaling 
components at both the mRNA and protein levels as well as increased expression of 
Cxcl10, a transcriptional output of TRIF pathway activation. The TRIF-dependent 
pathway changes appear to be both brain region- and time-specific, with the greatest 
increase in signaling components observed in the PFC 24 hours after the last ethanol 
exposure and an increase in transcriptional outputs at 0 hours (see Table 2.1). Moreover, 
we provide evidence that the TRIF-dependent pathway may regulate drinking by showing 
that a IKKe/TBK1 inhibitor decreases ethanol consumption. A potential role for the 
TRIF-dependent pathway in ethanol consumption points to the utility of drugs that target 
this system for treating AUDs.  
Chronic alcohol abuse encompasses a relapsing cycle of intoxication, withdrawal, 
and craving resulting in aberrant neuroplasticity in corticolimbic structures (e.g. PFC), 
mesolimbic (e.g. NAc), and the extended AMY circuit. Expression changes in immune-
related genes in the PFC, NAc, and AMY following chronic intermittent ethanol 
treatment showed little overlap between brain regions, suggesting that there are region-
specific differences in immune signaling (Osterndorff-Kahanek et al. 2015). Our results 
also support brain region-specific differences in neuroinflammatory signaling. The PFC 
showed the largest increase in Tlr mRNA expression and in TRIF-related expression of 
mRNA and protein. Similar changes in protein were found in the NAc, but only Tlr3 
mRNA increased in this region. This could be due to differences in temporal signaling 
events in these brain regions, suggesting a dominance of corticolimbic structures during 
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craving. It is also possible that TLR3 is the predominant subtype altered in the NAc, 
while TLR2, TLR3 and TLR4 all increase in the PFC. Interestingly, the AMY showed 
decreased Tlr3, Tlr4, and Cxcl10 mRNA levels and decreased IKKε protein at 24 hours. 
However, increased IRF3 protein expression was observed in the AMY at 24 hours, 
potentially due to decreased TLR signaling and compensatory increased IRF3 signaling. 
Although Tlr and TRIF-dependent changes in the AMY were the opposite of those seen 
in the PFC and NAc, all three brain regions showed an increase in Il1b at the 0-hour time 
point suggesting that there may be distinct signaling events occurring. This increase in 
Il1b is noteworthy because of the involvement of the IL-1 system with GABAergic 
transmission and evidence that IL1 is also involved in disorders, like depression, that 
have high comorbidity with AUDs (Bajo, Herman, et al. 2015; Bajo, Varodayan, et al. 
2015; Barnes et al. 2017). Gene expression studies support the idea that the PFC, NAc 
and AMY show both common and unique gene expression changes, with modules of co-
expressing genes sometimes changing in the opposite direction in different brain regions 
(Osterndorff-Kahanek et al. 2015). Our inhibitor (Amlexanox) results show that global 
inhibition of the TRIF pathway reduces ethanol consumption. It is important to note that 
inhibition of TLR4 signaling does not reduce alcohol consumption emphasizing the 
importance of the TLR3/TRIF pathway (Harris et al. 2017; Blednov et al. 2017).  
The EOD drinking paradigm produces escalation of intake and maintains high 
alcohol consumption on drinking days (Crabbe et al. 2012). The 0-hour and 24-hour time 
points were selected to compare neuroimmune responses at different stages during 
chronic alcohol consumption (i.e. craving vs. bingeing). The 0-hour time point assesses 
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immune activation during the last ethanol exposure while ethanol is still present, albeit in 
low levels; whereas, the 24-hour time point represents the post-withdrawal stage when 
the mice are anticipating the availability of alcohol. We observed effects of alcohol 
consumption that are dependent on the time after withdrawal with more MyD88-
dependent pathway changes at the 0-hour time point while most of the TLR and TRIF-
dependent pathway changes are at the 24-hour time point, consistent with the idea that 
the MyD88-dependent pathway is activated earlier than the TRIF-dependent pathway 
(Kawai & Akira 2007). In addition, we saw increased expression of Cxcl10, a 
transcriptional output of TRIF-signaling, at the 0-hour time point. This is consistent with 
the idea that the pathway is being activated at 24 hours leading to increased transcription 
observed at 0 hours. Because we observed the largest increase in TRIF-dependent 
components after 24 hours, we suggest that this pathway may be involved in the post-
withdrawal craving stage. Amlexanox reduced ethanol consumption when administered 
at this 24-hour time point (right before drinking was re-instated), further suggesting that 
TRIF signaling is involved in craving. There are some timing inconsistencies, such as 
Ikke increasing at the 0-hour time point and not the 24-hour time point or Il6 and Il1b 
changing at different time points. TLR signaling is complex and involves many levels of 
regulation, including negative and positive feedback as well as components that are 
common to multiple pathways (Medzhitov & Horng 2009). It is likely that any 
perturbation of this pathway could impact expression of other signaling molecules 
involved, and that the timing of these changes would depend on the speed and level of 
regulation.  
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Many of the TLR pathway components measured here have been studied 
following other methods of alcohol exposure. Il1b increased in mouse cortex after an 
ethanol-based diet and Il6 increased in mouse cerebellum after binge ethanol exposure 
(Whitman et al. 2013; Kane et al. 2013). Tlr2 and Tlr4 have been shown to increase after 
various drinking paradigms and Tlr3 was increased following chronic intragastric ethanol 
exposure (Crews et al. 2013; Whitman et al. 2013; Lippai et al. 2013). In vitro studies in 
microglia and astrocytes have shown that ethanol can activate both the MyD88-
dependent and TRIF-dependent pathway, consistent with our detection of changes in 
components of these pathways in vivo (Fernandez-Lizarbe et al. 2009; Pascual-Lucas et 
al. 2014). In contrast to our results, some studies reported increases in MyD88 and TLR 
protein, Gfap mRNA, TNF-α (mRNA and protein), and IL-1β protein (Alfonso-Loeches 
et al. 2010; Crews et al. 2013; Whitman et al. 2013; Lippai et al. 2013). These differences 
are likely due to the differing alcohol consumption paradigms, which are known to 
produce distinct effects on gene expression (Osterndorff-Kahanek et al. 2015; 
Osterndorff-Kahanek et al. 2013). Our current results represent the expression changes 
following chronic voluntary ethanol consumption and the differences that are manifested 
immediately after consumption and after withdrawal.  
A caveat of this study is that we were unable to show increased phosphorylation 
of IRF3 as a measure of pathway activation. We attempted to measure phosphorylated 
IRF3 and interferon expression, but were unable to detect them at high enough levels in 
brain (Fig. 2.10). However, we were able to measure the interferon inducible gene 
Cxcl10, which is transcribed in response to TRIF-pathway activation (Hirotani et al. 
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2005; Weighardt et al. 2004). Our data showing that the TLR3 ligand Poly I:C leads to 
increased Cxcl10 expression in the PFC, further supports this chemokine as a measure of 
pathway activation. Due to the transient nature of phosphorylation states, changes in 
transcriptional outputs is a more reliable measure of pathway activation. The increased 
Cxcl10 expression in the PFC at the 0-hour time point supports the idea that the TRIF-
dependent pathway is being activated in response to chronic ethanol. Cxcl10/IP-10 is a 
chemokine that is responsible for recruiting cells that express CXCR3 (microglia, 
dendritic cells, and T lymphocytes) and has roles in regulating apoptosis, cell growth and 
proliferation, and synaptic activity (Gruol 2016; Mingli Liu et al. 2011).  Increased IP-10 
therefore could increase the immune response to ethanol as well as contribute to the 
alcohol-induced damage or changes in neuronal activity. In addition, the fact that an 
inhibitor of this pathway decreases drinking and partially rescues Poly I:C-induced 
Cxcl10 increases, further supports the idea that TRIF-pathway activation is involved in 
the ethanol response as well as regulation of consumption.  
 
The fold changes reported here are relatively small and it is important to consider 
that there may be a dilution effect when examining heterogeneous cell populations. If 
immune signaling molecules are preferentially expressed in glial cells, studying the entire 
brain region would minimize any cell type-specific changes that may be present 
(Mayfield et al. 2013). We have observed greater differences in gene expression in more 
homogenous cell fractions, which can reveal discrete, localized changes (Most, 
Workman, et al. 2014). In addition, the drinking paradigm we used here is voluntary and 
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does not produce as extreme changes as those seen with high dose paradigms. For 
example, 5 g/kg intragastric ethanol daily for 10 days (a binge model) produced increases 
in Tlr mRNA that ranged from 1.5 -2.5 fold (Crews et al. 2013).  
In summary, voluntary chronic ethanol consumption increases expression of brain 
Tlrs, particularly Tlr3 and components of the TRIF-dependent pathway, 24 hours after 
ethanol exposure. These changes could promote ethanol consumption and dependence, 
supported by the fact that a TRIF-pathway inhibitor decreased ethanol consumption.  	
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2. VIII. FIGURES 
 
 
 
 
Figure 2.1: Ethanol induced mRNA changes in the PFC 
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Figure 2.1: Continued  
 
RT-qPCR analysis of the PFC 0 or 24 hours after ethanol removal (n=10/group). (a) The 
0-hour group showed increased Tlr7 expression while the 24-hour ethanol group showed 
increased Tlr2, Tlr3, Tlr4 and Cd14 mRNA expression. (b) The 0-hour ethanol group 
showed increased Myd88 and Irak4 expression. (c) Increased Ikki expression was 
observed in the 0-hour group, while increased Trif and Irf3 expression was found in the 
24-hour ethanol group. (d) The 0-hour group showed increased Irf7 expression with 
ethanol. (e) The 0-hour ethanol group showed increased Il1b and Cxcl10 expression 
while the 24-hour ethanol group showed increased Il6 expression. (e) The 24-hour 
ethanol group showed increased expression of Cd11b, a microglial marker. All values are 
expressed as fold change over control ± SEM. # p < 0.05 compared to control, 1-tailed t-
test, * p < 0.05 compared to control, 2- tailed t-test; ** p < 0.01 compared to control, 2-
tailed t-test; *** p <0.001 compared to control, 2-tailed t-test. 
 
 
  
 78 
 
Figure 2.2: Immunohistochemistry of IRF3 and IKKe after ethanol 
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Figure 2.2: Continued 
 
Immunohistochemistry for IRF3 and IKKε 0 and 24 hours after ethanol removal. 
Representative images are shown from one control and one ethanol sample. Graphs show 
quantification from all samples (n=5/ group) and values represent the average ± SEM 
percent of cells positive for either IKKε or IRF3 over the total number of DAPI positive 
cells. Scale bar for PFC and NAc = 50 μM and for AMY = 100 μM.  (a) In the PFC there 
is an increase in the percentage of IKKε positive cells at 0 hours and of both IKKε and 
IRF3 positive cells at 24 hours (b) In the NAc there is increase in the percentage both 
IKKε and IRF3 positive cells at 0 and 24 hours (c) in the AMY there are no changes at 0 
hours, and at 24 hours there is a decrease in IKKε positive cells and an increase in IRF3 
positive cells. # p < 0.05, 1-tailed t-test, * p < 0.05 compared to control, 2- tailed t-test; 
** p < 0.01 compared to control, 2-tailed t-test; *** p < 0.001 compared to control, 2-
tailed t-test. 
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Figure 2.3: Ethanol induced mRNA changes in the Nucleus Accumbens and 
Amygdala 
RT-qPCR analysis from the NAc and AMY 0 and 24 hours after ethanol removal (for the 
0-hour time point n=10/ group and for the 24-hour time point n= 10 for the control group 
and n= 9 ethanol group). (a) The NAc shows increased Tlr3 mRNA levels while the 
AMY shows decreased Tlr3 and Tlr4 at 24 hours. (b) No changes were seen in the TRIF 
pathway genes. (c) Both the NAc and AMY showed increased Il1b expression at 0 hours 
and the AMY showed decreased Cxcl10 expression at 24 hours. All values are expressed 
as fold change over control ± SEM. # p < 0.05 compared to control, 1-tailed t-test; * p < 
0.05 compared to control, 2- tailed t-test; ** p < 0.01 compared to control, 2-tailed t-test, 
*** p < 0.001 compared to control, 2-tailed t-test. 
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Figure 2.4: Effect of Amlexanox on ethanol consumption and preference 
 
Measures for Saline and Amlexanox (100 mg/kg) treatment groups at baseline (both 
groups received saline injections) and with treatment. All measurements are taken 5 
hours following injection. (a) The Amlexanox group shows decreased ethanol 
consumption compared to baseline and compared to the saline group. (b) The Amlexanox 
group shows decreased preference for ethanol compared to baseline and saline. (c) The 
Amlexanox group shows no change in total fluid intake compared to when it was treated 
with saline. Bars labeled with the same letter are not statistically different while bars with 
different letters are (2-way ANOVA with Tukey’s multiple comparisons test, n=11 per 
group).  
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Figure 2.5: Summary of Ethanol changes in the PFC 
Schematic of the TLR signaling pathways in the PFC. Dark blue represents RNA changes 
at 24 hours, purple represents RNA changes at 0 hours, black dots indicate that Poly I:C 
induced mRNA was decreased with Amlexanox, checkered hatching represents protein 
increases at 0 and 24 hours while diagonal hatching represents protein increases at 24 
hours. Grey represents no change and white indicates that the pathway component was 
not measured in this study. Light blue means that expression was too low to measure in 
this study.  
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Figure 2.6: Ethanol Consumption 
 
Average consumption shown as mean (g/kg/day) ± SEM for all animals over the course 
of the 15% ethanol EOD- 2BC drinking experiment (n= 15 for each time point). The x-
axis represents days where ethanol was present.  
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Figure 2.7: Control images for immunohistochemistry 
 
Quality Controls for Immunohistochemical Quantification. (a) Labeling 
staining controls for all staining conditionings in nucleus accumbens of a C57Bl6/J male 
mouse--primary antibody and secondary antibody omitted, 10% donkey serum only. 
Image taken on fluorescent microscope (20x).(b) Secondary controls for all secondaries 
in nucleus accumbens of a C57Bl6/J male mouse--primary antibody omitted, 10% 
donkey serum and appropriate secondary. Image taken on a fluorescent microscope 
(20x).  
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Supplementary Fig S1: Quality Controls for Immunohistochemical Quantification. A) Labeling
staining controls for all staining conditionings in nucleus accumbens of a C57Bl6/J male mouse--primary antibody 
and secondary antibody omitted, 10% donkey serum only. Image taken on fluorescent microscope (20x).
B) Secondary controls for all secondaries in nucleus accumbens of a C57Bl6/J male mouse--primary antibody omitted, 
10% donkey erum and appr pria e secondary. Image taken on a fluorescent microscope (20x). 
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Figure 2.8: Brain regions for immunohistochemistry 
 
Brain regions used for immunohistochemistry counts: (a) PFC, (b) NAc and (c) AMY.  
(a)	Prefrontal	Cortex
(b)	Nucleus	Accumbens
(c)	Amygdala
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Figure 2.9: Western blots 
Western blot analysis of the PFC 0 and 24 hours after ethanol removal. Representative 
blots are shown from one control (C) and one ethanol (E) sample. Graphs show 
quantification from a complete blot (n=10/group). Protein levels were normalized to β-
actin and GAPDH. No differences were seen in (a) TLR protein levels, (b) MYD88 
pathway protein levels, (c) TRIF pathway protein levels, (d) Cytokines protein levels, or 
(e) Glial marker protein levels. All values are expressed as relative protein expression 
(normalized to β-actin) ± SEM. Statistics were performed using a 2-tailed t-test. 
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Figure 2.10: Western blot tests for p-IRF3 
 
Western blots using 3 commercially available pIRF3 antibodies showing that signal is not 
able to be detected in the PFC despite being detected in the spleen. 
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Figure 2.11: Amlexanox inhibits Poly I:C response in PFC 
 
Cxcl10 qPCR analysis of the PFC after saline oral and saline I.P injection (S/S), saline 
oral and Poly I:C (5mg/kg) I.P. injection (S/P), Amlexanox oral (100 mg/kg) and saline 
I.P. injection (A/S), and Amlexanox oral (100 mg/kg) with Poly I:C (5 mg/kg) I.P. 
injection. Poly I:C significantly increases expression of Cxcl10 mRNA while Amlexanox 
significantly decreases Poly I:C induced expression. Different letters indicate 
significantly different means (ANOVA with Tukey’s multiple comparisons test, p < .05).  
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2.IX. TABLES 
 
 
Table 2.1: Blood alcohol content measurements 
Blood alcohol concentration (mg/dL) at the 0-hour time point. Values are an average of 
two reads. 
 
  
Sample	# mg/dL
1 13.3
2 10.1
3 12.2
4 5.6
5 9.7
7 11.0
8 7.8
9 15.1
10 11.1
11 18.2
13 18.7
14 7.0
15 15.6
16 5.3
17 8.2
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Table 2.2: Taqman Assay IDs 
 
Taqmanâ Gene Expression Assay IDs used for RT-qPCR 
 
  
Gene	Name Gene	Expression	Assay
Cd14 Mm00438094_g1
Cd68 Mm03047343_m1
Cxcl10 Mm00445235_m1
Gapdh Mm99999915_g1
Gfap Mm01253033_m1
Gusb Mm03003537_s1
Hprt Mm01545399_m1
Ikbkb	(Ikkb) Mm01222247_m1
Ikbke	(Ikki) Mm00444862_m1
Il1b Mm00434228_m1
Il6 Mm00446190_m1
Irak1 Mm01193538_m1
Irak4 Mm00459443_m1
Irf3 Mm00516784_m1
Irf7 Mm00516793_g1
Itgam	(Cd11b) Mm00434455_m1	
Myd88 Mm00440338_m1
Tbk1 Mm00451150_m1
Ticam1	(Trif) Mm00844508_s1
Tlr2 Mm00442346_m1
Tlr3 Mm01207404_m1
Tlr4 Mm00445273_m1
Tlr7 Mm00446590_m1
Tnf Mm00443258_m1
Traf3 Mm00495752_m1
Traf6 Mm00493836_m1
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Table 2.3: Antibodies used for western blots and immunohistochemistry 
Antibody names, manufacturers, and dilution information for (a) western blot primary 
antibodies, (b) western blot secondary antibodies, (c) immunohistochemistry primary 
antibodies, and (d) immunohistochemistry secondary antibodies. 
(a)	Primary	antibodies	used	for	western	blots
(b)	Secondary	antibodies	used	for	western	blots
(c)	Primary	antibodies	used	for	Immunohistochemistry
Antibody Manufacturer Catalog	# Host Dilution Diluant Detergent
IKKi	(M-17) Santa	Cruz sc-5693 Goat 1:50 1X	PBS 0.1%	Triton
IRF-3	(FL-425) Santa	Cruz sc-9082 Rabbit 1:50 1X	PBS 0.1%	SDS
Antibody Manufacturer Catalog	# Host Dilution Diluant
β-Actin Sigma A1978 Mouse 1:10,000 5%	NFDM
CD68 Abcam ab31630 Mouse 1:1000 5%	NFDM
GAPDH	(FL-335) Santa	Cruz sc-25778 Rabbit 1:5000 5%	NFDM
GFAP Invitrogen 18-0063 Rabbit 1:5000 5%	NFDM
Iba1 Wako 019-19741 Rabbit 1:1000 5%	NFDM
IKKi	(M-17) Santa	Cruz sc-5693 Goat 1:200 5%	NFDM
IKKβ	(P-20) Santa	Cruz sc-34673 Goat 1:200 5%	NFDM
IL-1β Santa	Cruz sc-7884 Rabbit 1:200 5%	NFDM
IRAK-1	(H-273) Santa	Cruz sc-7883 Rabbit 1:200 5%	NFDM
IRF-3	(FL-425) Santa	Cruz sc-9082 Rabbit 1:200 5%	NFDM
MYD88	(HFL-296) Santa	Cruz sc-11356 Rabbit 1:200 5%	NFDM
p-IRAK-1 Santa	Cruz sc-130197 Rabbit 1:200 5%	BSA
TLR2	(H-175) Santa	Cruz sc-10739 Rabbit 1:200 5%	NFDM
TLR3	 Enzo ALX-210-367-R200 Rabbit 1:500 5%	NFDM
TLR4	(25) Santa	Cruz sc-293072 Mouse 1:200 5%	NFDM
TRAF6	(H-274) Santa	Cruz sc-7221 Rabbit 1:200 5%	NFDM
Antibody Manufacturer Catalog	# Dilution
goat	anti-rabbit	IgG-HRP Santa	Cruz sc-2301 1:1000
goat	anti-mouse	IgG-HRP Santa	Cruz sc-2302 1:1000
donkey	anti-goat	IgG-HRP	 Santa	Cruz sc-2020 1:1000
(d)	Secondary	antibodies	used	for	Immunohistochemistry
Antibody Manufacturer Catalog	# Dilution Diluant
Alexa	Flour	488	goat-anti-rabbit Thermo	Scientific	 A-11034 1:1000 1X	PBS
Alexa	Flour	568	donkey-anti-goat Thermo	Scientific	 A-11057 1:1000 1X	PBS
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Table 2.4: Summary of mRNA and protein changes 
 
Effects of chronic ethanol on mRNA and protein levels in the (a) PFC, (b) the NAc and 
the (c) AMY were examined 0 and 24 hours after ethanol removal. Effects are shown as 
increases, decreases, or no change (-); blank cells indicate that mRNA or protein was not 
measured. Gene names are indicated in the left column, and the numbers in parenthesis 
indicate fold change compared to control group. PFC, prefrontal cortex; NAc, nucleus 
accumbens; AMY, amygdala; IHC, immunohistochemistry.  
0	hour 24	hour 0	hour 24	hour
Tlr2 − −
Tlr3 − ê 	(0.87)
Tlr4 − ê 	(0.87)
MyD88-dependent	pathway	signaling	molecules
Myd88 − −
TRIF-dependent	pathway	signaling	molecules
Trif − −
Ikki − − − ê 	(0.88)
Irf3 − − − é 	(1.15)
Il1b é 	(3.25) −
Cxcl10 − ê 	(0.37)
AMY
Toll-like	Receptors
Cyotkines	and	Chemokines
mRNA protein-IHC
0	hour 24	hour 0	hour 24	hour
Tlr2 − é 	(1.26)
Tlr3 − é 	(2.12)
Tlr4 − é 	(1.49)
Tlr7 é 	(1.15) −
Cd14 − é 	(1.19)
Myd88 é 	(1.07) −
Irak1 − −
pIrak1
Irak4 é 	(1.19) −
Ikkb − −
Trif − é 	(1.23)
Ikki é 	(1.17) − é 	(1.08) é 	(1.24)
Irf3 − é 	(1.56) − é 	(1.68)
Irf7* é 	(1.18) −
Traf3* − −
Traf6 − −
Il1b é 	(4.45) −
Tnfa − −
Il6 − é 	(1.58)
Cxcl10 é 	(2.11) −
Ccl5 * *
Ifnb * *
Cd11b/	 − é 	(1.26)
Gfap − −
Cd68 ê 	(0.89) −
PFC
mRNA protein-	IHC
Molecules	involved	in	both	pathways
TRIF-dependent	pathway	signaling	molecules
MyD88-dependent	pathway	signaling	molecules
Toll-like	Receptors	and	Co-receptors
Glial	Markers
Transcriptional	outputs	of	the	TRIF-dependent	pathway
Transcriptional	outputs	of	MyD88-dependent	pathway
(a)	mRNA	and	protein	changes	in	PFC (b)	mRNA	and	protein	changes	in	NAc
(c)	mRNA	and	protein	changes	in	AMY
0	hour 24	hour 0	hour 24	hour
Tlr2 − −
Tlr3 − é 	(1.15)
Tlr4 − −
MyD88-dependent	pathway	signaling	molecules
Myd88 − −
TRIF-dependent	pathway	signaling	molecules
Trif − −
Ikki − − é 	(1.05) é 	(1.36)
Irf3 − − é 	(1.10) é 	(1.31)
Il1b é 	(4.24) −
Cxcl10 − −
NAc
mRNA protein-IHC
Toll-like	Receptors
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3.I. ABSTRACT 
Innate immune signaling in the brain has emerged as contributor to many CNS 
pathologies, including mood disorders, neurodegenerative disorders, neurodevelopmental 
disorders, and addiction. Toll-like receptors (TLRs), a key component of the innate 
immune response, are particularly implicated in neuroimmune dysfunction. However, most 
of our understanding about TLR signaling comes from the peripheral immune response, 
and it is becoming clear that the CNS immune response is unique. One controversial aspect 
of neuroimmune signaling is which CNS cell types are involved. Although microglia are 
the CNS cell-type derived from a myeloid lineage, studies suggest that other glial cell types 
and even neurons express TLRs, although this idea is controversial. Furthermore, recent 
work suggests a discrepancy between RNA and protein expression within the CNS. To 
elucidate the CNS cell-type localization of TLRs and their downstream signaling 
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molecules, we isolated microglia and astrocytes from the brain of adult mice treated with 
saline or the TLR ligand lipopolysaccharide (LPS). Glial mRNA expression was compared 
to a cellular-admixture to determine cell-type enrichment. Enrichment analysis revealed 
that most of the TLR pathway genes are localized in microglia and increased in microglia 
following immune challenge. However, expression of Tlr3 was enriched in astrocytes 
where it increased in response to LPS. Furthermore, attempts to determine protein cell-type 
localization revealed that many antibodies are non-specific and that antibody differences 
are contributing to conflicting localization results. Together these results highlight the cell 
types that should be looked at when studying TLR signaling gene expression and suggest 
that non-antibody approaches need to be used to accurately evaluate protein expression.  
3.II. INTRODUCTION 
Innate immune signaling has been well characterized in the body for decades, but 
the recent appreciation for its role in the brain has raised several questions. In particular, 
it has brought to light the similarities and differences between the immune response in the 
periphery and the central nervous system (CNS). At the center of this discussion, are 
microglia, the resident immune cells of the brain. However, there is evidence that 
microglia have unique functions unrelated to immune signaling, and that other CNS cells 
can also participate in the immune response.  
A key component of innate immunity is Toll-like receptors (TLRs), a family of 
pattern recognition receptors that detect and respond to pathogen and danger signals. 
TLRs respond to a variety of bacterial and viral pathogens including the bacterial 
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endotoxin lipopolysaccharide (LPS), which is a ligand for TLR4 (Kawai & Akira 2007). 
In response to LPS, TLR4 with its co-receptor cluster of differentiation 14 (CD14) can 
signal through two distinct pathways, the Myeloid differentiation primary response 
protein 88 (MyD88)-dependent pathway and the TIR-domain containing adaptor protein 
inducing IFNb (TRIF)-dependent pathway (Takeda & Akira 2004) (Fig. 3.1). The 
MyD88-dependent pathway signals through Interleukin 1 receptor associated kinases 1 
and 4 (IRAK1 and IRAK4) and TNF receptor associated factor 6 (TRAF6) leading to 
activation of inhibitors of nuclear factor Kappa B Kinases (IKKs) (Kawai & Akira 2007). 
Activation of IKKs causes activation of NF-kB and the production of pro-inflammatory 
cytokines (e.g. TNF, IL-1b, IL-6). In contrast, the TRIF-dependent pathway utilizes the 
adaptor protein TRIF and signals through TRAF3, TBK1, and IKKe leading to 
phosphorylation and activation of interferon regulatory factor 3 (IRF3) (Takeda & Akira 
2005). Activated IRF3 translocates to the nucleus where it leads to the transcription of 
type I interferons and interferon inducible genes (e.g. IFN-b, CCL5/RANTES, 
CXCL10/IP-10).  
TLR signaling has been implicated in several CNS conditions, including 
ischemia, neurodegeneration, depression, and addiction (García Bueno et al. 2016; 
Gąsiorowski et al. 2017; Gambuzza et al. 2014; Gesuete et al. 2014; Crews et al. 2017; 
Hanke & Kielian 2011). However, the cell-type localization of TLR signaling within the 
CNS remains controversial and impairs our understanding and ability to develop 
treatments based on these signaling pathways. TLR signaling was originally 
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characterized in peripheral immune cells, thus, it was believed that CNS expression of 
TLRs would be limited to microglia, the immune cells of the brain. Several studies 
support microglial expression of TLRs, and many reaffirm the idea that expression is 
completely or mostly microglial  (Bsibsi et al. 2002; Lehnardt et al. 2002; Olson & S. D. 
Miller 2004; Hanke & Kielian 2011). However, recent studies suggest that TLRs are also 
expressed and functionally important in other glial cells like astrocytes and 
oligodendrocytes (Kielian 2006; Gorina et al. 2010; Borysiewicz et al. 2013; Park et al. 
2005; Blanco et al. 2005; Marinelli et al. 2015; Lehnardt et al. 2002; Bsibsi et al. 2002) or 
even non-glial CNS cells like neurons (Xing-Jun Liu et al. 2016; Aurelian et al. 2016; 
Peltier et al. 2010; Préhaud et al. 2005; Qi et al. 2011; Crews et al. 2013). These results 
are complicated by differences in methodology across studies, including differences in: 
protein or mRNA; in vivo, primary cells or in established cell lines; species; and 
techniques. Interestingly, there seems to be disagreement between mRNA and protein 
expression for the same molecule, which raises many questions. For example, a brain 
RNA expression database shows Tlr4 as highly microglial (Y. Zhang et al. 2014), while 
the human protein atlas (proteinatlas.org) shows it only detected in neurons (Uhlén et al. 
2015). Several other TLR signaling molecules (MyD88, IRAK1, TRIF, IRF3) also show 
highest mRNA expression in microglia, but highest protein expression in neurons.  
Although many studies have reported the localization of TLRs in the CNS, few 
have evaluated the expression of the downstream signaling molecules and pathway 
outputs that are responsible for functional changes. It is also remains unclear how 
immune activation might change cell-type expression of TLR signaling in vivo, as most 
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studies have evaluated the response to TLR agonists using cultured cells (Lawrimore & 
Crews 2017; Marinelli et al. 2015; Rosenberger et al. 2014; Hanke & Kielian 2011; June 
et al. 2015). Recent studies suggest that established cell-lines and even primary cultured 
glial cells don’t accurately reflect the expression profile in vivo (Butovsky et al. 2013). 
Although this discrepancy may seem esoteric, it is a major hindrance to the study 
of neuroimmune signaling. In our lab alone, we have had several problematic studies 
because it was unclear which cell type to use for a conditional knockout or viral vector, 
or a gene was knocked out in microglia but couldn’t be verified on the protein level 
because of neuronal expression. These uncertainties not only result in wasted time and 
money, but delay the discovery of important results. Given the key role of TLR signaling 
in CNS pathologies, and the desire to manipulate and understand these pathways in the 
brain, it is imperative that cell-type localization of these molecules is determined and 
agreed upon.  
Based on the disagreement in the field and preliminary results that suggested 
TLR-signaling mRNAs are localized in microglia while protein is localized in neurons, 
we sought to investigate TLR signaling localization using glial cells isolated from adult 
mouse brain. The goals of this study were to identify the cell-type enrichment of TLR 
pathway mRNAs and proteins with and without immune activation (LPS treatment) and 
to determine which cells exhibit expression changes following activation. There is 
literature supporting the idea of that cell-type protein expression can change after LPS 
(Béchade et al. 2014), so we hypothesized that key mRNAs will be abundant in microglia 
so to allow rapid translation into protein in response to immune activation. Our results 
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revealed that mRNA was primarily microglial, although there were some differences in 
expression profiles, and that LPS increased mRNA expression in microglia. In contrast, 
our protein results were inconclusive due to non-specific antibodies and conflicting 
results across antibodies for the same protein. Based on our results, we conclude that 
much of the disagreement in the field is due to antibody failures, and that better 
antibodies or alternative methods need to be developed to conclusively determine protein 
localization in brain cells.    
3.III. MATERIALS AND METHODS 
3.III.a. Ethics Statement 
All procedures were approved by the University of Texas at Austin Institutional 
Animal Care and Use Committee (animal protocol number AUP-2013-00061) and 
adhered to the NIH Guidelines. The University of Texas at Austin animal facility is 
accredited by the Association for Assessment and Accreditation of Laboratory Animal 
Care.  
3.III.b. Animals and LPS administration  
Studies were conducted in adult (6-8 weeks old) C57Bl/6J male mice (Jackson 
Laboratories, Bar Harbor, ME). Mice were individually housed and allowed to acclimate 
to upright bottles one week before the start of the experiment. The experimental rooms 
were maintained at an ambient temperature of 21±1°C, 40-60% humidity, and a regular 
light/dark schedule (7 AM-7 PM). Food and water were available ad libitum. The mice 
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were divided into 3 groups, each containing 7 LPS treated mice and 5 saline treated mice 
(additional mice were put in the LPS group in case of death before 24 hours) (Fig. 3.2). 
The mice were weighed and had water intake measured for 2 days prior to injection and 
then were injected with either LPS (2.0 mg/kg) or saline. Mice were weighed and water 
intake was measured 24-hours post-injection and the mice were sacrificed. Weight and 
water consumption data is provided in Figure 3.3.  
3.III.c. Knockout Animals  
Knockout (null mutant) mice for TLR2, TLR4, and MyD88 are described in 
(Blednov et al. 2017). Briefly, the TLR2 knockout mouse was B6.129S1-Tlr2tm1Dgen/J 
(Jackson Laboratories, Bar Harbor, ME) which has a neomycin cassette inserted in the 
gene making it non-functional (Werts et al. 2001). The TLR4 knockout mouse was 
B6.B10Scn-Tlr4lps-del/JthJ (Jackson Laboratories), which has the locus containing the Tlr4 
gene deleted (Poltorak et al. 1998). The MyD88 knockout mouse was B6.129P2(SJL)-
MyD88tm1.1Defr/J (Jackson Laboratories), and is a cross of Myd88tm1Defr mice (loxP sites 
flanking exon 3 of Myd88) with Tg(Zp3-cre)93Knw mice (Hou et al. 2008). RT-qPCR 
was used to determine the transcript expression in the knockout mice (Fig. 3.4). The 
TLR4 knockout mouse showed no transcript expression, consistent with previous studies 
(Poltorak et al. 1998).  The MyD88 knockout mouse showed decreased expression of 
MyD88, likely due the fact that only exon 3 is removed and the primers are not on exon 3. 
The TLR2 knockout mouse showed increased expression of Tlr2, which is consistent 
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with a larger transcript being produced due to the neomycin cassette (Wooten et al. 
2002).  
3.III.d. Tissue Harvest and microglial isolation  
5 mice per group were perfused with ice-cold saline and the brain was removed 
(each group was performed on a different day). The dissected tissue was pooled by 
treatment within group (ie. all of group 1 saline samples were combined, see Fig. 3.2). 
The reason for pooling samples was to get enough microglia to get enough cells for both 
qPCR and western blots. Approximately 1% of the minced tissue was taken as a total 
homogenate (TH) sample that includes all cell types. The total homogenate was further 
divided into 10% for RNA and 90% for protein and centrifuged at 1000 x g for 10 
minutes at 4°C. The supernatant was removed and the cells were flash frozen in liquid 
nitrogen. The remaining sample was used for microglial isolation as described by 
Nikodemova et al. 2015. Briefly, tissue suspension was enzymatically dissociated using 
the Neural Tissue Dissociation Kit- Papain (Miltenyi Biotec, Germany) in conjunction 
with Pasteur pipette manual dissociation. Dissociated tissue was passed through a 70 µM 
strainer (Miltenyi Biotec), centrifuged at 300 x g, then resuspended in 30% percoll 
(Sigma-Aldrich, St. Louis, MO). The percoll-cell suspension was centrifuged at 700 x g 
for 15 minutes at room temperature with the myelin fraction removed from the top 
fraction. Cells were washed and then incubated with CD11b MicroBeads (Miltenyi 
Biotec) and eluted using MS columns to collect CD11b+ cells.  Cells were again divided 
(10% for RNA and 90% for protein) and CD11b+ cell pellets were collected by 
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centrifugation at 300 x g for 10 minutes at 4°C and then flash frozen. The CD11b- 
fraction was also spun down and the pellet was resuspended in astrocyte-binding ACSA2 
MicoBeads (Miltenyi Biotec). The ACSA2+ fraction was collected as the CD11b+ 
fraction was, and the remaining negative fraction (CD11b/ACSA2-) and the astrocyte 
fraction (ACSA2+) were divided (10% for RNA, 90% for protein), spun down and pellets 
were flash frozen.  
 
3.III.e. RNA Isolation and qPCR  
RNA was isolated from all four fractions (TH, CD11b+, ACSA2+, 
CD11b/ACSA2-) using the MagMax-96 Total RNA Isolation Kit (Thermo Fisher 
Scientific Inc., Rockford, IL).  The RNA yield was quantified on a NanoDrop 1000 
spectrophotometer and assessed for quality on an Agilent 2200 TapeStation (Agilent 
Technologies, Santa Clara, CA). RNA was reverse transcribed into cDNA using the 
Applied Biosystems High-Capacity cDNA Reverse Transcription Kit (Thermo Fisher 
Scientific Inc.). cDNA was tested for genomic DNA contamination and showed at least a 
10 Cq difference between the +RT (reverse transcription) and –RT samples (Bustin et al. 
2009). Applied Biosystems TaqMan® Gene Expression Assay (Thermo Fisher Scientific 
Inc.) primers were used, and specific assay IDs are shown in Table 3.1. RT-qPCR 
reactions were performed using SsoAdvanced™ Universal Probes Supermix (BioRad, 
Hercules, CA) in 10-μL reactions containing 250 pg of cDNA. All reactions were 
performed in technical triplicates for each biological replicate and included a negative no-
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template control. Samples were normalized to 18s and relative expression was 
determined using the CFX software (BioRad). 
3.III.f. Protein isolation and western blots  
Cells or Tissue were homogenized in lysis buffer (150 mM NaCl, 50 mM Tris-
HCl pH 7.4, 1 mM EDTA, 1% Triton-X-100, 1% sodium deoxycholic acid, 0.1% SDS, 
1X Halt Protease and Phosphatase Inhibitor Cocktail (Thermo Fisher Scientific Inc.), 
rocked for 30 minutes at 4°C, centrifuged for 10 minutes at 10,000 x g, aliquoted, and 
frozen at -80°C. HEK-293 cells were kindly provided by Dr. Mihic’s laboratory. Cells 
were washed with cold PBS, scraped and washed with lysis buffer, and processed as 
described above.  Protein concentrations were determined using the DC Protein Assay 
(Bio-Rad). Cell lysates (20 μg for fractions, 40 ug for antibody tests) were boiled for 5 
minutes, run on 4-15% Mini-Protean TGX Precast Gels (Bio-Rad), and transferred to 
PVDF membranes using semi-dry transfer. All fraction blots contained a control sample 
(mouse whole brain lysate) for normalizing across blots. Membranes were blocked with 
5% dried milk in TBST (Tris-buffered saline with 0.5% Tween-20) and incubated 
overnight at 4°C with primary antibody (Table 3.2). Membranes were washed with 
TBST and incubated with HRP-conjugated secondary antibodies in 5% dried milk in 
TBST (Table 3.2). Bands were visualized using ECL (Pierce) and imaged on film and 
using G:BOX Chemi XX6 (Syngene, Cambridge, UK). Attempts were made to identify a 
loading control that was equal across all cell types, but every loading control examined 
showed differences in expression across fractions.  
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3.III.g. Combined Fluorescent in situ hybridization and immunohistochemistry  
Protocol adapted from Exiqon miRCURY microRNA ISH Optimization Kit. Mice 
were transcardially perfused with 4% paraformaldehyde (PFA), and the brains were post 
fixed overnight in 4% PFA at 4°C and transferred to 30% Sucrose overnight at 4°C. 
Brains were fresh frozen and coronally sectioned on a cryostat (20uM). Free-floating 
sections were post-fixed in 10% NBF overnight at room temperature. After three 1x PBS 
washes (3 minutes per wash), slices were hybridized with a double DIG-labeled custom 
Locked Nuclei Acid (LNA) probe (Exiqon) for 1 hour at appropriate hybridization 
temperature (Table 3.3). Following hybridization, slices were washed in 5x SSC, 1x SSC 
(2 times), and 0.2x SSC (2 times) at same temperature as hybridization for 5 minutes per 
wash. After a final 0.2x SSC wash at room temperature for 5 minutes, slices were 
blocked with blocking solution (1x PBS, 0.1% Tween-20, 2% donkey serum, and 1% 
BSA) at room temperature for 15 minutes. Slices were then incubated in anti-DIG 
antibody (for mRNA probe) and appropriate primary antibody for protein of choice 
(Table 3.3) overnight at 4°C. All antibodies were diluted in antibody solution (1x PBS, 
0.05% Tween-20, 1% donkey serum, and 1% BSA). After 3 1x PBS-T (0.1%) washes (3 
minutes per wash), appropriate secondary antibodies were applied to the slices and 
allowed to incubate at room temperature for 1.5 hours. After three final 1x PBS washes 
(10 minutes per wash), Finally, slices were mounted on charged slides and counterstained 
with DAPI (Fluoromount-G, Southern Biotech). Slides were visualized on a Zeiss 
Axiovert 200M Fluorescent Microscope and analysis was completed on Photoshop CC5 
(Adobe) and ImageJ. Probe and antibody information is found in Table 3.3. 
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3.III.h. Immunohistochemistry  
Brains were prepared as stated above and free floating sections were placed into 
PBS. Sections were permeabilized in detergent (.1% Triton-X-100) and blocked in 10% 
goat or donkey serum for 1 hour at room temperature. Antibody treatment and mounting 
was performed as described above. Antibody information is in Table 3.3. 
3.III.i. Statistical Methods 
RT-qPCR data was analyzed with a 2-way analysis of variance (ANOVA) and 
Tukey’s multiple comparisons test.  
3.IV. RESULTS 
3.IV.a. Fraction mRNA cell-type enrichment 
Four fractions were collected from the saline and 24-hour LPS treated samples: 
TH (total homogenate), CD11b+ (microglial fraction), ACSA2+ (astrocyte fraction), and 
CD/AC- fraction (cells remaining after isolation of microglia and astrocytes, referred to 
as the negative fraction). RT-qPCR was performed using cell-type markers to determine 
the cell-type enrichment for each of these fractions (Fig. 3.5). Cd11b/Itgam was used as a 
marker for microglia and expression was found to be highly expressed in the CD11b+ 
fraction, lowly expressed in the TH, and absent in the ACSA2+ and CD/AC- fractions 
(Fig. 3.5A). Glast/Slc1a3 was used as an astrocyte marker and was found to be lowly 
expressed in the TH and highly expressed in the ACSA2+ fractions under saline 
conditions (Fig. 3.5B). Neun was used as a neuronal marker and was expressed at high 
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levels in the TH and low levels in the CD/AC- fraction, expression was absent in the 
CD11b+ and ACSA2+ fractions (Fig. 3.5C). The reason for the lack of neuronal markers 
in the negative fraction is that adult neurons don’t survive the isolation procedure well, 
therefore, the TH taken before isolation contains the most neurons. Tek was used as a 
marker for endothelial cells and was highly expressed in the CD/AC- fraction and lowly 
expressed in the TH, CD11b+ fraction and ACSA2+ fraction (Fig. 3.5D). Tek expression 
decreased significantly in the CD/AC- fraction following LPS. Cd68 was used as a 
marker of activated microglia and was highly expressed in the CD11b+ fraction and 
increased following LPS treatment (Fig. 3.5F).  
 
3.IV.b. Tlr mRNA cell-type localization and LPS response 
qPCR was used to evaluate the expression of the most widely studied Tlrs, Tlr2, 
Tlr3, Tlr4, and the TLR4 co-receptor, Cd14. Under basal conditions, expression of Tlr2, 
Tlr4 and the co-receptor Cd14 was primarily localized to microglia, as evidenced by the 
high SAL-CD11b+ expression compared to SAL-TH expression (Fig. 3.6). In response to 
LPS, Tlr2 and Cd14 expression increased in microglia, 4-fold and 2.6-fold respectively. 
Alternatively, Tlr4 expression decreased by approximately 50% in microglia following 
LPS (Fig. 3.6C). In contrast to Tlr2, Tlr4, and Cd14, Tlr3 was expressed in all fractions, 
with highest expression in astrocytes. In response to LPS, Tlr3 expression increased in 
astrocytes, but not in any of the other fractions (Fig. 36B). No Tlr expression changes 
were detected in the total homogenate.  
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3.IV.c. MyD88-dependent pathway mRNA localization and LPS response 
To determine localization and LPS response, mRNA expression of components of 
the MyD88-dependent pathway (Myd88, Irak1, Irak4, Traf6, and Ikkb), as well as 
cytokines produced in response to MyD88-pathway activation (Il1b, Il6, Tnf) was 
measured (Fig. 3.7). While all MyD88-dependent pathway genes were expressed highest 
in microglia under basal conditions, the expression patterns were variable. Myd88 and 
Irak4 displayed low basal expression in other fractions, while Irak1, Traf6, and Ikkb were 
expressed at greater than 50% of the expression level of microglia, suggesting expression 
in astrocytes and endothelial cells as well. In contrast, the cytokines were almost 
exclusively expressed in microglia (Fig. 3.7F-H). In response to LPS, Myd88 expression 
increased in microglia while Irak4 decreased (Fig. 3.7A, C). Interestingly Traf6 
increased in astrocytes and the CD/AC- fraction while Irak1 trended towards an increase 
in astrocytes (p=.02 in t-test but not significant when corrected for multiple comparisons). 
Both Il1b and Tnf increased in microglia following LPS administration, however, Tnf 
increasing almost 14-fold. In contrast, Il6 expression did not increase in microglia, but 
trended towards an increase in astrocytes and the CD/AC- fraction (p = .04 astrocytes and 
p= .03 CD/AC-, uncorrected t-test) (Fig. 3.7G). 
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3.IV.d. TRIF-dependent pathway mRNA localization and LPS response 
Expression of TRIF-dependent pathway components (Trif, Traf3, Ikki, Irf3) and 
outputs (Ifnb, Ccl5, Cxcl10) were measured under basal conditions and in response to LPS 
to allow comparison with the MyD88-dependent pathway (Fig. 3.8). Trif and Irf3 had 
similar basal expression profiles with highest expression in microglia, but Irf3 was enriched 
in the astrocyte fraction and in the negative fraction as well and Trif showed modest 
expression in all fractions. Traf3 and Ikki were expressed relatively evenly across the 
fractions under basal conditions, although Ikki trended towards highest expression in 
astrocytes (p<.0001 using 1-way ANOVA for saline group). Under basal conditions, Ifnb, 
Ccl5, and Cxcl10 are virtually undetectable in all fractions except for some Ccl5 expression 
in microglia and some Cxcl10 expression in microglia and astrocytes. In response to LPS, 
Trif and Irf3 expression decreased in microglia, while Traf3 expression decreased in the 
TH. In contrast, Ikki showed 23.5-fold increase in expression following LPS.  Like Ikki, 
Ifnb and Ccl5 increased in microglia, while Cxcl10 trended towards an increase in 
microglia and astrocytes (p=.052).   
3.IV.e. Antibody validation in knockout tissue and HEK-293 cells 
Knockout mice for TLR2, TLR4, and MyD88 were available in the lab, so they 
were used to test the specificity of the antibodies for those proteins (Fig. 3.9). In addition, 
HEK-293 cell lysates were used for validation because these cells should not express 
TLR2, TLR3, TLR4, or IL-1b (www.proteinatlas.org) (Uhlén et al. 2015). Testing with 
the TLR2 antibody revealed expression in wild-type brain tissue, HEK-293 cells, and 
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TLR2 knockout tissue, suggesting non-specific binding (Fig. 3.9A). The TLR3 antibody 
showed strong expression (although at a lower molecular weight than expected) in the 
WT brain tissue, and no expression in the 293 cells (Fig. 3.9B). Two TLR4 antibodies 
were tested and both produced signal in the 293 lysates and in the TLR4 knockout tissue 
(Fig. 3.9C-D). Furthermore, the TLR4 (76B357.1) antibody appeared to run at a lower 
molecular weight than anticipated, although there were multiple bands that appeared at 
different molecular weights in each lysate (Fig. 3.9C). The IL-1b antibody produced a 
strong signal in the 293 lysates, suggesting it is also non-specific (Fig. 3.9E). Five 
MyD88 antibodies from 2 different companies were tested in MyD88 knockout tissue 
(Fig. 3.9F-J). All 5 antibodies produced a signal in the knockout tissue, and sc-74532 
appeared at the incorrect molecular weight, indicating that none of these antibodies were 
specific. These tests suggested that most the antibodies that we tested were non-specific, 
and made us skeptical of the ones we could not test in knockout tissue. Responses from 
the antibody vendors indicated that antibodies were never tested against negative 
controls, only against blocking peptides.  
3.IV.f. Fraction protein localization in western blots 
Because antibody specificity could not be verified, full replicates of western blots 
were not performed and thus, not quantified. However, sample western blot images for 
each antibody are shown in Fig. 3.10 to demonstrate the variety of expression profiles 
and how different antibodies to the same protein produce different results (Fig. 3.10).  
First, as with qPCR, cell-type marker expression was evaluated in the lysates using 
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antibodies for NEUN (neuronal marker), GFAP (astrocyte marker), and IBA1(microglial 
marker) (Fig. 3.10A). Differences in markers between qPCR and western blots were due 
to antibody availability and efficacy. Consistent with the qPCR data, NEUN was present 
in high amounts in the control sample and the total homogenate sample, but not in other 
fractions. GFAP was expressed in the control sample and the TH, but expressed highest 
in the astrocyte fraction, like the qPCR results. IBA1 was expressed very strongly in 
microglia and could be seen in the control and TH after a much longer exposure that left 
the microglial expression overexposed. These findings are consistent with the qPCR data 
which shows that expression of microglial markers is over 50x higher in the microglial 
fraction than the TH.  
Despite the determination that many of the antibodies were non-specific, 
localization of TLR protein and IL-1b was investigated to see if these results mirrored 
some of the confusing data in the literature suggesting non-microglial localization (Fig. 
3.10B). Even though Tlr2 mRNA expression was predominantly microglial, TLR2 
protein was detected in every fraction except microglia. TLR3, which was found to be 
microglial and astrocytic on the mRNA level, was found exclusively in the TH on the 
protein level, suggesting neuronal localization. TLR4 and IL1b were highly expressed in 
microglia on the mRNA level, but were expressed in all fractions on the protein level. 
Furthermore, IL-1b expression was lowest in microglia. These data suggest that studies 
detecting neuronal localization of TLRs, despite microglial mRNA, may be due to non-
specific antibodies.  
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Because we had so many antibodies that claimed to detect MyD88, this presented 
an opportunity to compare localization of the same protein using different antibodies 
(Fig. 3.10C). MyD88 (sc-11356) was expressed only in the TH, suggesting neuronal 
expression. In contrast, ab2064 and ab2068 were expressed in all fractions, although 
highest in microglia and in the negative fraction. MyD88 (sc-8197) gave such strange 
results with vastly different molecular weight bands across the fractions, that is was not 
included. MyD88 (sc-74532) was not used because tests revealed that the signal was at 
the wrong molecular weight (Fig. 3.9H).  These results were particularly concerning 
because every antibody tested in the knockout was non-specific and different antibodies 
produced different results. 
The rest of the MyD88-pathway produced equally confusing results. Like TLR2, 
IRAK1 protein was expressed in every fraction except microglia. TLR4 showed highest 
expression in the TH, but faint expression in other fractions at a slightly lower molecular 
weight. For TRAF6 we had two antibodies from the same company, sc-8409 (monoclonal 
mouse) and sc-7221 (rabbit polyclonal). Both antibodies produced several bands (Fig. 
3.10E), making it difficult to determine what signal was real. TRAF6 should run at 60 
kD, which corresponds to the middle band on the sc-8409 blot and top and on the sc-7221 
blot. Based on these bands, expression appears to be highest in the TH and the astrocyte 
fraction. IKKb was primarily localized to the TH (Fig. 3.10F), which is consistent with 
the neuronal localization seen in immunohistochemistry data from our lab (Truitt et al. 
2016), but inconsistent with the qPCR data.   
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Protein expression evaluation was limited for the TRIF-dependent pathway (due 
to antibody challenges) and expression of IRF3 and IKKe was determined (Fig. 3.10G-
H). IRF3 was expressed in all fractions, but highest expression was in the negative 
fraction. IKKe was evaluated using 2 antibodies, sc-5693 (goat polyclonal) and sc-
376114 (mouse monoclonal). IKKe sc-5693 is a very weak antibody, but detected some 
protein in the control sample and total homogenate (the bands in the astrocyte fraction are 
suspected to be bleed through). IKKe (sc-376114) is supposed to be expressed at 80 kD, 
which corresponds to the top band, however, the multiple bands raise concerns.  
 
3.IV.g. Protein and RNA expression in tissue sections 
Several of the proteins evaluated with western blot have also been investigated in 
brain tissue using immunohistochemistry with the same or different antibodies. An 
example of these are shown in Figure 3.11. Immunohistochemistry reveals highly 
neuronal expression in tissue for MyD88 (sc-8197), IRAK1 (sc-7883), and TRAF6 (sc-
7221). These results are relatively consistent across TLR-pathway antibodies that have 
been tested in our lab (high neuronal staining). Interestingly, attempts to look at Irf3 
mRNA expression also suggested neuronal localization (Fig. 3.12). Because we knew 
that Irf3 mRNA should be in microglia, we tested a microglial marker, Tmem119 
(Bennett et al. 2016), using the same protocol. Tmem119 also failed to express in 
microglia (Fig 3.12C-D), suggesting that there may be a permeability issue when 
targeting glial cells in tissue, resulting in high background staining in neurons. It is worth 
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noting that Irf3, which is more heterogeneous across cell types showed a much stronger 
neuronal signal than Tmem119, which should only be in microglia. This suggested to us 
that the small amount of Irf3 localized in neurons was all we could detect, while the 
detected neuronal Tmem119 was just background due to increased probe concentrations.  
 
3.V. DISCUSSION 
TLR signaling is a key component of the innate immune response and it 
contributes to many brain disorders, including alcohol use disorders. However, the cell-
type specific response to immune stimuli in the CNS remain unclear. Identification of the 
cell-type localization of TLR signaling and immune response within the brain is 
necessary to elucidate the functional implications of perturbed signaling and to design 
future studies with in vivo manipulations.  To address this, we used isolated glial cells 
from adult mice that been administered either saline or LPS. Using four distinct cell-
fractions, we evaluated the mRNA expression of TLRs, their downstream signaling 
molecules, and the transcriptional outputs of their signaling (Table 3.4, Fig. 3.13). In 
addition, we tried to profile the protein expression of TLR signaling molecules. 
Unfortunately, we were not able to draw any conclusions about the protein localization, 
but we have identified reasons why there may be disagreement in the field.  
Although expression of mRNA from the TLR signaling pathway was primarily 
microglial as expected, there were extremely variable expression profiles within the 
pathways. This is consistent with gene expression data from adolescent (P17) mice in the 
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RNA-Seq transcriptome database (Y. Zhang et al. 2014). While expression of Tlr2, Tlr4, 
and Cd14 were highly microglial, expression of Tlr3 was highest in astrocytes, where 
expression increased in response to LPS. These findings are consistent with several 
studies that have shown Tlr3 to be expressed and functional in astrocytes (Park et al. 
2005; Scumpia et al. 2005; Borysiewicz et al. 2013; Jack et al. 2005) as well as a study 
that shows in vitro LPS increases Tlr3 expression in primary astrocyte cultures while 
decreasing Tlr3 expression in primary microglial cultures (Marinelli et al. 2015). TLR3 
signals through the TRIF-dependent pathway, however, the components of the TRIF-
dependent pathway showed varied expression and LPS responses. This raises the 
question of how signaling molecules within a pathway could be expressed in different 
cell types. Although Trif and Irf3 expression is highest in microglia, there is still 
significant expression in astrocytes, and Ikki expression trends towards being mostly 
astrocytic under basal conditions. Therefore, it is possible that signaling is occurring in 
both cell-types and that the mRNA expression of the receptor and its signaling molecules 
are not 1:1 within the cell. Furthermore, microglial Trif and Irf3 expression decrease 
following LPS, while Ikki expression increases, suggesting they are independently 
regulated. This is supported by the involvement of Ikki in other LPS-responsive pathways 
(e.g. JAK/STAT signaling), that could have different cell-type specificity.  
It is surprising that the expression of Ifnb and Ccl5 is exclusively microglial. 
There is a trend towards increased expression of Cxcl10 in both astrocytes and microglia 
after LPS, suggesting that the TRIF-dependent pathway is being activated and inducing 
downstream signaling in both cell types. This raises the question of how expression of 
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Cxcl10 is increased without Ifnb there to induce it. It is possible that interferon-inducible 
genes are produced in response to IFNb in microglia, but changed in a different manner 
in astrocytes which lack a macrophage lineage. Astrocytes produce interferon in a TLR3 
and TLR4 dependent manner in vitro (Reinert et al. 2012; Pascual-Lucas et al. 2014), but 
it is possible that astrocytes respond differently in vivo. It is also plausible that the 
inflammatory response is temporally mediated within cell-type, and that increased 
expression of interferons would be detected in astrocytes if evaluated earlier or later. It is 
noteworthy that TLR4 also signals through the TRIF-dependent pathway and is highly 
microglial, so perhaps TLR3 signaling is predominant in astrocytes, while TLR4-induced 
TRIF dependent signaling dominates in microglia leading to the increased Ifnb, Ccl5, and 
Cxcl10 seen in the CD11b+ fraction.   
Expression of components of the MyD88 pathway were highest expressed in 
microglia, consistent with expression of Tlr2 and Tlr4, which signal through the MyD88-
dependent pathway. However, although Tlr2 and Tlr4 expression was highly enriched in 
microglia, some components of the MyD88-dependent pathway (Irak1, Traf6, Ikkb) were 
more evenly distributed across the fractions and Traf6 expression increased in the 
astrocyte fraction following LPS. The different expression profiles could be because 
Traf6 can also be activated via TRIF in response to TLR3 or TLR4, and is involved in 
other pathways like TGF-b signaling. Ikkb is also involved in every pathway that signals 
to NF-kB, not just TLR pathways. Consistent with the notion that MyD88-dependent 
signaling is mostly occurring in microglia, Il1b, Il6, and Tnf expression were primarily 
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microglial. However, there is a trend towards an increase in Il6 seen in astrocytes and the 
CD/AC- negative fraction in response to LPS. There is evidence that Il6 is also activated 
in response to LPS and TRIF-dependent signaling in cultured astrocytes(Marinelli et al. 
2015; Jack et al. 2005), so it is possible that TRIF-dependent increases in Il6 expression 
occur in astrocytes in vivo. 
It is worth noting that although several robust changes were observed in response 
to LPS within the cell fractions, none were observed in the total homogenate, which is the 
typical preparation for evaluation of gene expression. This highlights the importance of 
looking at discrete cell types when evaluating immune changes in the brain, particularly 
because expression could be decreasing in one cell type while increasing in another (as 
seen with Tlr3). A caveat to this is that even whole brain samples had to be pooled to get 
enough RNA for RT-qPCR. Because of this, any brain-region specific changes are 
missed and the statistical power is reduced. Furthermore, the primers used for RT-qPCR 
are designed to target a single exon-exon junction, so exon level expression and splice 
variants may be missed. 
Although expression of mRNA and protein is not always 1:1, we were unable to 
find any examples in the literature of all the mRNA residing in one cell-type while all the 
protein is in another cell-type. Because this is what our preliminary data suggested, we 
sought to test our hypothesis that many copies of mRNA were found inside microglia to 
ensure rapid translation in response to danger signals, although this hypothesis did not 
address why protein was found in neurons. After this study, we are just as unclear, if not 
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more, about the protein localization of TLR signaling molecules. However, we do have 
some thoughts as to what is causing this confusion.  
The western blots we performed show incredibly variable expression profiles, but 
the most concerning result is that several TLR signaling proteins do not appear to be 
expressed in microglia (TLR2, TLR3, MyD88 sc-11356, Irak1, IKKb), even though all of 
them show microglial mRNA expression and most show highest expression in microglia. 
However, after some quality control steps, we are unable to trust any of the protein 
results. For the antibodies we could test, all but one showed expression in the negative 
control. For the antibodies we were unable to test on null mutant tissue, we erred on the 
side of caution and assumed they are also non-specific. Furthermore, different antibodies 
to the same protein gave very different expression profiles (Fig. 3.9C), reaffirming that 
the antibodies cannot be trusted. We suspect that antibody specificity is one of the major 
reasons for disagreement in the field. Even though other researchers have told us that 
TLR antibodies are notoriously non-specific among, they continue to be used in 
publications and these results continue to be cited as accurate. Even resources like the 
human protein atlas use antibodies to determine cell type localization (Uhlén et al. 2015). 
For example, the data for MyD88 in the human protein atlas suggests that protein is 
highly neuronal, but RNA expression is mostly glial. Interestingly, the antibody they use 
is sc-11356, which I found to be non-specific (Fig. 3.8F). They do provide information 
about the antibody validation, but they are basing the validation on comparison of 
staining in one tissue type (colon) to the literature.  
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It isn’t surprising that antibodies are non-specific given that most manufacturers 
only validate them in transfected cell lines or with blocking peptide. Some companies, 
when asked, could not even suggest a negative control and claimed it would be too 
difficult to test all antibodies on knockout tissue. Unless this practice changes, every lab 
needs to test the antibody in their hands with positive and negative controls to be 
confident their results are accurate. Due to the difficulty of testing several antibodies for 
each protein, other approaches may be better suited for looking at several proteins at 
once. Proteomic approaches in glial cells have revealed protein changes that more closely 
match what is expected (Bell-Temin et al. 2013). Alternatively, construction of transgenic 
mice with GFP-tagged expression of TLR genes may be useful to show the CNS cell-type 
localization.   
In addition to our western blots, our immunohistochemistry and in situ results 
suggest that glial cells are less likely to be permeable to probes or antibodies. Therefore, 
more stringent permeabilization steps may be needed to detect intracellular molecules in 
glia. Although we attempted different permeabilization steps using the Exiqon protocol, 
we continued to see neuronal localization. However, using the RNAscopeÒ (Advanced 
Cell Diagnostics, Inc., Newark, CA) protocol, we could identify Tmem119 in microglia. 
In addition, we can see microglial staining with immunohistochemistry using the IBA1 
antibody (Wako), but several other microglial antibodies don’t work well. This further 
suggests that some antibodies are better able to get through the cell membrane, and this 
idea has been acknowledged in other studies (Melvin & Sutherland 2010).  
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In conclusion, this study confirms and expands on mRNA cell-type localization of 
TLR signaling molecules and evaluates cell-type specific increases following LPS 
administration. This study was unable to reliably determine the protein localization of 
TLR signaling molecules, and we suggest this is due to non-specific antibodies and 
problems with permeabilization. We suggest that future studies evaluating cell-type 
expression take these results into account and that perhaps other non-antibody approaches 
be used to determine the protein localization of this important pathway in the CNS.  
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3.VII. FIGURES 
 
Figure 3.1: TLR-signaling pathways 
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Figure 3.1: Continued  
 
Lipopolysaccharide (LPS) is recognized by TLR4 and its co-receptors MD2 and CD14. 
TLR4 signals through two different pathways, the MyD88-dependent pathway and the 
TRIF-dependent pathway. The MyD88-dependent pathway utilizes the adapter protein 
MyD88, which recruits IRAK4, IRAK1, and TRAF6. Phosphorylation of IRAK1 and 
ubiquitination of TRAF6 leads to activation of IKKs and NF-kB. Activated NF-kB 
translocates to the nucleus where it promotes transcription of pro-inflammatory cytokines. 
TLR2 also signals through the MyD88-dependent pathway. The TRIF-dependent pathway, 
utilized by TLR3 and TLR4, signals through the adapter protein TRIF. TRIF recruits 
TRAF6 and TRAF3. Signaling through TRAF6 leads to NF-kB activation, while signaling 
through TRAF3 utilizes IKKe to activate IRF3. Activated IRF3 translocates to the nucleus 
where it leads to transcription of Type I interferons and interferon inducible genes.  
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Figure 3.2: Schematic of study methods 
The mice were divided into three subgroups, each containing 5 mice per treatment. Mice 
were injected with either saline or 2 mg/kg LPS and sacrificed 24-hours later. The whole 
brain was removed and tissue was pooled within each group by treatment yielding 3 
biological replicates per treatment. 1% of minced tissue was taken as total homogenate 
and the remaining tissue was used to isolate microglia (Cd11b+) and astrocytes (Acsa2+). 
The remaining cells (Cd11b/Acsa2-) were also collected. 10% of each sample was used 
for RNA isolation and RT-qPCR and 90% was used for protein isolation and western 
blots.    
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are flushed out. Removal of 
MicroBeads is not required. The 
positively selected cells are 
immediately ready for further 
experiments.
Figure 1 The principle of MACS Cell Separation. Positive selection is shown as an example. For depletion 
the undesired cells are magnetically labeled and retained within the column during separation. The target 
cells f low through and are collected as non-labeled fraction. 
MACS® Technology— 
setting standards in cell separation
The gold standard in cell separation—a 
hallmark MACS® Technology has evolved 
int  since its ntroduction in 1989. Isolate 
any cell type from any species, fast and easy, 
with more than 250 cell separation reagents. 
A pivotal addition to the expanding 
portfolio are the products for isolation of 
neural cells.
Benefit from the gold standard
Specific—cell separation by MACS Technology 
is bas d on cell labeling with high y specific 
monoclonal antibodies, which recognize cell 
type–specific antigens on the cell surface. 
These antibodies ar  coupled to nanosized 
superparamagnetic particles. 
 
Easy—the conjugates of antibodies and 
magnetic particles, i.e., MACS MicroBeads, 
allow for eas  magnetic cell isolation 
(see fig. 1). 
Fast—the separation procedure takes as little 
as 30 minutes to complete and cells are ready 
for immediate use in downstream applications, 
such as flow cytometry or cell culture. 
Safe—MACS MicroBeads are non-toxic and 
biodegradable; removal of MicroBeads is not 
required. 
Gentle—the gentle separation process yields 
viable and functionally active cells. 
Reliable—MACS Cell Separation is highly 
reliable, achieving consistently optimal 
recoveries and purities.
Cell separation strategies
Positive selection—target cells can be 
isolated through positive selection (fig. 1) by 
magnetically labeling the desired target cell 
type.
Depletion—unwanted cells can be removed by 
magnetic labeling and subsequent separation 
from the unlabeled target cells. 
Both separation strategies can easily be com-
bined for the isolation of cell subpopulations.
MACS MicroBeads for indirect 
magnetic labeling
In addition to direct magnetic labeling using 
cell type–specific MicroBeads, researchers have 
the option to use a monoclonal or polyclonal 
primary antibody that recognizes a cell type–
specific epitope of choice for cell separation. 
The primary antibody can be unconjugated, 
biotinylated, or f luorochrome-conjugated. 
Miltenyi Biotec provides MicroBeads that
specifically recognize the antibody of choice 
resulting in indirect magnetic labeling of the 
desired cell type. 
For detailed information visit
www.macscellseparation.com
Target cell labeled with 
MACS MicroBead
MACS Separator MACS Column
7PMt  MACS & more4 www.miltenyibiotec.com/neuroscience
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Figure 3.3: Weights and water consumption after LPS 
Data verifying the effect of LPS treatment. A. All 3 LPS groups showed decreased weight 
following injection, data points are averages of 5 mice. B. All 3 LPS groups decreased 
water consumption following LPS injection, data points are averages of 5 mice. 
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Figure 3.4: Knockout mouse qPCR 
RT-qPCR on knockout mouse brain compared to wild type (C57/Bl6J). A. TLR4 knockout 
tissue showed no Tlr4 mRNA expression. B. TLR2 knockout tissue showed an increase in 
Tlr2 expression. C. MyD88 knockout tissue showed a decrease in Myd88 expression. * is 
p value < 0.05, 2-tailed t-test, n =10 per group. 
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Figure 3.5: Cell-type marker mRNA expression 
qPCR analysis of cell-type marker expression in the four fractions. A. The microglial 
fraction was highly enriched for the microglial marker Cd11b and Cd11b was absent in 
the astrocyte and negative fraction. B. The astrocyte fraction was highly enriched for the 
astrocyte marker Glast, and expression of Glast was extremely low or absent in the 
microglial and negative fractions. C. The total homogenate had high expression of the 
neuronal marker Neun. Neun was absent from the microglial and astrocytes fractions and 
was expressed in low levels in the negative fraction. D. The endothelial cell marker Tek 
was highly expressed in the negative fraction and lowly expressed in the other three 
fractions. Tek expression decreased with LPS in the negative fraction. E. The activated 
microglial marker Cd68 was highly expressed in the microglial fraction, and lowly 
expressed in the other fractions. Cd68 expression increased with LPS in the microglial 
fraction. 2 bars with the same letter are not statistically different, 2 bars with no letter in 
common are statistically different (2-way ANOVA with Tukey’s test for multiple 
comparisons, p < .05). 
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Figure 3.6: TLR mRNA expression 
Fraction localization and LPS expression changes for Toll-like receptors and co-receptors 
measured by qPCR. A. Tlr2 is expressed primarily in the microglial fraction and 
expression increases with LPS. B. Tlr3 is enriched in both microglia and astrocytes 
compared to the TH, with higher expression in astrocytes. Astrocyte Tlr3 expression 
increased with LPS. C. Tlr4 expression is highly microglial and decreases following LPS. 
D. Cd14 is highly enriched in microglia and increases with LPS. 2 bars with the same 
letter are not statistically different, 2 bars with no letter in common are statistically 
different (2-way ANOVA with Tukey’s test for multiple comparisons, p < .05). 
SAL
LPS
TH
CD
11
b+
AC
SA
2+
CD
/A
C-
0.0
0.5
1.0
1.5
Tlr2
Fraction
R
el
at
iv
e 
no
rm
al
iz
ed
 e
xp
re
ss
io
n
a a
b
c
a a a a
TH
CD
11
b+
AC
SA
2+
CD
/A
C-
0.0
0.5
1.0
1.5
2.0
Tlr3
Fraction
R
el
at
iv
e 
no
rm
al
iz
ed
 e
xp
re
ss
io
n
a ae
b
be
a
ab
c
d
TH
CD
11
b+
AC
SA
2+
CD
/A
C-
0.0
0.5
1.0
1.5
2.0
Tlr4
Fraction
R
el
at
iv
e 
no
rm
al
iz
ed
 e
xp
re
ss
io
n
a a
b
c
a a a a
TH
CD
11
b+
AC
SA
2+
CD
/A
C-
0.0
0.5
1.0
1.5
Cd14
Fraction
R
el
at
iv
e 
no
rm
al
iz
ed
 e
xp
re
ss
io
n
c
b
a a a a a a
A B
C D
 126 
 
Figure 3.7: MyD88-dependent pathway mRNA expression 
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Figure 3.7: Continued  
 
Fraction localization and LPS expression changes for components and outputs of the 
MyD88-Dependent Pathway, measured by qPCR. A. MyD88 is highest enriched in the 
microglial fraction and increases with LPS. B. Irak1 is highest enriched in the microglial 
fraction, but present in moderate levels (expression is 50% or more than that of microglia) 
in all other fractions. Irak1 expression increases in microglia with LPS. C. Irak4 expression 
is highly enriched in microglia under basal conditions, and decreases in microglia after 
LPS. D. With saline, Traf6 is enriched in the microglial fraction, but present in moderate 
levels in all other fractions. With LPS, Traf6 expression increases in the astrocyte fraction 
and the negative fraction. E. Ikkb expression was highest in microglia, but expressed in 
moderate levels in all other fractions. No significant expression changes were seen after 
LPS treatment. F. Expression of Il1b is only detected in microglia and increases with LPS. 
G. Expression of Il6 is only detected in microglia with saline, but is detected in all other 
fractions after LPS. H. Tnf was only detected in the microglial fraction and increased 
following LPS. 2 bars with the same letter are not statistically different, 2 bars with no 
letter in common are statistically different (2-way ANOVA with Tukey’s test for multiple 
comparisons, p < .05). 
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Figure 3.8: TRIF-dependent pathway mRNA expression 
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Figure 3.8: Continued  
 
Fraction mRNA localization for components and outputs of the TRIF-Dependent 
Pathway in saline and LPS treated animals. A. Trif was highest expressed in the 
microglial fraction with saline and decreased with LPS. B. Traf3 expression was 
relatively even across the fractions, with only significant difference being between the 
TH and the astrocyte fraction. There were no significant changes with LPS.  C. Ikki 
expression was not significantly enriched in any fraction with saline, but was highest in 
astrocytes. With LPS, expression increased in the microglial fraction. D. Irf3 expression 
was highest in the microglial fraction, but was also significantly enriched over the TH in 
the astrocyte fraction and negative fraction. E. Ifnb was not detected in any fractions with 
saline, but was expressed in microglia with LPS. F. Expression of Ccl5 was expressed in 
low amounts in microglia with saline, but was detected in the TH with LPS and increased 
in microglia. G. Cxcl10 was expressed in low levels in the microglial and astrocyte 
fractions with saline, but was detected in all fractions with LPS, although none of the 
changes were significant. 2 bars with the same letter are not statistically different, 2 bars 
with no letter in common are statistically different (2-way ANOVA with Tukey’s test for 
multiple comparisons, p < .05). 
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Figure 3.9: Antibody validation 
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Figure 3.9: Continued  
 
Antibody tests in negative controls. A. The TLR2 antibody produces a signal in HEK-293 
cells and TLR knockout tissue, neither of which should express TLR2. B. The TLR3 
antibody only produced signal in the WT tissue. C/D: Both TLR4 antibodies produced 
signal in the HEK-293 cells and the TLR4 knockout tissue, neither of which should 
express TLR4. E. The IL-1b antibody produced a signal in the HEK-293 cells, which 
should not express IL-1b. F-J. All five MyD88 antibodies produced a signal in the 
MyD88 knockout tissue. 
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Figure 3.10: Protein expression in fractions 
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Figure 3.10: Continued  
 
Protein measurement in fraction western blots. A. Cell-type specific antibodies verify cell-
type enrichment in the fractions. NEUN, a neuronal marker, is expressed in the control 
sample and the total homogenate. GFAP, an astrocytic marker, is expressed in low levels 
in the TH and higher levels in astrocytes. IBA1, a microglial maker, is expressed in 
microglia. B. Expression for TLR2 appears to be in all fractions except microglia, while 
TLR3 is only detected in the TH, and TLR4 and IL-1b are detected in all fractions C. 
Blotting with 3 different MyD88 antibodies produced different results. Sc-11356 suggested 
MyD88 is only expressed in the total homogenate, while ab2064 and ab2068 show 
expression in all fractions, with highest expression in microglia and the negative fraction. 
D. IRAK1 shows expression in all fractions except microglia and IRAK4 shows expression 
in all fractions, but highest expression in the TH. E. Two different TRAF6 antibodies 
produce multiple bands and different results. Based on predicted molecular weight, both 
antibodies show highest expression in the TH and lowest expression in microglia. F. IKKb 
showed expression in the TH and light expression in the negative fraction. G. IRF3 was 
detected in all fractions, but highest in the negative fraction. H. Two antibodies were used 
to evaluate IKKe. Sc-5693 gave signal only in the TH while Sc-376114 produced signal in 
all cell types. 
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Figure 3.11: Immunohistochemistry for MyD88, IRAK1, and TRAF6 
Immunohistochemistry evaluation of MyD88, IRAK1, and TRAF6 expression in the 
mouse cortex revealed co-localization with the neuronal maker NEUN. 
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Figure 3.12: In situ hybridization for Irf3 and microglial marker 
In situ hybridization compared mRNA expression with cell-type markers. A. Irf3 mRNA 
shows little overlap with the microglial marker IBA1. B. Irf3 mRNA shows high overlap 
with the neuronal marker NEUN. C. Tmem119, a microglial marker, shows little overlap 
with IBA1. D. Tmem119 shows high overlap with the neuronal marker NEUN.  
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Figure 3.13: Summary of mRNA enrichment and LPS response 
Microglial and astrocyte cell-type enrichment (compared to TH) is shown for TLR 
pathway genes in saline and LPS treated mice. The font size of each gene indicates fold-
enrichment, with larger sizes meaning larger fold-enrichment. Colors on the LPS side 
denote whether that gene changed in that cell type with LPS treatment. Red indicates 
increased gene expression while blue denotes decreased gene expression.  
Figure created using http://servier.com/Powerpoint-image-bank 
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3.VIII. TABLES 
 
Table 3.1: Taqman gene expression assays used for RT-qPCR 
 
  
Gene	Name Gene	Expression	Assay
18s 4333760T
Ccl5 Mm01302427_m1				
Cd14 Mm00438094_g1
Cd68 Mm03047340_m1
Cxcl10 Mm00445235_m1
IFNb Mm00439552_s1
Ikbkb	(Ikkb) Mm01222247_m1	
Ikbke	(Ikke) Mm00444862_m1
Il1b Mm00434228_m1
Il6 Mm00446190_m1
Irak1 Mm0119538_m1
Irak4 Mm00459443_m1
Irf3 Mm00516784_m1
Itgam	(Cd11b) Mm0434455_m1	
Myd88 Mm00440338_m1
Rbfox3	(Neun) Mm01248781_m1	
Slc1a3	(Glast) Mm00600697_m1
Tek Mm00443243_m1
Ticam1	(Trif) Mm00844508_s1
Tlr2 Mm00442346_m1
Tlr3 Mm01207404_m1
Tlr4 Mm00445273_m1
Tnf Mm00443258_m1
Traf3 Mm00495752_m1
Traf6 Mm0493836_m1
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Table 3.2: Antibodies used for western blots 
Primary	Antibodies	for	Westerns
Antibody Manufacturer Catalog	# Host Dilution Diluant predicted	MW
GFAP Invitrogen 18-0063 Rabbit 1:5000 5%	NFDM 50	kD
Iba1 Wako 019-19741 Rabbit 1:1000 5%	NFDM 17	kD
IKKi	(M-17) Santa	Cruz sc-5693 Goat 1:200 5%	NFDM 80	kD
IKKβ	(P-20) Santa	Cruz sc-34673 Goat 1:200 5%	NFDM 87	kD
IL-1β Santa	Cruz sc-7884 Rabbit 1:200 5%	NFDM 31	kD
IRAK-1	(F-4) Santa	Cruz sc-5288 Mouse 1:200 5%	NFDM 80	kD
IRF-3	(FL-425) Santa	Cruz sc-9082 Rabbit 1:200 5%	NFDM 50	kD
MYD88	(HFL-296) Santa	Cruz sc-11356 Rabbit 1:200 5%	BSA 33	kD
TLR2	(H-175) Santa	Cruz sc-10739 Rabbit 1:200 5%	NFDM 90-100	kD
TLR4	(25) Santa	Cruz sc-293072 Mouse 1:200 5%	NFDM 95/120	kD
TRAF6	(H-274) Santa	Cruz sc-7221 Rabbit 1:200 5%	NFDM 60	kD
TLR3 Enzo ALX-804-362-C100 Mouse 1:1000 5%	NFDM 117	kD
TLR4 Novus 76B357.1 Mouse 1:500 5%	NFDM 95	kD
MyD88	(F-19) Santa	Cruz sc-8197 Goat 1:200 5%	NFDM 33	kD
MyD88	(E-11) Santa	Cruz sc-74532 Mouse 1:200 5%	NFDM 33	kD
MyD88	 Abcam Ab2064 Rabbit 1:1000 5%	NFDM 33	kD
MyD88 Abcam Ab2068 Rabbit 1:1000 5%	NFDM 33	kD
NeuN Abcam ab177487 Rabbit 1:10,000 5%	NFDM 34	kD
Traf6	(D10) Santa	Cruz sc-8409 Mouse 1:200 5%	NFDM 60	kD
IRAK4 Cell	signaling 4363 Rabbit 1:1000 5%	BSA 55	kD
IKKI	(A-11) Santa	Cruz sc-376114 Mouse 1:200 5%	NFDM 80	kD
Secondary	Antibodies	for	Westerns
Antibody Manufacturer Catalog	# Dilution
goat	anti-rabbit	IgG-HRP Santa	Cruz sc-2301 1:1000
goat	anti-mouse	IgG-HRP Santa	Cruz sc-2302 1:1000
donkey	anti-goat	IgG-HRP	 Santa	Cruz sc-2020 1:1000
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Table 3.3: IHC and in situ antibodies/probes 
A. Antibodies used for immunohistochemistry in figure 3.10. B. Probes used for in situ 
hybridization in figure 3.11. C. Antibodies used for in situ hybridization in figure 3.11.   
Protein
Primary	antibody	
and	dilution
Secondary	antibody	
and	dilutionIba1 Anti-IBA1;	1:1000	(WAKO) Donkey	anti	rabbit	(488);	1:1000	(Life	Technologies	#)NeuN Anti-NeuN;	1:1000	(Millipore	#MAB377) Donkey	anti	mouse	(488);	1:1000	(Life	Technologies	#)
B
C
Primary	Antibodies	for	Immunohistochemistry
Antibody Manufacturer Catalog	# Host Dilution Diluant
IRAK-1	(H-273) Santa	Cruz sc-7883 Rabbit 1:50 2%	Goat	Serum
MyD88	(F-19) Santa	Cruz sc-8197 Goat 1:250 2%	Donkey	Serum
TRAF6	(H-274) Santa	Cruz sc-7221 Rabbit 1:50 2%	Goat	Serum
NEUN Millipore MAB377 Mouse 1:500 2%	Goat/Donkey	Serum
Secondary	Antibodies	for	Immunohistochemistry
Antibody Manufacturer Catalog	# Dilution
Alexa	Fluor	568	donkey	anti-goat	 Thermo	Scientific A-11057 1:1000
Alexa	Fluor	488	donkey	anti-mouse	 Thermo	Scientific A-21202 1:1000
Alexa	Fluor	594	goat	anti-mouse	 Thermo	Scientific A-11042 1:1000
Alexa	Fluor	488	goat	anti-rabbit Thermo	Scientific A-11034 1:1000
mRNA Custom	Probe	
Sequence
Probe	Label Probe	
Concentration
Probe	
Hybridization	
Temperature
Primary	antibody	
and	dilution
Secondary	
antibody	and	
dilutionIrf3 AGA	CTG	AGC	CTT	GTA	GAA	TAA 5’	and	3’	DIG 100nM 54°C Anti-DIG;	1:500	(Roche	#	11	333	089	001) Donkey	anti	sheep	(594);	1:1000	(Life	Technologies	#)Tmem119 5’	and	3’	DIG 120nM 54°C Anti-DIG;	1:500	(Roche	#	11	333	089	001) Donkey	anti	sheep	(594);	1:1000	(Life	Technologies	#)
A
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Table 3.4: Summary of qPCR data  
 
 
 
 
 
 
 
 
gene
primary	
localization	
with	SAL
fold	
enrichment	
over	TH	(SAL)
primary	
localization	
with	LPS
fold	
change	
over	TH	
(LPS)
change	in	
TH	with	LPS
change	in	
CD	with	
LPS
change	in	
AC	with	
LPS
change	in	
CD/AC-	
with	lps
Tlr2 Cd11b+	 8 Cd11b+ 32 ↑	4.0
Acsa2+	 8
Cd11b+ 5
Tlr4 Cd11b+	 25 Cd11b+ 18 ↓0.53
Cd14 Cd11b+ 75 Cd11b+ 21 ↑	2.6
Myd88 Cd11b+	 9 Cd11b+	 6 ↑	1.4
Irak1 Cd11b+	 2.5 Cd11b+ 2.5
Irak4 Cd11b+	 8 Cd11b+ 12 ↓0.64
Acsa2+ 2.5
CD/AC- 2
Cd11b+ 3
Acsa2+ 2
Il1b Cd11b+	 not	detected	
in	TH
Cd11b+ 90 ↑	1.6
Il6 Cd11b+ not	detected	
in	TH
Cd11b+ 3.3
Tnf none	significant Cd11b+	 277 ↑	13.7
Trif Cd11b+ 5 Cd11b+ 4 ↓0.73
Traf3 none	significant ↓0.62
Ikki none	significant Cd11b+ 6 ↑	23.5
Cd11b+ 4 Cd11b+ 7
Acsa2+			 3 Acsa2+ 2.5
CD/AC-	 2 CD/AC- 2.5
Ifnb none	
significant
Cd11b+
not	
detected	in	
TH
only	
detected	
with	LPS
Ccl5 none	significant Cd11b+	 13 ↑	36.5
Cxcl10
none	
significant
3
Irf3 ↓.79
2.5
Ikkb Cd11b+
MyD88-Dependent	Pathway
TRIF-Dependent	Pathway
Toll-like	Receptors	and	CD14
Tlr3 Acsa2+ 8 ↑	1.5
↑	2.1Traf6 Cd11b+ ↑	2.1
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Table 3.4: Continued  
 
Summary of 24 hour LPS qPCR data. Colors indicate fraction, with the microglial 
fraction being shown in teal, the astrocyte fraction in yellow, and the negative fraction in 
orange. Primary localization with SAL is determined by fraction enrichment compared to 
the total homogenate under saline conditions, with fold-enrichment shown in the next 
column. Primary localization with LPS is determined by fraction enrichment compared to 
the total homogenate with LPS treatment, with fold change shown in the next column. 
Change in each fraction with LPS is determined by comparing expression in that fraction 
with saline to expression in that fraction with LPS, with direction and fold-change noted.  
Red indicates increased expression while blue indicates decreased expression. Only 
significant differences are noted (p<.05, 2-way ANOVA with Tukey’s multiple 
comparisons test).  
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Chapter 4: Microglia-specific transcriptome changes following chronic 
alcohol consumption 
Gizelle M. McCarthy, Sean P. Farris, Yuri A. Blednov, R. Adron Harris, and R. Dayne 
Mayfield 
 
4. I. ABSTRACT 
Microglia are fundamentally important immune cells within the central nervous 
system (CNS) that respond to environmental challenges to maintain normal physiological 
processes. Alterations in steady-state cellular function and over-activation of microglia 
can facilitate the initiation and progression of neuropathological conditions such as 
Alzheimer’s disease, Multiple Sclerosis, and Major Depressive Disorder. Alcohol 
consumption disrupts signaling pathways including both innate and adaptive immune 
responses that are necessary for CNS homeostasis.  Coordinate expression of these genes 
is not ascertained from an admixture of CNS cell-types, underscoring the importance of 
examining isolated cellular populations to reveal systematic gene expression changes 
arising from mature microglia. Unbiased RNA-Seq profiling was used to identify gene 
expression changes in isolated prefrontal cortical microglia in response to recurring bouts 
of voluntary alcohol drinking behavior. The voluntary ethanol paradigm utilizes long-
term consumption ethanol that results in escalation and models cortical plasticity seen in 
humans.  Gene coexpression analysis identified a coordinately regulated group of genes, 
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unique to microglia, that collectively are associated with alcohol consumption. Genes 
within this group are involved in toll-like receptor signaling and transforming growth 
factor beta signaling. Network connectivity of this group identified Siglech as a putative 
hub gene and highlighted the potential importance of proteases in the microglial response 
to chronic ethanol.  In conclusion, we identified a distinctive microglial gene expression 
signature for neuroimmune responses related to alcohol consumption that provides 
valuable insight into microglia-specific changes underlying the development of substance 
abuse, and possibly other CNS disorders.  
 
4.II. INTRODUCTION 
Microglia comprise 5% of all cells present within the adult brain (Lawson et al. 
1990) and serve as the principal cell type responsible for innate and adaptive immune 
processes. Mature microglia change morphological and expression profiles to participate 
in CNS homeostasis and respond to pathological insults. 
Acute and chronic substance abuse cause persistent changes in gene expression, which 
can cause functional changes that contribute to maladaptive behavior (Nestler et al. 1993; 
Kerns et al. 2005; Piechota et al. 2010). Neurogenomic studies for substance abuse have 
primarily utilized whole tissue homogenates, representing a mixture of cell-types, 
including neurons, astrocytes, oligodendrocytes, and microglia. These cell types express 
many common genes; however, they each have a unique transcriptional landscape (Cahoy 
et al. 2008; Y. Zhang et al. 2014). While studying the gene expression changes of whole 
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tissue is important to understand communication within a cellular ensemble, this 
approach may fail to discern specific cellular responses occurring within an individual 
cell-type (Lacagnina et al. 2016). Isolated microglial cells have been shown to undergo a 
unique set of gene expression changes associated with aging, neurodegeneration, and 
depression (Chiu et al. 2013; Gonzalez-Pena et al. 2016; Hickman et al. 2013; M. D. Li et 
al. 2015; Vincenti et al. 2016; Orre et al. 2014). Exposure to in vitro alcohol leads to 
microglial activation and the release of specific proinflammatory cytokines, while long-
term alcohol consumption results in microglial activation in rodent models and human 
postmortem brain (He & Crews 2008; Fernandez-Lizarbe et al. 2009). These studies have 
led to the idea that alcohol exposure leads to an inflammatory state which further drives 
ethanol consumption. We hypothesize that microglial gene expression represents an 
important molecular phenotype correlated with alcohol consumption, and that 
characterizing the transcriptome of microglia versus total cell populations will provide a 
framework for the identification of specific alcohol-induced alterations in neuroimmune 
gene expression.    
The prefrontal cortex (CTX) is an important brain region involved in alcohol use 
disorders (AUDs), serving as a key link in both positive and negative affect associated 
with substance abuse (Koob & Volkow 2010). Alcohol exposure triggers a cascade of 
immune-related gene expression changes within adolescent and adult CTX (Osterndorff-
Kahanek et al. 2013) suggesting that microglia may be critical mediators underlying the 
transition from abuse to dependence. We utilized RNA-sequencing to profile the 
transcriptome of isolated microglia in response to voluntary alcohol consumption and 
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identified coordinated gene expression changes that were specific to the microglial cell 
population. These findings support the hypothesis that neuroimmune genes underlie the 
progression of alcohol use to AUDs.   
4.III. MATERIALS AND METHODS 
4.III.a. Ethics Statement 
All procedures were approved by the University of Texas at Austin Institutional 
Animal Care and Use Committee (animal protocol number AUP-2013-00061) and 
adhered to the NIH Guidelines. The University of Texas at Austin animal facility is 
accredited by the Association for Assessment and Accreditation of Laboratory Animal 
Care.  
 
4.III.b. Animals and voluntary ethanol consumption 
Studies were conducted in adult (6-8 weeks old) C57BL/6J (B6) male mice 
(Jackson Laboratories, Bar Harbor, ME). Mice were individually housed and allowed to 
acclimate to upright bottles one week before the start of the experiment. The experimental 
rooms were maintained at an ambient temperature of 21±1°C, 40-60% humidity on a 
regular light/dark schedule, with ad libitum access to food and water. 
An every-other-day 2-bottle choice (EOD-2BC) paradigm (Osterndorff-Kahanek 
et al. 2013) was used with mice randomly assigned to control or alcohol-consumption 
treatment groups. Control and treatment groups each contained 12 mice per group (24 
total). Control animals had daily access to water while treatment groups had every-other-
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day access to both water and a 15% (v/v) alcohol solution (access to water only on non-
treatment days). An empty cage control was used to account for spillage.  Alcohol bottle 
positions were alternated at each exposure to control for potential side preferences. 
Alcohol and water bottles were weighed on treatment days, and animals were weighed 
once per week to calculate consumption. The study concluded after 60 total days (30 
drinking days) and blood alcohol concentrations were determined prior to sacrifice.  
4.III.c. Tissue harvest and microglial isolation 
Mice were sacrificed immediately after the final alcohol drinking session and 
anaesthetized using isoflurane followed by transcardial perfusion with PBS. The CTX was 
dissected as previously described (Osterndorff-Kahanek et al. 2013) and put into cold 
Hank’s Balanced Salt Solution (HBSS). Microglial isolations (Nikodemova & Watters 
2012) were performed by first mincing individual CTX tissue on ice and suspending in 
cold HBSS. Approximately 1% of the minced tissue mixture per sample was taken as a 
total homogenate sample (includes all cell types). Homogenates were centrifuged at 1000 
x g for 10 minutes at 4°C. The supernatant was removed and the cells were flash frozen in 
liquid nitrogen. The remaining minced tissue was used for microglial isolation with 
magnetic bead sorting technology. This method was chosen because it is shown to preserve 
cellular phenotype and RNA integrity as well as result in high purity compared to other 
methods (Nikodemova & Watters 2012; Ju et al. 2015).  Briefly, tissue solution was 
manually dissociated using the Neural Tissue Dissociation Kit (Papain) (Miltenyi Biotec, 
Germany). Dissociated tissue was passed through a 70 µM strainer (Miltenyi Biotec), 
centrifuged at 300 x g, then resuspended in 30% percoll (Sigma-Aldrich, St. Louis, MO). 
The percoll-cell suspension was centrifuged at 700 x g for 15 minutes at room temperature 
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with the myelin fraction removed from the top of the suspended solution. Cells were 
incubated with Cd11b MicroBeads (Miltenyi Biotec) and eluted using MS columns to 
collect Cd11b+ cells. Previous studies have shown that microglial isolation using this 
protocol yields pure microglia and does not perturb gene expression (Nikodemova & 
Watters 2012) (Ju et al. 2015; de Haas et al. 2008). 
 
4.III.d. RNA isolation and PCR validation 
RNA, from individual samples, was isolated using the RNeasy Micro Kit (Qiagen, 
Germany). RNA concentration and quality (RNA integrity number) was determined 
using the Agilent 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA) using the 
Agilent RNA 6000 Pico Kit. All of the examined total homogenate and microglia 
samples met quality-control criterion. There were no significant different differences in 
RNA integrity number (RIN), evaluated based upon the 28S to 18S ratio, between total 
homogenate and microglia samples (P = 0.61). There were no significant differences in 
quality or quantity of microglial RNA between the control and ethanol groups. Total 
RNA was reverse transcribed into cDNA using the Applied Biosystems High-Capacity 
cDNA Reverse Transcription Kit (Thermo Fisher Scientific Inc., Rockford, IL). Applied 
Biosystems Taqman® Gene Expression Assay primers were used for quantitative real-
time PCR (q-rtPCR). Assay ID’s included Mm0434455_m1 (Itgam/Cd11b), 
Mm01253033_m1 (Gfap), Mm01248771_m1 (Rbfox3/Neun), Mm00443243_m1 (Tek), 
Mm00495930_m1 (Ugt8a), and 4333760T (18s). Q-rtPCR reactions were performed 
using SsoAdvanced™ Universal Probes Supermix (BioRad, Hercules, CA) in 10-μL 
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reactions containing 1 ng of cDNA. All reactions were performed in technical triplicates 
for each biological replicate and included a negative no-template control. Q-rtPCR 
reactions were carried out using the CFX384 Real-Time System (BioRad). Samples were 
normalized to 18s and relative expression was determined using the CFX software 
(BioRad). Examining the five cellular makers with Q-rtPCR verified Cd11b positive cells 
were enriched compared to the Cd11b negative fraction and total homogenate (Fig. 4.6).  
4.III.e. RNA Sequencing and Bioinformatics Analysis 
Samples were Poly(A) selected using the Poly(A) Purist Kit (Thermo Fisher 
Scientific Inc.) and prepared using NEBNext® Ultra™ Directional RNA Library 
Preparation Kit (New England BioLabs, Ipswich, MA). Samples were sequenced on the 
NextSeq 500 (Illumina, San Diego, CA) using (75 bp; paired-end reads) to a minimum 
target depth of 20 million reads per sample. Reads were mapped to the mouse reference 
genome (UCSC, mm10) using the alignment tool STAR (Dobin et al. 2013). Raw RNA-
sequencing files were evaluated for quality control using FastQC (0.11.13) and one 
control microglial sample was excluded from further analysis due to low sample quality. 
HTSeq, was used for counting mapped sequencing reads. Expression profiles among 
individual biological replicates within each group were strongly correlated with a mean 
pearson's correlation coefficient of 0.97 for total homogenate (range: 0.93-0.99) and 0.95 
for microglia samples (0.90-0.97). Quantified read counts were normalized and analyzed 
for differential expression using DESeq2 (v 1.10.1), between alcohol drinkers and water 
drinking controls for microglial and homogenate tissue preparations, within the R 
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statistical computing environment (v3.3.1)(Love et al. 2014). Statistical significance was 
assessed using a nominal p-value less than or equal to 0.05; this threshold was selected to 
balance type-1 and type-2 error rates for performing pathway and network analyses.   
 Normalized read counts, scaled according to the library size of individual 
samples, were filtered for non-replicable low-abundance measurements by removing the 
lowest 5% of mean expression occurring in less than 95% of samples. The ratios, of 
major cell-type specific microglial markers Itgam (Cd11b) and Tmem119, using reads per 
kilobase per million mapped reads (RPKM), were compared within and across all groups 
to assess potential confounds of the isolation protocol on transcriptome measurements. 
Itgam and Tmem119 were similar between the TH and Cd11b+ fractions, with an average 
ratio (Cd11b+/TH) of 0.88 ± 0.11. Because Cd11b levels increase with immune 
activation while Tmem119 levels do not (Satoh et al. 2016; Roy et al. 2006), the ratios of 
these two markers remaining similar after isolation suggests that the magnetic-bead 
isolation did not disassociate cellular signatures. Weighted gene coexpression network 
analysis (WGCNA), using filtered log2 transformed expression data, was then applied to 
construct scale-free networks that specify coordinately regulated gene sets (i.e. modules) 
(Langfelder & Horvath 2008). Parameters used for WGCNA were performed in 
agreement with prior specifics used in our laboratory (Farris et al. 2014), including a 
minimum module size equal to 100 genes and a 0.99 tree-cut height. Microglial and total 
homogenate global gene expression correlations were each separately raised to a beta 
value equal to 6, reaching a common scale-free threshold above 0.75 for a signed hybrid 
analysis. The maximal statistical significance for microglial and total homogenate gene 
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set composition was determined using a fishers-exact test, corrected for multiple 
comparisons using a Benjamini & Hochberg false discovery rate (FDR) less than 0.05. 
Individual gene sets were functionally annotated using the web-based software 
application Enrichr  (Kuleshov et al. 2016; E. Y. Chen et al. 2013). Select gene sets, 
based upon statistical and biological significance, were assembled to visualize network 
properties using the bioinformatics tool Cytoscape (v3.4.0) (Shannon et al. 2003). RNA-
Seq data can be accessed under GSE91387. 
 
4.IV. RESULTS AND DISCUSSION 
4.IV.a. Transcriptome profiles of isolated microglia and total homogenate 
Transcriptome profiles of the microglia (Cd11b+) and tissue homogenate (TH) 
from the CTX of individual samples were sequenced to a target depth of 20 million reads. 
A total of 17,377 genes were reliably detected in Cd11b+ samples and 19,876 genes 
detected in TH. Among the two preparations 17,172 genes were commonly expressed, 
with 205 unique transcripts in the Cd11b+ fraction and 2,704 unique transcripts in the 
TH. In agreement with single-cell sequencing of major CNS cell-types (Darmanis et al. 
2015), the microglial population expressed not only a fewer number of genes, but the 
overall expression distribution of detected transcripts was lower in magnitude (Fig. 4.1). 
Although the isolated microglial population is being compared to a cumulative admixture 
of all major CNS cell-types present within CTX, this blunted profile further underscores 
the need for examining a solitary cellular population. Mean expression of genes present 
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in isolated cells versus the mean expression of genes common to TH demonstrates the 
relative enrichment of genes more highly localized to microglia. The cellular marker 
Cd11b+ (Itgam) used for separation of the microglial fraction showed nearly 50 times 
higher abundance relative to TH. Tmem119, an additional microglia-specific marker 
(Satoh et al. 2016; Bennett et al. 2016), was elevated to approximately the same degree as 
Itgam; extending PCR validations (Fig. 4.6) and substantiating the enrichment protocol 
for assessing transcriptome-wide measurements derived from microglia. Consistent with 
the predominant function of microglia, gene ontology analysis of the top 100 microglial-
enriched genes affirmed an over-representation for genes involved in mediating an 
‘inflammatory response’ (GO:0006954) and ‘cytokine receptor binding’ (GO:0005126).  
 
4.IV.b. Differential expression following chronic ethanol consumption 
An every-other-day 2-bottle choice alcohol-drinking paradigm (EOD-2BC) was 
undertaken to evaluate gene expression changes related to chronic alcohol exposure (Fig. 
4.7). EOD-2BC, compared to other voluntary alcohol drinking mouse models, leads to 
escalation of drinking over time and high alcohol consumption (Melendez 2011). 
Previous work has shown that EOD-2BC leads to the greatest number of neuroimmune 
related changes in CTX (Osterndorff-Kahanek et al. 2013); however, a portion of these 
changes may not have been cell-type specific. RNA-Seq of an isolated microglial 
population using EOD-2BC was undertaken to determine the contribution of gene 
expression changes within this cell-type compared to tissue homogenate. Differential 
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gene expression analysis for alcohol drinking exposure respectively identified 1,010 
microglia and 2,461 total homogenate changes (Fig. 4.2). The reduced number of 
changes occurring in microglia is expected given the additional CNS cell-types present 
within the total homogenate.  
Contrasting the gene expression profiles for the two preparations shows isolated 
microglia have a similar range in fold-changes within the CTX due to alcohol (Fig. 4.2a). 
The observed changes are less than two-fold for either microglia or the total homogenate; 
however, labeling the top 20 statistically significant genes shows there are definitive 
biological differences between the experimental conditions due to EOD-2BC alcohol 
consumption. Small fold-change differences in alcohol-induced gene expression, and 
other biological responses, are not uncommon for the CNS (Lovinger & Crabbe 2005).  
Chronic alcohol exposure in B6 mice evokes time-dependent change in gene expression 
(Osterndorff-Kahanek et al. 2015) (Smith et al. 2016), which may not achieve a chronic 
cumulative steady-state of induction suggested for some other drugs of abuse (Hope et al. 
1994). The observed changes in gene expression may serve as a surrogate measure for 
cellular mechanisms activated as a result of EOD-2BC alcohol consumption, with select 
differences that are representative of microglial activation.    
A subset of genes (164 genes in total) is regulated by EOD-2BC in both microglia 
and the total homogenate (Fig. 4.2b). Despite this mutual overlap, 44% of these changes 
(72 genes) occur in opposite directions. Additionally, although a small percentage of 
microglia are present within the total homogenate a total of 864 gene expression changes 
are uniquely discerned in the isolated cells. Alcohol-induced changes within microglia 
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affected a broad spectrum of functional categories, several of which were not enriched 
within the admixture of CNS cell-types. For example, alcohol-induced microglial 
changes were over-represented in genes attributed to ‘TGF-beta receptor signaling’ 
(GO:0007179, P = 9.08 E-05) and ‘chronic inflammatory response’ (GO:0002544, P = 
1.57 E-03). TGF-beta is a cytokine expressed in brain, capable of controlling microglial 
activation and triggering neuroinflammation (Lodge & Sriram 1996). Excessive and 
chronic alcohol abuse modulates similar inflammatory processes in the liver (Dooley & 
Dijke 2012), involving TGF-beta and downstream signaling involving SMAD proteins (P 
= 5.21 E-04). The extent to which these systems are affected within the brain due to the 
alcohol abuse is largely unknown, but corresponding changes in CNS microglial may 
indicate their involvement may extend beyond liver dysfunction in an AUD. Importantly, 
these alterations in gene expression pathways witnessed in the isolated CNS microglial 
population are obscured within the total homogenate. The selective effects registered 
indicates the value of cellular separation to draw upon microglial-specific gene 
expression changes that take place in mouse CTX following alcohol drinking exposure. 
4.IV.c. Gene coexpression networks related to chronic alcohol exposure 
Coordinate expression of multiple genes enables biological function of intricate 
cellular systems. Weighted correlation networks, including all genes within their 
respective cellular populations, were evaluated to distinguish particular subsets of 
coordinately regulated gene expression clusters (i.e. modules). The assayed 
transcriptomes partitioned into 18 microglial modules (MGM) and 19 total homogenate 
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modules (THM) (Fig. 4.8). Each of the individual gene expression modules were 
representative of varied biological categories, demonstrating the utility of this approach 
for delineating transcriptome substructure. Ranking the relative conservation of MGM 
and THM, based upon coinciding genes, illustrates the overall similarity and dissimilarity 
of the two experimental factions (Fig. 4.3).  
Altogether, there are seven MGM and THM duos sharing a significant number of 
common genes. Examining the top seven strongest MGM-THM pairwise relationship 
shows each of these shared overlapping gene sets denote a meaningful intracellular 
group, such as ‘chromatin modification’ (MGM5-THM6, P = 4.21E-03), ‘mitochondrial 
matrix’ (MGM1-THM3, P = 1.70 E-10), and ‘RNA splicing’ (THM16–MGM8, P = 4.60 
E-12). Only one of the MGM-THM pairs, MGM5-THM6, showed evidence of chronic 
alcohol-responsive changes in gene expression; however, the direction of MGM5 change 
was opposite to THM16. Transcriptional regulation through epigenetic modification of 
chromatin is proposed as a major component in neuronal plasticity (Maze et al. 2015). 
DNA methylation alters chromatin structure, affecting persistent regulation of gene 
expression and CNS plasticity. Stimulation of neuronal firing leads to a redistribution of 
DNA methylation (J. U. Guo et al. 2011), suggesting pharmacological interactions 
affecting neuronal activity impacts epigenetic mechanisms of transcriptional regulation.  
Increased expression of genes involved in histone modification after chronic alcohol may 
be a surrogate indicator of epigenomic adaptations in neuronal circuits, or potentially 
other non-microglial cell types (Starkman et al. 2012).  
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EOD-2BC alcohol consumption altered the expression of seven THMs, four of 
which (THM19, THM15, THM13, THM12) were distinctly separate from MGMs. 
Alcohol-induced changes in these THM likely represent molecular processes set apart 
from microglial responses. THM19 is significantly decreased in EOD-2BC mice, 
representing an overall alcohol-driven reduction in kindred genes within CTX. THM19 is 
made-up of a significant number of oligodendrocytes-related genes (P = 3.31 E-03); 
which is the CNS cell responsible for myelinating neuronal axons. Human 
oligodendroglial genes are decreased in human alcoholic CTX (Lewohl et al. 2005), 
featuring cellular adaptations that are potentially conserved between human and mouse 
CTX subjected to repeated alcohol. THM19 is inversely correlated to THM15, 13, and 
THM12; wherein these three THM are intrinsically related with an average rank-based 
intermodule correlation equal to 0.88. THM15, THM13, and THM12 are collectively 
enriched for neuronal gene expression signatures (P = 1.72 E-05).  
Gene expression for MGM5, MGM15, MGM3, and MGM13 are differentially 
regulated by EOD-2BC alcohol consumption. MGM15, MGM3, and MGM13 are by and 
large unrelated to THMs, indicating transcriptome measurements from an admixture of 
CNS cells may fail to notice genes affected by alcohol drinking behavior within these 
MGM groups. Cd11b is an integral membrane-associated protein that is a cellular marker 
of CNS microglia; however, Cd11b is also present on the surface of other monocyte-
derived lineages, including macrophages. Macrophages are capable of invading the CNS, 
sparking neuroinflammation and neurodegeneration (Shemer & Jung 2015). MGM15, 
MGM3, and MGM13 were further assessed for unintended non-microglial cellular gene 
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expression arising from Cd11b+ enrichment. Expression of genes belonging to MGM13 
and MGM15 were indistinguishable from other CNS or immune cell-types. The highest 
mean expression of MGM15 and MGM13 containing genes occurred in macrophage and 
stromal cellular populations (Fig. 4.9). MGM3 encompassing 1,135 genes, showed 
increased expression following EOD-2BC alcohol exposure (Fig. 4.4). MGM3 is 
significantly enriched for microglial-expressing genes involved in immune-related 
signaling systems (Fig. 4.4B). Genes within MGM3 are positively correlated with the 
total amount of alcohol consumed (Pearson r=0.77, P = 0.01). Matching the same genes 
within the total homogenate obscured this correlation with alcohol consumption (Pearson 
r=-0.04, P = 0.88), stressing the importance of isolating a microglial cellular population 
in an animal model of alcohol consumption to unveil a genomic relationship with the 
neuroimmune system. Although additional cell-types are capable of relaying an immune 
response, MGM3 expression was significantly higher in microglia compared to other 
major CNS or immune cell-types (Fig. 4.4C/D). There are several known microglia 
genes within MGM3, including cell-type specific markers Tmem119, Cx3cr1, Aif1 (Iba1), 
suggesting MGM3 expression is mainly restricted to this particular CNS immune cell.  
The top biological processes representative of MGM3 were ‘activation of innate 
immune response’ (GO:0002218) and ‘toll-like receptor signaling pathway’ 
(GO:0002224), which affect alcohol neurotoxicity and consumption (Blednov, 
Benavidez, et al. 2011) (Lippai et al. 2013). The MGM3 coexpression network (Fig. 4.5) 
was constructed to identify specific genes relevant to the interaction of microglia with 
EOD-2BC alcohol consumption.  Central to MGM3 lies sialic acid binding Ig-like lectin 
 157 
H (Siglech). Siglech is a putative marker of isolated microglia (Chiu et al. 2013); which 
modulates type I Interferon secretion associated with microglial activation and 
phagocytosis of glioma cells (Blasius et al. 2006; Kopatz et al. 2013). Brain specific 
expression and function of Siglech has yet to be completely ascertained, however, 
because MGM3 shows ontologies related to TLR signaling, particularly endosomal TLRs 
which promote interferon secretion, it is possible that Siglech is regulating this response 
in brain. Although not all of the genes expressed within MGM3 are individually altered 
in relation to alcohol consumption, there is a dense interrelationship among MGM3 
containing genes that may be important for the observed phenotype. Cathepsin proteases 
Ctsf and Ctss are examples of two MGM3 genes previously shown to causally affect 
multiple behavioral models of alcohol consumption (Blednov, Ponomarev, et al. 2011). 
The presence of Ctsf and Ctss among the most connected genes within the MGM3 
network may suggest there are additional microglial-immune genes involved in alcohol 
consumption that are unaddressed by examining the total homogenate. For example, 
legumain (Lgmn, also known as asparagine endopeptidase or AEP), 16.5-fold enriched 
within microglia, is differentially expressed and correlated with total alcohol 
consumption in the microglial but not in total homogenate. Acting as an asparagine 
endopeptidase, Legumain is important for the cleavage and activation of toll-like 
receptors (Sepulveda et al. 2009). Legumain works in concert with cathepsins on toll-like 
receptors, also expressed within MGM3, to bring about optimum signaling (Ewald & 
Barton 2011). The joint presence of numerous cellular markers alongside genes with 
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shared activity in immune function asserts MGM3 is a microglia-specific gene network, 
which may designate a convergence of an alcohol-responsive microglial signature.     
In addition to highlighting ethanol-induced changes in TLR and immune 
signaling, the changes in MGM3 suggest that ethanol is perturbing microglial TGF-b 
signaling. Specifically, looking at the differentially expressed genes within MGM3 
revealed (Table 4.1) enrichment for transforming growth factor beta receptor signaling 
pathway (GO:0007179) and R-SMAD binding (GO:0070412). Recent studies have 
highlighted the important role of TGF-b in microglial homeostasis and in the regulation 
of immune response. Butovsky et al. found that Tgfb1 was specific to microglia in the 
adult CNS and that treatment of cultured microglia with TGF-b1 resulted in increased 
expression of 60 genes, half of which were identified in MGM3 (Butovsky et al. 2013). 
Furthermore, CNS-TGF-b1 -/- mice had deficits in extracellular glutamate and synaptic 
plasticity, suggesting a key role for TGF-b1 in regulating these processes. Butovsky and 
group also looked at perturbations of microglial molecules that are involved in TGF-b 
signaling and were suppressed in the CNS-TGF-b1 -/- mice. Of the 32 TGF-b signaling 
molecules they detected changes in, 22 (including Ctss, Ctsf) were identified in MGM3, 
further suggesting this module is involved in TGF-b signaling and that TGF-b could be 
regulating the immune changes.  
The perturbation in TGF-b signaling in MGM3 has many functional implications 
for the effects of alcohol on microglia. TGF-b signals to SMADs, and SMAD3  knockout 
mice have impaired immune function, suggesting SMAD signaling is involved in 
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regulating the immune response (X. Yang et al. 1999; Datto et al. 1999). Additionally, 
TGF-b and SMAD levels are altered following brain injury and neurodegeneration 
(Bernhardi et al. 2015; Villapol et al. 2013). Thus, the perturbation in TGF-b signaling 
we observed in microglia could be responsible for the altered immune profile. TGF-b can 
also regulate excitotoxicity (Boche et al. 2003), which is often a consequence of glial 
activation and thought to be a mediator of ethanol-induced neurodegeneration (Vetreno & 
Crews 2014).  
TGF-b signaling is also responsible for controlling important cellular processes 
such as differentiation, maturation, and survival of CNS cells (Villapol et al. 2013). There 
is evidence that ethanol disrupts these processes as ethanol-induced TGF-b1 signaling 
promotes neuronal apoptosis during development (C. P. Chen et al. 2006). In addition, 
TGF-b2 can regulate synaptic transmission (Dobolyi et al. 2012), which indicates that 
altered TGF-b signaling may contribute to alterations in synaptic function in response to 
chronic ethanol. THM13, which was upregulated in response to ethanol, is enriched for 
biological processes related to synaptic plasticity. TGFb is also important for survival of 
dopamine neurons (Roussa et al. 2009), which play an important role in the rewarding 
properties of ethanol. Therefore, altered TGFb signaling could be altering dopamine 
transmission and contributing to the dependent phenotype.  
Although TGF-b has been implicated in ethanol-induced liver injury (Dooley & 
Dijke 2012) and expression is increased in the blood of alcohol dependent subjects (Kim 
et al. 2009), no studies have investigated the role of TGF-b in ethanol-induced immune 
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signaling in the brain. Thus, future studies would benefit from investigating TGF-b 
signaling in the brain following ethanol consumption. Futhermore, although there haven’t 
been any studies thus far investigating the interaction between TGFb and Siglec-H, there 
is evidence for other Siglecs regulating TGFb signaling in immune cells (Takamiya et al. 
2013; Wu et al. 2016). Thus, the interaction between Siglec-H and TGFb in microglia is 
also worthy of investigation.  
 
4.V. CONCLUSIONS 
 
The transcriptional landscape of microglia is a significant faction within the CNS 
immune system. Intermingled with other cell-types, microglia are instrumental in 
maintaining CNS homeostasis. The innate and adaptive immune systems are proposed as 
interrelated cellular mechanisms involved in chronic alcohol and excessive alcohol abuse 
(Vetreno & Crews 2014).  CNS cell composition varies by brain region, influencing 
enduring immune responses and neurobehavioral traits. Identifying the molecular 
response of individual cell-types provides a foundation for inferring the 
immunomodulatory effects that are instigated.  
 
Neuroimmune signaling can affect neuronal transmission and actions of alcohol 
(Bajo et al. 2014; Bajo, Herman, et al. 2015). Although gene expression alterations are 
not entirely equivalent with protein levels due to cellular stochastic processes increased 
coordinate gene expression within microglia following alcohol consumption is consistent 
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with the activation and proliferation of microglia in alcoholic brain tissue (Dennis et al. 
2014). The associated gene expression puts forth a broader portrait of an alcohol-
responsive microglial gene network, which is notably distinct from other CNS- and 
immune-related cell-types. Microglial studies in alcohol dependence and other 
psychiatric conditions have mainly focused on a role in neurotoxicity (M. A. Pascual et 
al. 2011; Alfonso-Loeches et al. 2010; Crews et al. 2006), but our studies indicate that 
voluntary alcohol consumption which is much less toxic has marked effects on the 
microglial transcriptome and suggest that microglia may regulate alcohol consumption. 
Several genes within this microglial network (Ctss, Ctsf, Tlr3, Tlr9, Irak1, Casp8, and 
Ctsb) have been implicated in AUDs, further validating this module (Blednov, 
Ponomarev, et al. 2011; Qin & Crews 2012; Lippai et al. 2013; Antón et al. 2016; Pla et 
al. 2016). The cathepsins, Ctss and Ctsf, have been causally implicated in alcohol 
consumption, suggesting that other members of this module may regulate consumption. 
These results also suggest the involvement of many additional microglial genes that have 
not previously been studied with alcohol.  
 Of particular importance in this study, was the identification of MGM3, which 
contains co-expressing microglial genes that are regulated by ethanol. Within this 
module, we highlighted TLR and immune signaling, possibly regulated by the hub gene 
Siglech. In addition, this module presented the novel hypothesis that chronic ethanol is 
regulating TGFb signaling. The perturbations in TGFb could be regulating the changes in 
immune signaling, as well as driving changes in synaptic plasticity (Fig 4.5). Further 
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studies are necessary to elucidate to the role of TGFb and Siglec-H in modulating the 
response to ethanol.  
The transcriptome of isolated cells is informative for clarifying target genes and 
functional networks that may be important for ameliorating imbalanced systems (Lamb et 
al. 2006). Brain pathologies exemplified by disturbances in CNS immune function 
benefit from surveying the transcriptome of isolated microglia. Animal models 
incorporating such cellular preparations refine gene expression signatures procured from 
an admixture of cell-types present within homogenized tissue, permitting an in-depth 
characterization of particular cellular responses. Discriminating the microglia-specific 
perturbations initiated can call attention to a series of subtle molecular modifiers of 
immune system function relevant to human conditions. Our results emphasize a cluster of 
microglial genes aligned in relation to alcohol consumption. Further research into 
microglial gene networks, and the development of molecular tools to selectively 
manipulate microglia, will uncover CNS immune responses inherent to substance abuse 
and dependence.   
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4.VIII. FIGURES 
 
Figure 4.1: Read count distribution 
Frequency distribution of log2 normalized counts for the total homogenate and microglia 
(Cd11b+). The total homogenate has a higher frequency of counts than the microglia. 
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Figure 4.2: Differential Expression 
 
Differential expression in response to chronic ethanol for microglia and total homogenate. 
A. Volcano plot showing log2 fold-change against log10 p-value. Differentially expressed 
genes (p < .05) are shown as green or blue dots. The top 20 differentially expressed genes 
are labeled. The total homogenate has larger fold-changes and lower p-values than the 
microglia. B. Venn Diagram showing the number of unique and overlapping differentially 
expressed genes (p < .05) in each of the preparations. 164 genes were differentially 
expressed with alcohol in both the microglia and total homogenate. Of these 164 genes, 
44% (72 genes) were changed in different directions in the two preparations. 
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Figure 4.3: Microglial and Total homogenate module overlap 
Overlap between the microglia and total homogenate modules based on gene membership 
(Fishers-exact-test, correct for multiple comparisons using a false discovery rate less than 
.05). The modules contained in the hatched box show high overlap between the two 
fractions and likely represent shared genes and processes. The modules outside the 
hatched box are unique to that fraction. * denotes differentially expressed with ethanol (p 
< .05) and the color indicates the direction of the change. 
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Figure 4.4: Microglial module 3 
Microglial module 3 (MGM3) was selected for further investigation based on its 
differential expression, biological function, and microglial specificity. A. MGM3 shows 
increased expression with chronic ethanol consumption (p < .05, Kruskal-Wallis Rank 
Sum Test). B. Genes contained in MGM3 are associated with several GO Biological 
Processes related to innate immune signaling. C. When compared to other CNS cell 
types, MGM3 shows highest relative expression of microglial genes (p < .05, ANOVA).  
D. When compared to other immune cell types, MGM3 shows highest relative expression 
of microglial genes (p < .05, ANOVA).  
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Figure 4.5: Summary of Microglial response 
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Figure 4.5: Continued 
 
A. Connectivity map containing the top 250 connections in MGM3. Warmer colored nodes 
have smaller p-values for differential expression with alcohol. Larger nodes have larger 
fold changes with alcohol. Larger connecting lines indicate higher topological overlap 
measure (TOM), or connectivity between 2 genes. Warmer colored lines indicate higher 
edge betweenness centrality, or importance of the connection in the network. Siglech is 
highly connected to many genes in MGM3. B. Hypothesis about the effects of chronic 
ethanol on microglia in the frontal cortex. Chronic ethanol exposure leads to expression 
changes of genes involved in Toll-like receptor signaling, regulation of NF-kB, and TGF-
b signaling. These gene expression changes lead to a pro-inflammatory environment and 
microglial dysfunction contributing to altered CNS plasticity. Cortical alterations in CNS 
plasticity then promote additional alcohol consumption.  
Figure created using http://servier.com/Powerpoint-image-bank 
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Figure 4.6: qPCR validation of isolation 
Relative expression of cell-type markers in the total homogenate (TH), microglia (Cd11b+) 
and cells remaining after isolation (Cd11b-) measured using RT-qPCR. Neun was used as 
a neuronal marker, Gfap as an astrocyte marker, Cd11b as a microglial marker, Tek as an 
endothelial cell marker, and Ugt8a as an oligodendrocyte marker. The Cd11b+ fraction is 
highly enriched for Cd11b compared to other cell type markers. The Cd11b- fraction shows 
low levels of Cd11b, indicating that most of the microglia were successfully isolated in the 
Cd11b+ fraction. 
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Figure 4.7: Ethanol consumption  
Ethanol consumption data for every other day 2 bottle choice using 15% ethanol. Each data 
point is the average of consumption data for all 12 mice in a 24-hour period. Days represent 
only days where alcohol was present (every other day).  
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Figure 4.8: Gene dendograms 
Gene dendograms for modules in the total homogenate and microglia. 
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Figure 4.9: MGM13 and MGM15 cell-type enrichment 
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Figure 4.9: Continued  
 
Comparison of the other two differentially expressed microglial modules, MGM13 and 
MGM15, to other immune cell types. A. MGM13 shows highest relative expression of 
stromal cell genes. B. MGM15 shows highest relative expression of macrophage genes. 
These two modules do not show the same microglial signature as MGM3 does. 
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4.IX. TABLES 
 
Table 4.1: Differentially expressed microglial genes in MGM3 
 
Table of some MGM3 genes that are differentially expressed in microglia but not in the 
total homogenate. Gene symbol, gene name, T-statistic and p-value are given. All genes in 
the table show no significant change in the total homogenate.  
 
  
Gene	Symbol Gene	Name Microglia	Statistic
Microglia	
P-value
Tgfbr2 transforming	growth	factor,	beta	receptor	II	 2.32 2.01E-02
Ctsf cathepsin	F	 2.67 7.69E-03
Smad3 SMAD	family	member	3	 2.68 7.28E-03
Lgmn legumain	 2.07 3.83E-02
Serpine1 serine	(or	cysteine)	peptidase	inhibitor,	clade	E,	member	1	 2.25 2.43E-02
Zfp36l1 zinc	finger	protein	36,	C3H	type-like	1	 5.13 2.90E-07
Rhob ras	homolog	family	member	B	 4.35 1.34E-05
Etv5 ets	variant	5	 3.59 3.25E-04
Apbb1ip
amyloid	beta	(A4)	precursor	protein-binding,	family	B,	
member	1	interacting	protein	 2.65 7.96E-03
Gpr56 adhesion	G	protein-coupled	receptor	G1	 4.01 6.19E-05
Ccl12 chemokine	(C-C	motif)	ligand	12	 2.54 1.10E-02
Cd276 CD276	antigen	 3.36 7.93E-04
Emr1 adhesion	G	protein-coupled	receptor	E1	 2.09 3.69E-02
Rnf135 ring	finger	protein	135	 2.81 5.00E-03
Tnfsf12Tnfsr13
tumor	necrosis	factor	(ligand)	superfamily,	membrane-
bound	member	13	 2.08 3.75E-02
Cebpa CCAAT/enhancer	binding	protein	(C/EBP),	alpha	 2.92 3.49E-03
Il10ra interleukin	10	receptor,	alpha 2.55 9.00E-04
Klf4 Kruppel-like	factor	4	(gut) 3.79 1.50E-04
Rtn4rl1 reticulon	4	receptor-like	1	 3.39 6.98E-04
Numb numb	homolog	(Drosophila)	 2.47 1.36E-02
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Chapter 5: Microglial gene expression changes 1-week after LPS and 
comparison to ethanol 
Gizelle M. McCarthy, Yuri A. Blednov, R. Adron Harris, and R. Dayne Mayfield 
 
5.I. ABSTRACT 
Alcohol Use Disorder (AUD) is a widespread and debilitating disorder that is 
characterized by the inability to stop consuming alcohol. Altered immune signaling in the 
prefrontal cortex (PFC) is one proposed mechanism by which chronic alcohol use changes 
behavioral control. The neuroimmune changes that occur in response to alcohol are often 
compared to the changes induced by the endotoxin lipopolysaccharide (LPS). Furthermore, 
ethanol-induced LPS leakage into the blood stream is thought to mediate the neuroimmune 
response. Although previous studies have identified the gene expression changes that occur 
in the brain following LPS exposure, none have characterized the changes that are 
occurring specifically in microglia, the immune cell of the brain. In this study, we profiled 
the gene expression changes that occur in PFC microglia 1 week after peripheral LPS 
administration. In addition, we compared the gene expression changes from LPS to ethanol, 
and found that although post treatments altered immune signaling in microglia, they 
changed different specific processes and pathways. Comparison to previous data sets 
suggest that the overlap between ethanol and LPS gene expression changes might be 
attributed to other non-microglial cell types. Together these data reveal that the microglial 
response in the PFC differs between ethanol and LPS, suggesting that distinct mechanisms 
are mediating the neuroimmune response to these two treatments.  
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5.II. INTRODUCTION 
Alcohol Use Disorders (AUDs) are major problem in United States, with a 
lifetime prevalence of 29.1% (Grant et al. 2015). AUDs are highly comorbid with other 
psychiatric disorders and lead to disability for those effected and an economic burden for 
the country. Despite the prevalence, only 20% of individuals with AUDs ever seek 
treatment, emphasizing the need for new and better therapeutic options. Dysregulated 
immune signaling in the brain has recently emerged as a mediator of alcohol dependence, 
and due to the number of existing immunomodulatory drugs, has potential to be a 
therapeutic target.  Thus, it is important to understand how immune signaling occurs in 
response to alcohol and how this differs from other well characterized immune responses.  
The innate immune response to the bacterial endotoxin lipopolysaccharide (LPS) 
has been well characterized, and the immune response to ethanol has frequently been 
compared to LPS (Alfonso-Loeches et al. 2010; M. A. Pascual et al. 2011; Bajo et al. 
2014; Fernandez-Lizarbe et al. 2009). Peripheral LPS administration leads to increased 
immune signaling in the brain, although it is hypothesized to be an indirect response 
(Bossù et al. 2012). Chronic alcohol use alters the intestinal microbiome and 
compromises the tight junctions in the intestines, resulting in increased permeability and 
bacterial ‘leakage’ into the blood stream (Ferrier et al. 2006; Keshavarzian et al. 1999). 
Consistent with this idea, increased intestinal permeability and serum endotoxin levels 
are seen in alcohol dependent subjects (Leclercq et al. 2012; Leclercq, Matamoros, et al. 
2014). Increased circulating endotoxin leads to activation of the LPS ligand Toll-like 
receptor 4 (TLR4) and production of proinflammatory cytokines (Leclercq, De Saeger, et 
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al. 2014). Pro-inflammatory cytokines in the blood stream can then lead to immune 
activation and amplification in the liver and other peripheral tissues. Although LPS is a 
large molecule that does not cross the healthy blood-brain barrier, cytokines (e.g. TNFa) 
that are increased in response to peripheral LPS do (Szabo & Lippai 2014; Bossù et al. 
2012; Lippai et al. 2013). CNS inflammation causes neurodegeneration and increased 
ethanol consumption in rodents, leading to the hypothesis that immune signaling in the 
brain contributes to alcohol induced brain damage and dependence (Qin et al. 2007; 
Blednov, Benavidez, et al. 2011).  
Microglia are the immune cells of the brain and are thought to mediate at least a 
part of the neuroimmune response to alcohol and LPS. Studies using cultured primary 
microglia have demonstrated that both ethanol and LPS lead to microglial activation and 
TLR4 signaling in vitro (Fernandez-Lizarbe et al. 2009; Fernandez-Lizarbe et al. 2013).  
However, it is becoming clear that although LPS and ethanol both activate TLR 
signaling, their effects on the immune response in the CNS differ in vivo (Whitman et al. 
2013). The differences in effects are not suprising considering the distinctions between 
LPS and ethanol. For example, ethanol can cross the blood-brain barrier while LPS 
remains in the periphery and is thought to activate the CNS immune response through 
peripheral cytokine release (Banks & S. M. Robinson 2010; Qin et al. 2007). LPS is also 
a direct ligand for TLR4, while ethanol is believed to activate TLR signaling through 
increases in endogenous TLR ligands (Whitman et al. 2013). In addition, ethanol has 
multiple effects on distinct cell types within the brain; thus, it is likely that other effects 
of ethanol modulate immune signaling. Additional work is needed to better understand 
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the similarities and distinctions between the effects of alcohol and LPS on microglia in 
vivo. 
A previous study compared gene expression profiles in the prefrontal cortex 
(PFC) following various chronic ethanol exposures and LPS administration (Osterndorff-
Kahanek et al. 2013). These data showed that every other day ethanol consumption and 
LPS (1 week after administration) had a significant number of overlapping gene 
expression changes, most of which changed in the same direction. Although these results 
suggested an overlap in the immune response, it is unclear how the microglial-specific 
changes are similar and different between the two treatments. Recent advances in 
microglia isolation techniques from brain have allowed for closer evaluation of cell-type 
specific changes in the adult CNS. We sought to define the microglial response to 
peripheral LPS using isolated microglia from mouse PFC. Furthermore, we compared the 
microglial LPS response to our recent data profiling the microglial ethanol response 
(chapter 4). Our results highlight some unexpected microglial changes in response to LPS 
and highlight distinct microglial response to LPS and chronic ethanol.   
 
5.III. MATERIALS AND METHODS 
5.III.a. Ethics statement 
All procedures were approved by the University of Texas at Austin Institutional 
Animal Care and Use Committee (animal protocol number AUP-2013-00061) and adhered 
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to the NIH Guidelines. The University of Texas at Austin animal facility is accredited by 
the Association for Assessment and Accreditation of Laboratory Animal Care. 
5.III.b. Animals and LPS administration 
Studies were conducted in adult (6-8 weeks old) C57Bl/6J male mice (Jackson 
Laboratories, Bar Harbor, ME). Mice were individually housed and allowed to acclimate 
to upright bottles one week before the start of the experiment. The experimental rooms 
were maintained at an ambient temperature of 21±1°C, 40-60% humidity, and a regular 
light/dark schedule (7 AM-7 PM). Food and water were available ad libitum. Mice were 
randomly assigned to either LPS or saline groups (n=5/group). Mice were weighed one 
day prior to LPS (1.5 mg/kg) or saline injection (intraperitoneally; IP). Mice were 
weighed daily and sacrificed after 1 week (Fig. 5.4). The one week time point was chosen 
because previous data has shown that ethanol consumption is increased 1 week after 
acute LPS and that PFC gene expression changes at 1 week overlapped with every other 
day ethanol consumption (Blednov, Benavidez, et al. 2011; Osterndorff-Kahanek et al. 
2013).  
 
5.III.c. Microglia and RNA Isolation 
Mice were perfused with ice-cold saline, brains were removed, and the PFC was 
dissected as described previously (Osterndorff-Kahanek et al. 2013). The tissue was 
minced on ice, re-suspended in cold HBSS followed by microglial isolation as described 
by Nikodemova et al. 2015. Briefly, tissue suspension was enzymatically dissociated 
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using the Neural Tissue Dissociation Kit- Papain (Miltenyi Biotec, Germany) in 
conjunction with Pasteur pipette manual dissociation. Dissociated tissue was passed 
through a 70 µM strainer (Miltenyi Biotec), centrifuged at 300 x g, then resuspended in 
30% Percoll (Sigma-Aldrich, St. Louis, MO). The Percoll-cell suspension was 
centrifuged at 700 x g for 15 minutes at room temperature to separate the myelin from the 
isolated cells, and the myelin was subsequently removed. Cells were washed and then 
incubated with CD11b MicroBeads (Miltenyi Biotec) and eluted using MS columns to 
collect CD11b+ cells.  CD11b+ cell pellets were collected by centrifugation at 300 x g 
for 10 minutes at 4°C and then the supernatant was removed and the pellet flash frozen. 
RNA was isolated using the RNeasy Micro Kit (Qiagen, Germany). RNA concentration 
and quality (RNA integrity number) was determined using the Agilent 2100 Bioanalyzer 
(Agilent Technologies, Santa Clara, CA) with the Agilent RNA 6000 Pico Kit. 
 
5.III.d. RNA Sequencing and Analysis 
Samples were Poly(A) selected using the Poly(A) Purist Kit (Thermo Fisher 
Scientific Inc.) and prepared using NEBNext® Ultra™ Directional RNA Library 
Preparation Kit (New England BioLabs, Ipswich, MA). Samples were sequenced on the 
NextSeq 500 (Illumina, San Diego, CA) using (75 bp; paired-end reads) to a minimum 
target depth of 20 million reads per sample. Reads were mapped to the mouse reference 
genome (UCSC, mm10) using the alignment tool STAR (Dobin et al. 2013). Raw RNA-
sequencing files were evaluated for quality control using FastQC (0.11.13). HTSeq, was 
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used for counting mapped sequencing reads. Quantified read counts were normalized and 
analyzed for differential expression using DESeq2 (v 1.10.1), between saline and LPS 
treated isolated microglia, using the R statistical computing environment (v3.3.1)(Love et 
al. 2014). Statistical significance was assessed using a nominal p-value less than or equal 
to 0.05. Individual gene sets were functionally annotated using the web-based software 
application Enrichr  (Kuleshov et al. 2016; E. Y. Chen et al. 2013)  
 
5.III.e. Comparison to other data sets 
The microglial response to LPS was compared to the microglial response to 
chronic voluntary ethanol consumption using previously published data (chapter 4). 
Additional analyses compared the microglial LPS and ethanol overlap to previously 
published microarray data that profiled the PFC including all cell types in response to 1 
week post-LPS treatment (Osterndorff-Kahanek et al. 2015).  
 
5.IV. RESULTS AND DISCUSSION  
5.IV.a. Microglial transcriptome 1 week after LPS 
RNA sequencing was used to evaluate gene expression changes in the PFC one 
week after IP LPS administration. A total of 17,192 genes were detected (genes were 
excluded that had no reads detected in any sample), and differential expression analysis 
identified 898 differentially expressed genes at a p value less than .05. The p value cut off 
was based on a previous study that measured alcohol and 1 week post-LPS gene 
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expression differences (Osterndorff-Kahanek et al. 2013)(Chapter 4: Microglia-specific 
transcriptome changes following chronic alcohol consumption).  Of the 17,192 genes 
detected in this study, 470 genes were upregulated and 428 were downregulated. 
Enrichment analysis revealed that the most significantly enriched biological processes 
were driven by differential expression of ribosomal RNAs. These biological processes 
included RNA catabolic process (GO:0006401), protein targeting to ER (GO:004507) 
and translation (GO:0006412) (Fig. 5.1). The enrichment of ribosomal RNAs was not 
expected given that LPS treatment results in immune signaling activation and ribosomal 
genes have been used as housekeeping genes in LPS studies (van Schaarenburg et al. 
2016; Siegfried et al. 2013). However, given the importance of altered gene expression in 
immune signaling, it expected that innate immune signaling would change regulation of 
transcription, RNA processing, and translation (Carpenter et al. 2014). GWAS studies 
have identified ribosomal protein L5 (Rpl5) as a susceptibility gene for Multiple Sclerosis 
(Rubio et al. 2008) and Rpl13 as a susceptibility gene for Alzheimer’s Disease (De Jager 
et al. 2014). Both of these CNS disorders involve microglial activation and recent studies 
suggest that increased expression of ribosomal proteins in activated microglia may play 
an important role in the inflammatory response in the CNS (Lee et al. 2012). 
Furthermore, gene expression analysis of microglia isolated from a mouse model of 
neurodegeneration(Vincenti et al. 2016) and aged mice (Orre et al. 2014) revealed several 
differentially expressed genes related to translation that were also differentially expressed 
in our LPS data (e.g. Rpl5,  Rpl12, Eif4b). Therefore, ribosomal RNAs represent a 
potential area that deserves more study with regards to microglial activation, and careful 
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consideration should be taken before using these genes as endogenous controls in 
inflammatory models.  
There were also several gene expression changes related to the response to 
topologically incorrect protein (GO:00035966), including many genes encoding heat 
shock proteins. LPS treatment in macrophages induces ER stress, splicing, and unfolded 
protein response (UPR) that amplifies immune signaling through cytokine production 
(Grootjans et al. 2016). Furthermore, misfolded proteins are able to activate microglia via 
TLRs, and decreased phagocytosis of unfolded proteins in response to immune stimuli is 
thought to contribute to the pathology of neurodegenerative diseases (Heneka et al. 
2014).  
As expected, the inflammatory response (FO:0006954) was altered 1 week after 
LPS, including increases in several cytokines (e.g. Tnf, Il1b, Ccl5, and Cxcl10). These 
results are consistent with other studies that have showed long lasting cytokine responses 
to a single LPS exposure (Bossù et al. 2012). TNFa signals through two different 
receptors and regulates many cellular processes, including cytokine production, cell 
adhesion, gliosis, cell survival and proliferation, and apoptosis (Kraft et al. 2009). 
Consequently, the differentially expressed biological processes also include positive 
regulation of tumor necrosis factor superfamily cytokine production (GO:1903555), 
regulation of cell motility (GO:2000147), and regulation of apoptotic signaling pathway 
(GO:2001233) (Fig. 5.1). In addition, TNFa signaling impacts other cells within the 
CNS. For example, microglial TNFa can potentiate glutamate toxicity by binding to 
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astrocytes and neurons (Olmos & Lladó 2014), can cause demyelination through its 
effects on oligodendrocytes (Probert 2015),  and can induce apoptosis in neuronal 
progenitor cells (Guadagno et al. 2013).  
 
5.IV.b. Microglial response to LPS differs from total homogenate response 
Previous work used microarrays to evaluate PFC gene expression changes in the 
total homogenate 1 week after LPS and found that 1049 genes were differentially expressed 
(Osterndorff-Kahanek et al. 2013). In contrast to the microglial genes, these genes were 
enriched for biological processes related to positive regulation of protein kinase activity 
(GO:0045860).  Comparison between the total homogenate and microglia differential 
expression data revealed an overlap of 77 genes. Like the microglial ontologies, many of 
the overlapping genes were related to RNA catabolic process (GO:0006401) and regulation 
of translation (GO:0006417). These results suggest that while microglia have many 
changes related to regulation of mRNA and protein expression, changes in these processes 
can also be detected in the total homogenate 1 week after LPS. 
5.IV.c. Comparison of microglial response to LPS and ethanol 
In a recent study, we used isolated microglia to profile the microglial response to 
chronic ethanol consumption (Chapter 4). Immune changes resulting from ethanol 
administration are often compared to the immune changes induced by LPS, so we were 
interested in investigating how microglial gene expression changes differed between the 
two treatments. A comparison of differential expression data revealed that LPS (1-week 
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post-administration) had greater fold-changes than changes observed in response to 
chronic ethanol administration, although all were less than 2-fold (Fig. 5.2). There were a 
great number of differentially expressed genes with p values < .05 in the ethanol group 
compared to the LPS group; however, this is likely due to the smaller sample size in the 
LPS group.  
 
Evaluation of differential expression within each treatment revealed several 
overlapping biological processes, although many expression changes were in different 
directions (Fig. 5.2B). Both groups showed increased expression of genes related to cell 
chemotaxis (GO:0060326), leukocyte migration (GO:0050900), and inflammatory 
response (GO:0006954). The genes driving these ontologies include chemokines and 
chemokine receptors (e.g. Cxcr2, Ccl5), metalloproteinases (e.g. Adam8, Mmp9), solute 
carriers (Slc7a5, Slc7a8), and integrins (Itgal, Itgb2). Metalloproteinases, particularly 
Mmp9, have recently emerged as important mediators of immune response, synaptic 
plasticity, cognitive impairments, and alcohol-seeking behavior (Stefaniuk et al. 2017; Y. 
Yang et al. 2011; Lasek 2016). Microglial migration, chemotaxis, and invasion are an 
important part of the neuroimmune response (Vincent et al. 2012). Previous studies have 
suggested that LPS alters microglial migration, although the direction of change varies 
(Lively & Schlichter 2013; Hu et al. 2014). There are few studies directly investigating 
microglial migration in response to ethanol, but there is evidence that ethanol alters 
chemotaxis in astrocytes (Davis & Syapin 2004) and liver macrophages (Kupffer 
cells)(Bautista 2002). Furthermore, several molecules involved in chemotaxis are 
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changed in the brain after chronic ethanol and regulate ethanol consumption (BLEDNOV 
et al. 2005; He & Crews 2008; Kane et al. 2013). Therefore, microglial migration is a 
potential process changed both with LPS and ethanol, and warrants further investigation 
in alcohol studies.  
Although both treatments led to an increase in genes related to inflammatory 
response, they showed differences in specific inflammatory pathways. The LPS group 
showed increased expression of genes related to lipopolysaccharide-mediated signaling 
pathway (GO:0031663) and positive regulation of MAPK cascade (GO:0043410), while 
decreased expression was observed in the ethanol group. Thus, it appears that while LPS 
produces a typical pro-inflammatory response even a week after administration, ethanol 
does not. Microglial MAPK signaling is activated by TNFa, and is responsible for LPS-
induced neuronal damage (Xing et al. 2011). Given that TNFa expression was 
upregulated in the LPS-treat group, but downregulated in the ethanol-treated group, 
MAPK signaling might also be expected to change in opposite directions. Furthermore, 
microglial MAPK signaling promotes apoptosis{Xie:2010in(Xie et al. 2010), and several 
genes related to apoptosis were also increased with LPS and decreased with ethanol. 
Previous studies have demonstrated increased microglial MAPK expression following 
ethanol exposure in vitro, however, this was accompanied by an increase in TNFa 
expression (Fernandez-Lizarbe et al. 2009). Therefore, it appears that microglial cytokine 
and MAPK expression is regulated differently in response to chronic ethanol in vivo. 
Because MAPK signaling can regulate many processes, including growth, differentiation, 
 188 
apoptosis, and inflammation, it is an attractive target for modulating the neuroimmune 
response.  
In contrast, genes that were upregulated with ethanol and downregulated with 
LPS were enriched for transforming growth factor beta signaling pathway (0007179) and 
response to topologically incorrect protein (GO:0025966). TGF-b signaling has recently 
emerged as an important component regulator of microglial function and immune 
response, and loss of TGF-b in the CNS results in reduced microglial numbers, impaired 
synaptic plasticity, and deficits in extracellular glutamate (Butovsky et al. 2013; 
Koeglsperger, Li, Brenneis, Saulnier, Mayo, Carrier, Selkoe & Weiner 2013a). Studies 
suggest that increased TGF-b signaling inhibits expression of chemokines and receptors, 
genes responsible for cell migration, apoptosis, and infection response (Paglinawan et al. 
2003). Some of these genes inhibited by TGF-b (Ccl3, Samhd1, Vcam1, Tnf, Gbp2) were 
found to be upregulated with LPS and downregulated with ethanol. However, there are 
some of these inhibited genes that are upregulated with ethanol, suggesting that the 
response in vivo is more complicated and cytokine and TGF-b related signaling can 
increase simultaneously. In addition, TGF-b signaling involves cross-talk with multiple 
pathways, including MAPK, PI3K/Akt, and TNFa/IL/NF-kB (X. Guo & X.-F. Wang 
2009). Nevertheless, TGF-b’s interactions with many pathways makes it an interesting 
target in CNS disorders that involve neuroimmune dysregulation. In support of this, 
microglial TGF-b expression is increased and signaling is dysregulated in models of 
aging and neurodegeneration (Bernhardi et al. 2015). Although TGF-b 
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involved in the liver immune response to chronic ethanol, the influence of TGF-b 
signaling in the CNS response to ethanol has been unexplored and is worthy of future 
investigation.  
Both treatments also had biological processes that were downregulated, including 
mitotic cell cycle (GO:0000278) (Fig. 5.2). Although down regulation of cellular 
processes may occur during inflammation, proliferating microglia usually have increased 
expression of cell-cycle genes. Cell cycle inhibition reduces the inflammatory response 
and provides neuroprotection, and could therefore be a compensatory mechanism in 
response to inflammation (Skovira et al. 2016). In keeping with this idea, TGF-b 
activation is known to cause cell cycle arrest (Hocevar & Howe 1998) and this response 
is seen in microglial cell lines in response to LPS (Kaneko et al. 2015) and in splenic NK 
cells isolated from alcohol consuming mice (Gallucci & Meadows 1996). The notch 
signaling pathway (GO:0007219) is also downregulated with both treatments and 
regulates immune response in microglia (Yao et al. 2013) and cell-cycle in other glial 
cells (Conner et al. 2014; Bongarzone et al. 2000). Therefore, downregulation of notch 
signaling and cell-cycle genes may serve to limit microglial proliferation in response to 
inflammation.  
 It is worth noting that although genes changing in one direction might be enriched 
for a pathway (e.g. TGF-b signaling, MAPK signaling, apoptosis), these pathways often 
include genes that both activate and inhibit signaling.  
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5.IV.d. Ethanol and LPS gene expression overlap 
A comparison of the differentially expressed genes between ethanol and LPS 
revealed an overlap of 120 genes, which is greater than expected by chance (p=2.2e-16, 
Fisher’s test) (Fig. 5.3). Of these 120 genes, 73% had expression changes in opposite 
directions, suggesting that even the overlapping genes are showing opposite responses 
(Fig. 5.3A-B). Investigation into the overlapping genes revealed that the ontologies for 
changes in the same and opposite directions were like those seen in all the DE genes (Fig. 
5.2). The top ontologies for genes that changed in the same direction for both groups 
were extracellular matrix organization (GO:0030198) and integrin cell surface 
interactions (R-HAS-216083) (Table 5.1). The extracellular matrix (ECM) plays an 
important role in cell adhesion, synapse formation, regulation of neurotransmitter 
diffusion, as well as maintenance of the blood-brain barrier (Y. Yang et al. 2011; Lasek 
2016). Cytokine expression and microglial activation are known to influence the 
expression of ECM genes, such as metalloproteinases and integrins (Milner & Campbell 
2003). Furthermore, changes in ECM components can degrade the blood-brain barrier 
and propagate the immune response by acting as pathogen receptor ligands (Gaudet & 
Popovich 2014; Colton 2009). ECM components are known to change with ethanol 
administration and may regulate consumption (Lasek 2016), making microglial 
expression of these genes an interesting focus in future studies.   
Genes that were upregulated with LPS and downregulated with ethanol were 
enriched for positive regulation of inflammatory response (GO:0050729) and consisted of 
several cytokines (Ccl3, Ccl12, Tnfa, Il17ra). In contrast, genes that were upregulated 
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with alcohol but downregulated with LPS were related to regulation of transcription from 
RNA polymerase II promoter in response to stress (GO:0043618) and included several 
genes related to TGF-b signaling (Smad3, Klf6, Pmepa1, Ubb). These changes are 
consistent with the with the cytokine/TGF-b changes seen looking at all the differentially 
expressed genes in each treatment.   
 
5.IV.e. Comparison of microglial LPS-Ethanol overlap to total homogenate 
In contrast to the differences in microglial response to LPS and ethanol, previous 
microarray data showed a high overlap between LPS and ethanol differentially expressed 
genes (Osterndorff-Kahanek et al. 2013). This study utilized RNA from the PFC 
(containing all cell types, referred to as total homogenate) and found that there was a 
greater overlap between LPS and chronic intermittent ethanol than expected by chance 
and that most of these changes were in the same direction. Given that most of these 
changes seemed to be unidirectional and that the majority of of the microglial changes 
were in the opposite direction, we were interested how the gene ontologies between the 
two differed (Table 5.1: Ontologies for ethanol-LPS gene overlap in microglia and total 
homogenate).  
In contrast to the cytokine and TGF-b-related genes that distinguished LPS and 
ethanol in microglia, the overlap in the total homogenate was related to synaptic 
transmission (GO:0007268). Genes that were changed in the same direction were related 
to histone H3 deacetylation (GO:0007268) and neurotransmitter receptor binding and 
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downstream transmission in the postsynaptic cell (RHSA_112314). However, it is worth 
noting that many of the ontologies for these genes were driven by only a few genes, 
emphasizing the heterogeneity of the overlap. These results suggest that the common 
changes between LPS and ethanol may be more related to neuronal response than to 
microglial response. There are several studies that suggest LPS acutely alters synaptic 
transmission (Gao et al. 2014; Bajo, Varodayan, et al. 2015) and has long-term effects on 
spine dynamics (Kondo et al. 2011), behavior (Bossù et al. 2012; Valero et al. 2014) and 
cortical neuromodulation (Ming et al. 2015). Additionally, decreases basal firing of 
ventral tegmental area (VTA) dopamine neurons 7-10 days after LPS administration, 
confirming that synaptic activity remains changed at the 1 week time point (Blednov, 
Benavidez, et al. 2011).   Although the mechanism of LPS changing synaptic 
transmission is likely an indirect effect through microglia (J. George et al. 2016; J. Zhang 
et al. 2014), there is work supporting direct effects of LPS on neurons (Leow-Dyke et al. 
2012; Juan Liu et al. 2011). In contrast to LPS, ethanol is known to have direct effects on 
synaptic activity (Moriguchi et al. 2007), however, the overlap with LPS suggests a 
common mechanism as well, possibly through immune activation.  
Histone deacetylation represses transcription and increased deacetylation is 
thought to counteract the inflammatory response (Yoza et al. 2002), as well as contribute 
to psychiatric disorders including alcohol use disorder (Sakharkar et al. 2014) . In 
neurodegenerative disease models histone deacetylase (HDAC) inhibitors improve 
degeneration, learning and memory, and synaptic plasticity (Konsoula & Barile 2012), 
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suggesting that these cognitive processes may mediate the effects HDAC inhibitors on 
alcohol consumption.   
Although not the top ontology, several of the overlapping total homogenate genes 
were related to growth factor signaling, particularly FGF signaling. FGF signaling has 
important roles in neurogenesis, neuroinflammation, and psychiatric illness (Galvez-
Contreras et al. 2016). FGF signaling influences and is influenced by TGF-b signaling, 
highlighting the role of growth factor signaling in the regulation of the neuroimmune 
response and alcohol use disorders.  
A caveat of this comparison of LPS-ethanol overlap in total homogenate and 
microglia is that there were differences in experimental design. The microglial gene 
expression data were evaluated by RNA sequencing and analyzed using DESeq2, while 
the total homogenate gene expression was measured using microarray technology and 
analyzed using Limma. In addition, the total homogenate data was taken from female 
mice, and there are observed  ethanol and immune differences between sexes (Alfonso-
Loeches et al. 2013; Agrawal et al. 2013). Furthermore, the total homogenate ethanol 
mice were collected at a different time point (24 hours after ethanol removal), which 
could also contribute to differences.  
 
5.V. CONCLUSIONS 
Because the LPS response is well characterized and directly activates TLR 
signaling, other CNS disorders that activate immune signaling, like chronic alcohol use, 
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are often compared to LPS. However, the results presented in this chapter suggest that 
although LPS and ethanol both elicit an immune response, this microglial response 
differs between the two treatments. These results are consistent with a recent study that 
profiled spinal cord microglia from an Amyotrophic Lateral Sclerosis (ALS) mouse 
model and LPS treatment (Chiu et al. 2013). Despite previous comparisons between 
microglia in ALS and the microglial response to LPS, they found a distinct microglial 
ALS profile. Furthermore, they found that ALS microglia, like ethanol microglia, co-
express typical anti-inflammatory and pro-inflammatory genes. These differences 
highlight the heterogeneity of the microglial response to disease and emphasize the need 
to characterize microglia by their stimulus in vivo, instead of trying to divide them into 
M1 (LPS-induced) or M2 (IL-10/TGF-b induced) categories (Ransohoff 2016a).  
 It is important to note that time is always a factor when evaluating neuroimmune 
response. Microglia in this study were taken immediately after ethanol removal, however, 
some studies suggest that the immune response to ethanol is biphasic and that largest 
immune changes in the brain are found 24-hours after ethanol removal (Whitman et al. 
2013). Therefore, although ethanol and LPS response show little overlap in this study, 
they might show higher overlap at another time point. Furthermore, the idea of biphasic 
responses as well as ontologies including activators and inhibitors, makes direction of 
changes less important, and dysregulation of processes more important. Thus, microglia 
do show dysregulation in similar pathways in response to LPS and ethanol.  
 In summary, although LPS is known to activate microglia, this is the first study to 
characterize microglial changes 1 week after LPS exposure and these data provide new 
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insights into the more persistent microglial changes in response to pathogens. In addition, 
this study highlights the similarities and differences between the effects of alcohol and 
LPS on microglia and highlights new processes that may contribute to the microglial 
response.  
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5.VII. FIGURES 
 
Figure 5.1: Altered biological processes in microglia 1 week after LPS 
Biological processes that LPS differentially expressed genes were enriched for (p < .05), 
with some of the genes that are driving the ontologies (overlapping genes were removed, 
but several genes drove multiple ontologies). 
Figure created using http://servier.com/Powerpoint-image-bank 
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Figure 5.2: Microglial differential expression after LPS and ethanol treatments 
Comparison of differential expression in microglia following LPS and Ethanol treatments. 
A. Volcano plots showing differential expression by log2 fold change vs. log10 p value. 
Colored dots have a p value < .05 and the top 20 differentially expressed genes (by p value) 
are labeled. B. Enriched Biological Processes based on significantly upregulated genes 
(red) or downregulated genes (blue) within each treatment. Color intensity is based on log10 
p value (darker colors correspond to lower p values), while red or blue indicates whether 
the genes were up or down regulated. All ontologies met a p value of < .05. 
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Figure 5.3: Microglial gene expression overlap between LPS and ethanol 
Comparison of the differentially expressed genes that overlap between Ethanol and LPS. 
A. Ethanol resulted in 1008 differentially expressed genes and LPS resulted in 898 
differentially expressed genes. The overlap between the two groups is 120, which is greater 
than expected by chance (2.2e-16, Fisher’s test). Analysis of the direction of fold change 
within this overlap shows that only 27% of the changes are occurring in the same direction. 
B. Heat map showing expression of the 120 overlapping genes. Color intensity indicates 
log2 fold change, with red being upregulated and blue being downregulated. Gene symbols 
are shown on the right. 
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Figure 5.4: Verification of LPS effect 
Data verifying the effect of LPS treatment. The mice were treated with LPS or saline and 
sacrificed 1 week later. Weights were measured 1 day before injection and each subsequent 
day until sacrifice. The LPS group showed significantly lower weight compared to the 
saline group on days 1-4 (p < 0.05, t-test). Weight increased after day 2 and was not 
significantly different from the saline group on day 7. 
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5.VIII. TABLES 
 
Table 5.1: Ontologies for ethanol-LPS gene overlap in microglia and total homogenate 
GO Biological Process and Reactome ontologies for genes that overlap between ethanol 
and LPS microglia and genes that overlap between ethanol and LPS total homogenate. 
Ontologies are given for the entire set of overlapping genes, as well as those changed in 
the same and opposite directions (broken up by direction). *Total homogenate analysis is 
based on data from Osterndorff-Kahanek et al. 2013. 
 
  
#	of	genes GO	Biological	Process p	value Reactome p	value
120 positive	regulation	of	response	to	wounding	(GO:1903036) 1.35E-05 Integrin	cell	surface	interactions_Homo	sapiens_R-HSA-216083 5.13E-05
32 extracellular	matrix	organization	(GO:0030198) 1.96E-05 Integrin	cell	surface	interactions_Homo	sapiens_R-HSA-216083 3.85E-06
up	in	both 26 extracellular	matrix	organization	(GO:0030198) 5.45E-06 Extracellular	matrix	organization_Homo	sapiens_R-HSA-1474244 1.38E-06
down	in	both
6
transcytosis	(GO:0045056) 2.70E-03
Synthesis	of	IP2,	IP,	and	Ins	in	the	cytosol_Homo	sapiens_R-HSA-
1855183
3.30E-03
88 cellular	response	to	cytokine	stimulus	(GO:0071345) 2.27E-04 Regulation	of	TNFR1	signaling_Homo	sapiens_R-HSA-5357905 3.38E-04
LPS	up,	EtOH	down
42
positive	regulation	of	inflammatory	response	(GO:0050729) 3.45E-05
Cytokine	Signaling	in	Immune	system_Homo	sapiens_R-HSA-
1280215
1.76E-03
EtOH	up,	LPS	down
46
regulation	of	transcription	from	RNA	polymerase	II	promoter	in	
response	to	stress	(GO:0043618)
1.14E-04
TGF-beta	receptor	signaling	activates	SMADs_Homo	sapiens_R-HSA-
2173789
5.39E-05
104 synaptic	transmission	(GO:0007268) 8.85E-05
Neurotransmitter	Receptor	Binding	And	Downstream	Transmission	
In	The	Postsynaptic	Cell_Homo	sapiens_R-HSA-112314
9.88E-05
86 histone	H3	deacetylation	(GO:0070932) 9.65E-05 Neurotransmitter	Receptor	Binding	And	Downstream	Transmission	
In	The	Postsynaptic	Cell_Homo	sapiens_R-HSA-112314
3.40E-05
up	in	both
52
histone	H3	deacetylation	(GO:0070932) 2.13E-05
Cooperation	of	PDCL	(PhLP1)	and	TRiC/CCT	in	G-protein	beta	
folding_Homo	sapiens_R-HSA-6814122
1.77E-04
down	in	both
34
blood	vessel	development	(GO:0001568) 9.17E-03
Glutamate	Binding,	Activation	of	AMPA	Receptors	and	Synaptic	
Plasticity_Homo	sapiens_R-HSA-399721
1.27E-03
18 activation	of	signaling	protein	activity	involved	in	unfolded	
protein	response	(GO:0006987)
2.46E-05 Unfolded	Protein	Response	(UPR)_Homo	sapiens_R-HSA-381119 5.98E-05
LPS	up,	EtOH	down
10
activation	of	signaling	protein	activity	involved	in	unfolded	
protein	response	(GO:0006987)
4.46E-04 Unfolded	Protein	Response	(UPR)_Homo	sapiens_R-HSA-381119 8.04E-04
EtOH	up,	LPS	down 8 neurotransmitter-gated	ion	channel	clustering	(GO:0072578) 3.20E-03 Molybdenum	cofactor	biosynthesis_Homo	sapiens_R-HSA-947581 2.40E-03
Description
Microglia	LPS-EtOH	
Same	Direction
Opposite	Directions
Opposite	Directions
Same	Direction
Total	Homogenate	LPS-
EtOH	overlap	*
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Chapter 6: Summary and Future Directions 
6.I. SUMMARY OF RESULTS 
Despite their prevalence and impact, AUDs are largely undertreated, in part 
because few individuals seek treatment (only 20%) and in part because existing 
treatments aren’t effective in preventing relapse (Grant et al. 2015). The emerging link 
between neuroimmune signaling and brain pathologies has revealed a role for immune 
signaling in alcohol-induced damage and dependence. Studies have shown that ethanol 
induces neuroimmune signaling, which further promotes consumption, suggesting that 
targeting the innate immune responses in the brain may have therapeutic potential. My 
work has provided important insight about which neuroimmune pathways are changing in 
response to chronic ethanol, and which glial cell types are contributing to these changes 
(Fig. 6.1).  
Studies regarding the neuroimmune effects of alcohol have largely focused on the 
importance of TLR4, NF-kB activation, and cytokine production (G. Robinson et al. 
2014). However, few studies have investigated the effects of ethanol on the two TLR4 
signaling pathways, the MyD88-dependent pathway and the TRIF-dependent pathway. 
We hypothesized that because the MyD88-dependent pathway signals to NF-kB and is 
utilized by almost every TLR, components of this pathway would change with ethanol. 
However, in chapter 2, I showed that many of the gene expression changes in the PFC 
were occurring in the TRIF-dependent pathway, the pathway that increases expression of 
interferons and interferon-inducible genes. Cxcl10, an interferon inducible gene produced 
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in response to TRIF-pathway signaling, was also increased, suggesting that the pathway 
is not just increased, but also activated. 
Going against the idea that TLR4 is central to the ethanol-immune response, I 
showed that Tlr3, an endosomal TLR which signals exclusively through the TRIF-
dependent pathway, was increased more than Tlr4. In addition, I showed that ethanol 
increased expression of Tlr7, another endosomal TLR that can activate interferons, and 
its downstream transcription factor Irf7. Collectively, these data suggested that chronic 
ethanol alters TRIF-dependent signaling in the PFC. In addition, because we looked at 2 
time-points and multiple brain regions (PFC, nucleus accumbens, amygdala), we 
identified brain-region- and time- dependent changes in TLR expression. These changes 
emphasized that most TLR changes occur in the PFC 24-hours after ethanol removal, but 
that some similar changes occur in the accumbens, while changes seem to be in the 
opposite direction in the amygdala. While previous data has shown an ethanol-induced 
TRIF-pathway response in vitro, this study was the first to provide evidence of the 
pathway changing in vivo. Additionally, this was the first study to show that rodent 
voluntary ethanol consumption, which has minimal effects on glial markers, can change 
TLR and cytokine expression. Furthermore, we showed that a TRIF-pathway inhibitor 
decreased ethanol consumption, suggesting a causal role of this signaling in the 
regulation of drinking behavior.  
Because my work in chapter 2 suggested that TRIF-dependent signaling may 
mediate the ethanol-neuroimmune response, we were interested in determining which 
CNS cell types express these genes and proteins. In chapter 3, I used isolated microglia 
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and astrocytes to determine the cell-type enrichment of TLR pathway genes with and 
without immune activation. I discovered that most of the TLR pathway genes were 
enriched and changed in microglia, particularly cytokines. However, I did notice some 
differences in cell-type expression within the same pathway, suggesting that these genes 
may be involved in other pathways in non-microglial cells. In addition, I determined that 
Tlr3 expression is most enriched in astrocytes, and that astrocyte expression increases 
following LPS. In combination with astrocyte enrichment of Irf3, these results suggest a 
possible role for TRIF-dependent signaling in astrocytes. Although I was unable to 
determine the protein cell-type localization due to technical problems, I did determine 
that many of TLR antibodies are non-specific and several of these antibodies show no 
protein expression in microglia. Furthermore, different antibodies to the same protein 
give different localization results. These data highlight the reasons for disagreement over 
protein localization in the neuroimmune field and provide rationale for using alternative 
methods to determine protein localization.  
After determining that some, but not all, of the ethanol-induced gene expression 
changes from chapter 2 were likely coming from microglia, I sought to further elucidate 
the microglial response to ethanol. Because ethanol-induced gene expression changes in-
vivo are measured using a mix of cell types, it was unclear how microglia changed 
following chronic ethanol consumption. In chapter 4, I used isolated PFC microglia and 
revealed that most ethanol-induced microglial changes are not detected in a typical gene 
expression preparation (e.g. total homogenate). Furthermore, I found that ethanol 
increased expression of a network of genes related to endosomal TLR signaling and 
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TGF-b signaling. These results not only validate the results from chapter 2, but also 
suggest an important role for the cytokine TGF-b in the ethanol neuroimmune response. 
TGF-b has recently emerged as an important mediator of microglial function (Butovsky 
et al. 2013), and has been implicated in peripheral immune responses to ethanol (Dooley 
& Dijke 2012; Kim et al. 2009), but has not been studied regarding the ethanol-
neuroimmune response. In addition, the lack of cytokine gene expression changes, 
suggested that the microglial response to ethanol differs from the typical pro-
inflammatory response to immune activators like LPS. To further evaluate these 
differences, I profiled the microglial response to LPS in chapter 5.  
Because our results in chapter 3 suggested that the microglial response to LPS 
early on includes increased expression of pro-inflammatory cytokines that were 
unchanged in microglia by ethanol, we decided to evaluate the microglial response 1 
week after LPS exposure. Previous work from the lab revealed that PFC gene expression 
changes 1 week after LPS were similar to changes induced by chronic ethanol 
(Osterndorff-Kahanek et al. 2013). However, my work in chapter 5 revealed that the 
effects of LPS and ethanol on microglia are very different. These results suggest that 
some of the overlapping effects are due to other cell types, not microglia.  
Collectively, my dissertation reveals novel ideas about how ethanol is altering 
neuroimmune signaling and the microglial response. Specifically, I discovered that 
endosomal TLRs and interferon producing pathways respond to chronic ethanol and 
mediate consumption. At a time where manipulations of TLR4 have failed to change 
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consumption (Harris et al. 2017), this finding presents a new pathway to explore. In 
addition, I found that microglial specific changes in response to chronic ethanol involve 
altered expression of the TGF-b signaling pathway. Given the importance of TGF-b in 
microglial function and cross-talk with other CNS cell types (Koeglsperger, Li, Brenneis, 
Saulnier, Mayo, Carrier, Selkoe & Weiner 2013a; Lodge & Sriram 1996; C. P. Chen et 
al. 2006), these data present a rationale to further study the role of this pathway in the 
ethanol neuroimmune response. Finally, I showed that the microglial response to ethanol 
is different from the LPS response ex vivo, highlighting the unique immunomodulatory 
function of alcohol in the CNS. These results provide new evidence about how alcohol 
changes neuroimmune signaling but also leave us with many unanswered questions. 
Therefore, several studies that will expand on my work are already ongoing. Specifically, 
future experiments will be determine the role of endosomal TLR signaling in regulating 
alcohol consumption as well as revealing the brain-region specific and cell-type specific 
contributions. Other studies should elucidate the role of microglial function in the 
ethanol-induced immune response. Lastly, future work will uncover the role of TGF-b 
signaling in the microglial response to ethanol, and use drugs targeting this pathway to 
modulate ethanol consumption.  
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6.II. FUTURE DIRECTIONS 
6.II.a. The role of TLR3/TRIF signaling in ethanol consumption 
My work in chapter 2 revealed increased expression of endosomal TLRs, TRIF-
dependent signaling, and interferon inducible genes following ethanol consumption. 
While inhibition of the TRIF-dependent pathway decreased consumption, these results do 
not explain how these pathways are changing or how they regulate ethanol consumption. 
 
6.II.a.i. How alcohol alters TLR3/TRIF/Interferon signaling 
Studies regarding the neuroimmune effects of alcohol suggest that alcohol induces 
innate immune signaling both through peripheral and direct CNS effects. To better 
understand and target specific immune changes, it is necessary to understand the 
mechanism by which they occur. One way to determine if the observed CNS changes are 
a result of peripheral immune signaling is to inject cytokines that are induced peripherally 
in response to ethanol, such as TNF-a and IL-1b. If peripheral cytokines can induce the 
same changes that occur with alcohol consumption, the effect is likely indirect and should 
be targeted in the periphery. However, studies also suggest that ethanol directly induces 
neuroimmune signaling in the brain, via the production of endogenous ligands and the 
clustering of TLRs into lipid rafts (Fernandez-Lizarbe et al. 2008; Coleman et al. 2017; 
Whitman et al. 2013).  
Interestingly, Consuelo Guerri’s group has shown that adding ethanol to 
microglial cultures leads to activation of the TRIF-dependent pathway (Fernandez-
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Lizarbe et al. 2009). Another study using astrocyte cultures overexpressing TLR4, 
revealed that ethanol induces TLR recruitment to lipid rafts and internalization to 
endosomes, and that TRIF-dependent signaling is dependent on clathrin-mediated 
endocytosis (Pascual-Lucas et al. 2014). Both studies suggest that ethanol can directly 
induce TLR4-TRIF dependent signaling in microglia and astrocytes, however, they did 
not measure changes in TLR3. Furthermore, these studies conclude that the microglial 
induction of TRIF-dependent signaling is entirely TLR4 dependent, but did not look at 
the effects of TLR4 knockout on TRIF-signaling in astrocytes. Therefore, TLR3 induced 
TRIF signaling could be occurring in astrocytes in response to ethanol. Future studies 
using primary cultures could better elucidate the direct effects of ethanol on TLR4-TRIF 
signaling and TLR3-TRIF signaling in astrocytes and microglia. Because of the overlap 
between the two pathways, knockout of TLR3 or TLR4 could be used to determine which 
pathway is responsible.  
 Additional work has suggested that ethanol causes the release of endogenous TLR 
ligands, including HMGB1 and miRNAs (Coleman et al. 2017; Whitman et al. 2013; 
Crews et al. 2013). qPCR analysis could be used to determine whether our voluntary 
ethanol paradigm produced changes in expression of these molecules or other 
endogenous TLR ligands. If these molecules are increased in response to voluntary 
ethanol, glial cultures or slice cultures could be used to further investigate whether these 
molecules activate TRIF-dependent signaling in the brain. Additionally, direct infusion of 
these ligands into the brain could determine whether they alone can induce the changes 
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seen in response to chronic ethanol. Conversely, antagonists or siRNAs could be used to 
see if preventing activity of these ligands prevents gene expression changes.  
  
6.II.a.ii. How TRIF-dependent signaling regulates consumption 
My results from chapter 2 suggest that TRIF-dependent signaling increases in 
response to chronic ethanol, and that changes in TRIF-signaling regulate drinking 
behavior. However, due to the myriad of changes we observed, it remains unclear which 
TLRs, brain regions, and cell types are mediating this response.  
 To determine which TLR is responsible for the changes, knockout animals can be 
used, and in part this has already been done. Yuri Blednov has showed that TLR4 
knockout mice do not decrease consumption (Harris et al. 2017), while MyD88 knockout 
mice increase consumption (Blednov et al. 2017), and CD14 (Blednov et al. 2017) and 
TLR3 knockout mice decrease consumption (unpublished data). These results suggest 
that TLR3 signaling increases consumption, while MyD88 signaling decreases 
consumption. However, these studies have not measured brain gene expression changes 
following consumption to see how they are changed, therefore it is not clear whether 
these knockouts are modulating drinking by changing TRIF-dependent gene expression. 
Furthermore, although TLR3 primarily signals through the TRIF-dependent pathway, it 
can also activate NF-kB through TRAF6 (Kawai & Akira 2010). Therefore, to determine 
whether TRIF-dependent signaling specifically is responsible, knockout mice for 
components of the TRIF-dependent pathway need to be studied.  
 209 
The Blednov/Messing group plans to obtain and test mice that are null mutants for 
components of the TRIF pathway and the interferon response (TRIF, IKKe, and 
IFNAR1) as part of the INIA consortium grant (2U01AA013520-16). Additionally, it 
would be interesting to investigate whether knockout of Lgmn impacts drinking. In 
chapter 4, Lgmn expression was changed in microglia in response to ethanol and was 
correlated with ethanol consumption. Lgmn encodes the protein endopeptidase, which is 
involved in the cleavage of endosomal TLRs, and could therefore regulate activation of 
multiple TLRs (Sepulveda et al. 2009). Furthermore, cathepsins are also involved in the 
cleavage of endosomal TLRs, and mutant mice null for cathepsin f and s decrease ethanol 
consumption (Blednov, Ponomarev, et al. 2011). Therefore, cleavage of TLRs might 
represent an important point of regulation. Lgmn/AEP inhibitors also exist and could be 
tested in ethanol consumption paradigms.  
In addition to measuring alcohol consumption, gene expression analysis could be 
performed on mutants after ethanol consumption and compared to wild type littermates to 
see if the gene knockout impacts ethanol-induced changes. Furthermore, functional 
consequences of neuroimmune signaling could be studied (e.g. neuronal death, decreased 
neurogenesis, hyperexcitability, changes in neurotransmitter and neuropeptide levels). 
Behavioral changes related to cortical function (anxiety, impulsivity, learning and 
memory) could also be evaluated in mutant mice in response to ethanol and compared to 
wildtype littermates.  
 Although global knockout mice have been effective in determining genes that 
influence consumption, they provide little insight into the mechanism by which they alter 
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drinking behavior. Because of the widespread effects of alcohol on immune-signaling, 
global mutants make it difficult to determine whether the behavioral response is due to 
the periphery or the CNS. These distinctions become important not only for 
understanding the changes, but also for developing treatments that need to cross the 
blood-brain barrier. In addition, gene knockouts during development can result in 
compensatory signaling of other pathways, possibly distorting results. There is also 
evidence of global knockouts not changing drinking, but brain-region specific 
knockdown producing effects (Harris et al. 2017; Juan Liu et al. 2011). Therefore, CNS 
specific manipulations would be useful to understand whether the PFC is responsible for 
changes in behavior. One way to go about doing this is using viral vectors to deliver 
shRNAs or cre-recombinase into the brain region of interest (Truitt et al. 2016). This 
method additionally has the advantage and drawback of cell-type specificity. Viral 
vectors targeting a specific cell type can be helpful when trying to determine the cell-type 
specific contributions. However, this can also present a challenge because microglia are 
notoriously difficult to target with viral vectors.  
 In addition to using viral vectors, conditional knockout mice could be used to 
investigate cell-type specific effects. For example, recent studies profiling brain cell types 
have identified microglial and astrocyte specific genes. Mouse lines could be developed 
with cre under control of these cell type-specific promoters and could be crossed with 
floxed mice to create cell-type specific mutants. These experiments would further our 
understanding of how different brain cell-types contribute to the immune ethanol 
response in vivo.   
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 If reduction of TLR3/TRIF signaling should reduce ethanol consumption, then 
activation should increase consumption. Consistent with this idea, recent work in the lab 
has revealed that injection of the TLR3 ligand Poly I:C alters brain gene expression and 
increases ethanol consumption. Additionally, work profiling the response in TLR3 and 
MyD88 knockout aims to determine the mechanism of change. Although TLR3 and 
TRIF-signaling are the primary target, results in chapters 2 and 4 suggest a potential role 
for other endosomal TLRs. In keeping with this, the effect of a TLR7/8 agonist is also 
currently being investigated.  
6.II.b. Glia and ethanol consumption 
6.II.b.i. Localization of TLR proteins 
One of the goals of chapter 3 was to determine the CNS cell-type localization of 
TLR pathway genes and proteins. However, due to non-specific antibodies, I was unable 
to make any conclusions. I hope that someone considers my findings about antibodies 
and uses a different approach to determine cell-type localization in the CNS. As I 
mentioned in chapter 3, a proteomic approach using isolated cells may be better suited to 
answer this question. Additionally, development of transgenic mice with a GFP tagged 
gene would be useful for this purpose. Although I suspect that protein data collected 
using non-antibody techniques would mirror my qPCR results, it is important that this be 
determined conclusively.  
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6.II.b.ii. Effects of microglial depletion on microglial immune response 
Recent studies have developed the ability to deplete microglia from the adult 
mouse brain (Asai et al. 2015). This technique has been used to reveal the role of 
microglia in CNS pathology and could be useful in understanding how microglia 
influence the ethanol response. Currently, the lab is planning to use microglial depletion 
(Asai et al. 2015) to see how it changes ethanol consumption. In addition, it would be 
insightful to evaluate gene expression changes following ethanol exposure in the 
microglial-depleted brain. If microglia are responsible for the neuroimmune changes we 
are observing, we would expect those changes to go away. In contrast, if other cells are 
contributing to the neuroimmune response, changes would be detectable in the microglia-
depleted brain.   
Furthermore, if microglial depletion does change ethanol consumption, it would 
be important to determine the effects of microglial depletion on ethanol changes in brain 
activity (e.g. neurotransmitter activity, synaptic plasticity, neurogenesis, neuronal 
damage) and ethanol induced changes in cortical function.  
6.II.b.iii. Effects of alcohol on microglial immune response and function 
Although my gene expression data in chapter 4 provided some insight into the 
ethanol-induced microglial changes, any functional consequences are speculation. Recent 
studies suggest that certain disease states, such as Alzheimer’s, reflect a change in the 
microglial response to stimuli (Bernhardi et al. 2015). Furthermore, studies using isolated 
immune cells from alcoholics have found changes in immune cell response to TLR 
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ligands (Leclercq, De Saeger, et al. 2014) (Szabo & Saha 2015). Therefore, I think it 
would be informative to culture microglia from mice that had undergone ethanol 
consumption. Then, the cells can be exposed to stimuli in vitro and any functional 
changes can be determined. Many processes could be evaluated, including cytokine and 
ROS production, phagocytosis, and migration and invasion. In addition, other cell types 
(neurons, astrocytes, oligodendrocytes, etc.) could be co-cultured or cultured in 
conditioned microglial media, to determine the effect of microglial changes on other CNS 
cells. These experiments would help to elucidate how microglial function changes in 
response to chronic ethanol consumption, and how microglia could be mediating some of 
the detrimental effects of alcohol consumption.  
6.II.b.iv. Microglial changes and CNS cross-talk 
The results I presented in chapter 4 highlight the microglia specific changes that 
occur in response to ethanol in vivo. However, one of the reasons for evaluating these 
changes in vivo is that the neuroimmune response in the brain is the product of cross-talk 
between microglia and other cell-types. Thus, it would be useful to isolate multiple cell 
types from the same ethanol-exposed mouse and profile the gene expression changes. 
Currently, the lab has collected both microglial and astrocyte gene expression data from 
ethanol-exposed mice. Analysis of these data should provide interesting insight about 
how the glial responses differ and potentially highlight some cross-talk signals that are 
perturbed.  
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6.II.c TGF-b signaling and the neuroimmune response to ethanol 
My results in chapter 4 suggest that microglial TGF-b signaling is perturbed in 
response to chronic ethanol. Given the role of TGF-b in microglial function, alcoholic 
liver diseases, and CNS cross-talk, I believe this pathway warrants further investigation.   
6.II.c.i. Further evaluate changes in TGF-b pathway expression 
Although my microglial data suggest that TGF-b signaling is perturbed in 
microglia in response to ethanol, the next logical step would be to investigate this further. 
There are multiple TGF-b ligands and receptors and they vary in their cell type 
expression. qPCR analysis could be used to determine if changes in the TGF-b pathway 
are detected in the total homogenate from the PFC and other brain regions. In addition, 
immunohistochemistry could be used to look at protein level changes within the CNS cell 
types. Rodent models are a good resource for evaluating ethanol-induced changes, 
particularly using isolated cell preparations that require live cells. However, it is 
important to know that the changes observed in rodent models are also observed in 
humans. Therefore, it would be worthwhile to also look at human-postmortem tissue to 
see if there are any changes in TGF-b. 
 
6.II.c.ii. LINCS analysis and drugs that target the microglial response 
The Library of Network Based Cellular Signatures (LINCS) program uses 
genomic signatures to identify drugs and compounds that could normalize the gene 
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expression changes seen with a particular disease or disorder (Hurle et al. 2013; Lamb et 
al. 2006). The LINCS project has tested approximately 20,000 drugs and compounds on 
several different cell lines and has collected gene expression data. In order to make this 
process high throughput, LINCS only profiles gene expression for 978 landkmark genes 
which they call they call the landmark 1000, but use this gene expression information to 
infer expression of other genes.  
With the help of Laura Ferguson, we input the ethanol microglial gene expression 
data to identify drugs that would either mimic or oppose the ethanol-induced genomic 
signature. We tried two different methods for inputting the microglial data, one using the 
top 100 differentially expressed genes in microglial module 3, and the second using the 
differentially expressed genes in microglial module 3 that were also landmark 1000 
genes. Using the overlap between these two searches, we identified several drugs that 
should act as a strong negative or a strong positive. In theory, a strong negative drug 
would produce the opposite gene expression changes that what we observed and would 
restore homeostasis, while a strong positive drug would mimic our ethanol-induced gene 
expression changes, thus exacerbating the phenotype. The top 10 strong negative and 
strong positive results are shown in Figure 6.2. 
Based on the microglial gene expression changes we observed in response to 
chronic ethanol, we identified several drugs that would theoretically normalize gene 
expression. These drugs included a TGF-b/p38 MAPK inhibitor (LY-364947), a JNK 
inhibitor (CG-930), and FGFR and VEGFR inhibitor (brivanib), and a MEK/MAPK 
inhibitor (PD-0325901), all of which are currently involved in clinical trials. Future 
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studies could use these drugs in rodent consumption models and determine whether the 
drug normalizes gene expression changes and decreases ethanol consumption.  
6.II.c.iii. TGF-b mutant mice 
Recently, Koeglsperger et al. developed a mutant mouse line lacking TGF-b1 
specifically in the CNS. They found that this mouse displayed hippocampal neuronal 
loss, decreased astrocyte glutamate transporter expression and uptake, and GluN2B-
dependent aberrant synaptic plasticity (Koeglsperger, Li, Brenneis, Saulnier, Mayo, 
Carrier, Selkoe & Weiner 2013b). Given the role of glutamate signaling in neuroimmune-
induced damage and synaptic activity, it would be interesting to further study this mouse. 
Future studies could look more closely at the PFC in these mice to see if there are similar 
dysfunctions. In addition, using these mice for ethanol consumption experiments could 
elucidate the role of TGF-b signaling in regulating drinking behavior. If CNS-TGF-b1 
mutant mice show changes in ethanol consumption, the effects of ethanol on pro-
inflammatory environment, brain activity, and cortical function could also be evaluated.  
 
6.II.d. Effects of Neuroimmune signaling on Neuotransmission 
Within our lab, the primary focus is on identifying gene expression changes and 
then using these changes to identify drug targets for regulating ethanol consumption. Thus, 
many of the future studies I have proposed mostly involve determining whether genetic or 
pharmacological manipulation change ethanol consumption (Fig. 6.3). However, it is also 
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important to determine how altering neuroimmune signaling changes ethanol consumption. 
As I described in Chapter I.V.b., there are several proposed mechanisms by which altered 
neuroimmune signaling changes neuronal activity and therefore changes behavior. 
Although these changes are not necessarily a focus of our lab, it is important for future 
studies to elucidate these mechanisms. Therefore, any genetic or pharmacological 
manipulations that are found to alter drinking behavior, could be further studied to 
determine how neuronal activity is impacted. I have pointed out some of these potential 
studies in Figure 6.3.  
 
6.II.e. Treatment in humans 
Although cell culture and rodent models are important for discovering and 
understanding the role of neuroimmune signaling in ethanol consumption, the end goal is 
developing treatments for humans. Thus, the long-term future goal with regards to this 
project, is understanding the neuroimmune response well enough that we can identify a 
therapeutic treatment for use in humans.  
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6.III. FIGURES 
 
Figure 6.1: Summary of results within hypothesized cycle 
The hypothesized cycle from chapter 1 of how alcohol changes neuroimmune signaling 
and thus regulates consumption behavior. Results from each chapter are shown with arrows 
indicating which part of the cycle these findings expand on. Most of the findings in this 
dissertation reveal how alcohol changes neuroimmune gene expression. Future studies 
should address how these gene expression changes influence the pro-inflammatory 
environment, brain activity, cortical function, and alcohol consumption.  
  
Alcohol	Consumption
-LPS	increases	EtOH	intake	21
-Immune	gene	knockouts	
decrease	EtOH	intake	22,23,	25
-Immuno-modulatory	 drugs	
decrease	EtOH	intake	24,25
Neuroimmune	Gene	Induction
- Increased	expression	of	TLRs	and	
endogenous	 ligands	1,3
-Increased	cytokine	 expression	1,2
-Increased	expression	of	glial	markers	3
Pro-inflammatory	Environment
-Glial	activation	6,7,16
-NF-kB	activation	4,8,16,6
-Secretion	of	cytokines	 and	ROS	5,16,6
-Increased	extracellular	glutamate	19,29
Altered	brain	activity
-altered	neurotransmitter	and	
neuroendocrine	 activity	8,19,21,27,28
-impaired	synaptic	plasticity	28,29
-decreased	neurogenesis	 4,8,10,28,29
-Neuronal	damage	and	death	5,6,9,16,20
Cortical	Dysfunction
-Decreased	cell	density,	 reduced	white	
matter	volume	12
-Reduced	cortical	activity12
-impaired	impulse	 inhibition,	 decision	
making,	memory,	 anxiety9,11,20
Chapter	2
Chronic	 voluntary	ethanol	
increases	expression	of	Tlr2,	
Tlr3,	Tlr4,	Tlr7	,	TRIF-
dependent	 pathway,	and	
interferon	inducible	 gene
Chapter	2
Amlexanox	reduces	Poly	I:C	
induced	 gene	expression	
and	decreases	ethanol	
consumption	 and		
Chapter	4
Chronic	 voluntary	ethanol	changes	
expression	of	microglial	genes	
associated	with	endosomal	 TLR	
signaling	and	TGF-β	signaling
Chapter	3
Gene	expression	of	TLR	
signaling	molecules	 are	
primarily	microglial,	although	
some	are	astrocytic
Chapter	5
The	microglial	gene	
expression	 response	 to	LPS	
and	ethanol	differs	in	the	PFC
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Figure 6.2: LINCS Analysis 
 
Differentially expressed genes (DEGs) within MGM3 were used to query the LINCS-
L1000 database, which contains the transcriptional responses of a diverse set of human 
cell lines in culture to thousands of chemical compounds. We constructed 2 different 
inputs – One comprised of the top 100 differentially expressed genes (based on fold 
change), and the other comprised of only the differentially expressed landmark genes. 
Landmark genes are those that are directly measured to construct the LINCS-L1000 
database. We submitted these inputs using the clue.io website. A connectivity score is 
computed that assesses the similarity of the input and drug transcriptional signatures. A 
negative score indicates the drug has an opposing effect on gene expression, while a 
positive score indicated the drug has a similar effect on gene expression. The top 10 
positive and negative scoring compounds are shown in the tables.   
  
194 42136
97 8527
Landmark DEGs Top 100 DEGs
Landmark DEGs
Top 100 DEGs
Strong Negative Drugs 
Strong Positive Drugs
Drug	Name Description Top	100	Score
Landmark	
Score
LY-364947 TGF	beta	receptor	inhibitor,	p38	MAPK	inhibitor -99.26 -99.93
iloperidone dopamine	receptor	antagonist,	serotonin	receptor	
antagonist -99.72 -99.05
cobalt(II)-chloride HSP	agonist -99.15 -97.22
VX-222 HCV	inhibitor,	RNA-directed	RNA	polymerase	inhibitor -98.2 -98.45
NECA adenosine	receptor	agonist -98.87 -97.29
CG-930 JNK	inhibitor -94.57 -99.4
demeclocycline 30S	ribosomal	subunit	inhibitor -95.1 -99.12
brivanib
alcohol	dehydrogenase	inhibitor,	FGFR	inhibitor,	
fibroblast	growth	factor	receptor	(FGFR)	inhibitor,	
vascular	endothelial	growth	factor	receptor	(VEGFR)	
inhibitor,	VEGFR	inhibitor -99.12 -95.36
PD-0325901
MEK	inhibitor,	MAP	kinase	inhibitor,	protein	kinase	
inhibitor -97.74 -97.56
hydroxycholesterol
LXR	agonist,	ABC	transporter	expression	enhancer,	
alpha	secretase	activator,	beta	secretase	inhibitor,	
glutamate	receptor	modulator -98.54 -94.44
Drug	Name Description Top	100	Score
Landmark	
Score
calyculin protein	phosphatase	inhibitor 99.93 99.93
withaferin-a
acetylcholinesterase	inhibitor,	butyrylcholinesterase	
inhibitors,	IKK	inhibitor,	NFkB	pathway	inhibitor,	PKC	
inhibitor 99.44 99.47
KI-8751
PDGFR	alpha	and	c-Kit	inhibitor,	vascular	endothelial	
growth	factor	receptor	2	(VEGFR2)	inhibitor,	VEGFR	
inhibitor 98.51 99.61
QL-XII-47
BMX	inhibitor,	Bruton's	tyrosine	kinase	(BTK)	
inhibitor,	bruton's	tyrosine	kinase	inhibitor,	
cytoplasmic	tyrosine	protein	kinase	BMX	inhibitor 98.7 99.19
tacedinaline HDAC	inhibitor,	cell	cycle	inhibitor 98.17 99.47
menadione
CDC	inhibitor,	mitochondrial	DNA	polymerase	
inhibitor,	phosphatase	inhibitor,	pyruvate	kinase	
isozyme	inhibitor 98.56 99.15
HU-211
glutamate	receptor	antagonist,	apoptosis	stimulant,	
NFkB	pathway	inhibitor,	reducing	agent 98.17 99.15
homoharringtonine apoptosis	stimulant,	protein	synthesis	inhibitor 98.52 98.94
calmidazolium calcium	channel	blocker,	calmodulin	antagonist 99.26 98.66
alitretinoin
RXR	agonist,	ABC	transporter	expression	enhancer,	
apoptosis	stimulant,	RAR	agonist,	retinoid	receptor	
agonist 98.31 99.01
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Figure 6.3: Summary of future directions within hypothesized cycle 
The hypothesized cycle from chapter 1 of how alcohol changes neuroimmune signaling 
and thus regulates consumption behavior. Future directions are shown with arrows 
indicating which part of the cycle these findings expand on. Future studies aim to not only 
determine whether manipulation of gene expression changes alters consumption, but also 
how. To elucidate how, studies can investigate ethanol-induced changes in gene 
expression, pro-inflammatory environment, brain activity, and cortical dysfunction in 
mutant mice that show altered ethanol consumption.  
  
Alcohol	Consumption
-LPS	increases	EtOH	intake	21
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decrease	EtOH	intake	22,23,	25
-Immuno-modulatory	 drugs	
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Neuroimmune	Gene	Induction
- Increased	expression	of	TLRs	and	
endogenous	 ligands	1,3
-Increased	cytokine	 expression	1,2
-Increased	expression	of	glial	markers	3
Pro-inflammatory	Environment
-Glial	activation	6,7,16
-NF-kB	activation	4,8,16,6
-Secretion	of	cytokines	 and	ROS	5,16,6
-Increased	extracellular	glutamate	19,29
Altered	brain	activity
-altered	neurotransmitter	and	
neuroendocrine	 activity	8,19,21,27,28
-impaired	synaptic	plasticity	28,29
-decreased	neurogenesis	 4,8,10,28,29
-Neuronal	damage	and	death	5,6,9,16,20
Cortical	Dysfunction
-Decreased	cell	density,	 reduced	white	
matter	volume	12
-Reduced	cortical	activity12
-impaired	impulse	 inhibition,	 decision	
making,	memory,	 anxiety9,11,20
6.II.a.i
How	alcohol	alters	
TLR3/TRIF	signaling	 through	
peripheral	or	CNS	
mechanisms
6.II.a.ii
How	TRIF-signaling	
regulates	consumption:	
specific	 pathways,	brain	
regions,	cell	types
6.II.b.ii
Does	microglial	depletion	
change	ethanol	
consumption
6.II.b.iii
Effects	of	alcohol	 on	microglial	
function:	 immune	response	
and	interaction	with	other	cell	
types
6.II.b.iv
Investigation	of	glial	cross-talk	
in	response	 to	ethanol
6.II.c.i.
Further	evaluate	changes	in	
TGF-β	pathway	expression	
in	response	 to	ethanol
6.II.c.ii
Use	LINCS	drugs	to	
modulate	ethanol	
consumption
6.II.b.ii/6.II.c.iii
Does	microglial	depletion	of	CNS-
TGF-β1	mutation	impact	ethanol-
induced	 changes	in	brain	activity	
or	cortical	function
6.II.b.ii/6.II.c.iii
Does	microglial	depletion	of	CNS-
TGF-β1	mutation	impact	ethanol-
induced	pro-inflammatory	
environment?
6.II.a.ii.
Do	TRIF	mutant	mice	show	different	
changes	in	brain	activity	in	response	
to	ethanol	than	WT	mice?
6.II.a.ii.
Do	TRIF	mutant	mice	show	different	
behavioral	deficits	in	response	 to	
ethanol	compare	to	WT?
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Abbreviations/Glossary 
Amlexanox:  Inhibitor of IKKe and TBK1. Approved in the US as a topical paste 
used for the treatment of aphthous ulcer (canker sores).  
AMY:  Amygdala. Brain region that is part of limbic system and is involved 
in decision making and emotional reactions. Further divided into the 
central nucleus of the amygdala and the basolateral amygdala. The 
amygdala has reciprocal connections with the prefrontal cortex.   
AP-1:  Activator protein 1. Transcription factor that is a heterodimer of 
proteins Fos and Jun proteins. Activated in response to TLR 
signaling through the MAPK pathway. Leads to the transcription of 
pro-inflammatory cytokines as well as genes regulating 
differentiation, cell-cycle, and apoptosis. 
AUD: Alcohol use disorder. DSM-5 term for alcohol dependence or abuse. 
Individuals meeting 2 out of 11 criteria during a 12-month period 
receive a diagnosis of AUD. AUD severity is based on the number 
of criteria met.  
CCL2:  C-C motif chemokine ligand 2; also known as monocyte chemotactic 
and activating factor (MCP-1). Pro-inflammatory chemokine that is 
transcribed in response to activation of NF-kB. Considered a marker 
of M1 microglia. Signals through the receptor CCR2.  
CCL5:  C-C motif chemokine ligand 5; also known as RANTES. Chemokine 
that is transcribed in response to activation of the TRIF-dependent 
pathway and the IRF3 transcription factor.  
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CD11b: Cluster of differentiation molecule 11b; Also known as integrin 
alpha M (ITGAM). Cd11b is expressed on immune cells and 
mediates adhesion, migration, and chemotaxis. Within the CNS, it 
is used as a microglial marker.  
CD14: Cluster of differentiation 14. Pattern recognition receptor that acts 
as a co-receptor with TLR4 and MD-2 to detect LPS. There is also 
evidence that it acts as a co-receptor for TLR2, TLR3, TLR7, and 
TLR9.  
COX-2: Cyclooxygenase 2; also known as prostaglandin-endoperoxide 
synthase 2 (PTGS2). Enzyme that is involved in the conversion of 
arachidonic acid to prostaglandin. Released in response to TLR 
signaling and NF-kB activation.  
CREB:  Cyclic AMP (cAMP) response element-binding protein. 
Transcription factor that binds to cAMP response elements. CREB 
increases expression of genes like BDNF that promote neuronal 
survival.  
CXCL10: C-X-C motif chemokine 10, also known as Interferon gamma-
induced protein 10 (IP-10). Chemokine secreted in response to 
interferon gamma, and in response to TRIF-pathway and IRF3 
activation. Binds to chemokine receptor CXCR3.  
CXCL12: C-X-C motif chemokine 12; also known as stromal cell-derived 
factor 1 (SDF1). Chemokine that plays a role in neurogenesis and 
GABA release.  
DAMP: Damage-associated molecular pattern; also known as danger-
associated molecular pattern. Host molecules that are released 
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during cell damage or death and can be recognized by pattern 
recognition receptors and initiate an inflammatory response. 
Examples of DAMPs include HMGB1, heat shock proteins, 
extracellular matrix proteins, and S100 proteins. In addition, DNA 
and RNA outside of the cell can act as a DAMP. 
ECM:  Extracellular matrix. Extracellular molecules secreted by cells that 
provide structural support for the surrounding cells. The ECM is 
involved in cell adhesion, synapse formation, regulation of 
diffusion, and maintenance of blood brain barrier. ECM components 
are altered in response to neuroimmune signaling and can propagate 
the immune response by activating microglia.  
EOD-2BC: Every other day 2 bottle choice paradigm. Rodent voluntary ethanol 
consumption paradigm that provides 24-hour access to both water 
and an ethanol solution every other day. Only water is provided on 
the off days. Every other day exposure leads to escalation in ethanol 
consumption over time.  
GABA: Gamma-aminobutyric acid. GABA is the primary inhibitory 
neurotransmitter. Acute ethanol increases GABA activity, but long-
term ethanol exposure leads to decreased GABA activity. GABA 
expression and activity can be regulated by cytokines.  
HMGB1: High mobility group box 1. Chromatin protein that is secreted by 
immune cells. Can act as a ligand for TLR2, TLR3, TLR4 and 
RAGE. 
HPA: Hypothalamic-pituitary-adrenal axis. Neuroendocrine system that 
involves interactions between three endocrine glands, the 
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hypothalamus, the pituitary gland, and adrenal glands. The HPA 
axis controls response to stress and immune signaling.  
IBA1: Ionized calcium binding adapter molecule 1; also known as 
Allograft inflammatory factor 1 (AIF1). Iba1 is specifically 
expressed in microglia within the brain and is upregulated with 
microglial activation.  
IFNb: Interferon beta. Type I interferon that binds to IFN-a/b receptor 
(IFNAR). Activated in response to TRIF pathway/IRF3 activation. 
Has antiviral activity. 
IFNg: Interferon gamma. Cytokine that is a member of the type II 
interferon family. IFN-g causes macrophage/microglial activation 
into an M1 state and induces Class II MHC molecules. 
IKKa: Inhibitor of nuclear factor kappa-B (IkB) kinase subunit alpha. Part 
of the IKK enzyme complex (IKKa, IKKb, IKKg) that is activated 
in response to the MyD88-dependent pathway. The IKK complex 
phosphorylates IkB (inhibitor of NF-kB) leading to NF-kB 
activation. It is also involved in the MyD88-dependent interferon 
response.  
IKKb: Inhibitor of nuclear factor kappa-B (IkB) kinase subunit beta. Part 
of the IKK enzyme complex (IKKa, IKKb, IKKg) that is activated 
in response to the MyD88-dependent pathway. The IKK complex 
phosphorylates IkB (inhibitor of NF-kB) leading to NF-kB 
activation. 
IKKe: Inhibitor of nuclear factor kappa-B (IkB) kinase subunit epsilon; 
also known as IKKI. Interacts with TBK1 to phosphorylate IRF3.   
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IL-1b: Interleukin 1 beta. Pro-inflammatory cytokine that is transcribed in 
response to NF-kB activation. Exists as a precursor that is cleaved 
to form mature and active form. Binds to the IL1 receptor.  
IL-4: Interleukin 4. Anti-inflammatory cytokine that induces 
macrophages and microglia into an M2 state.  
IL-6: Interleukin 6. Pro-inflammatory cytokine that is transcribed in 
response to NF-kB activation.  
IL-10: Interleukin 10. Anti-inflammatory cytokine that can block NF-kB 
activation. IL-10 expression can induce microglia and macrophages 
to a M0 state and serves as a marker of M0/M2 activation states.  
IL-13: Interleukin 13. Anti-inflammatory cytokine that induces a M2 state.  
iNOS: Inducible nitric oxide synthases. Enzyme involved in the production 
of free radical nitric oxide.  
IRAK1: Interleukin-1 receptor-associated kinase 1. Enzyme involved in the 
MyD88-dependent pathway. Activated in response to 
phosphorylation by IRAK4. Interacts with TRAF6 resulting in 
activation of NF-kB.  
IRAK4: Interleukin-1 receptor-associated kinase 4. Recruited in the 
MyD88-dependent pathway and phosphorylates IRAK1 leading to 
downstream activation of NF-kB. 
IRF3: Interferon regulatory factor 3. Transcription factor activated by the 
TRIF-dependent pathway. Activation results in transcription of type 
I interferons and interferon inducible genes.  
IRF7: Interferon regulatory factor 7. Transcription factor activated by the 
MyD88-dependent pathway in response to endosomal TLR 
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signaling. Transcribes type I interferons, particularly interferon 
alpha.  
Lgmn: Gene encoding legumain, also known as asparaginyl endopeptidase 
(AEP). Lysosomal protease that cleaves asparaginyl bonds. It is 
responsible for the cleavage of TLR9, leading to its activation in 
dendritic cells. It also appears to be involved in cleavage of TLR3 
and TLR7. It may also be involved in the processing of peptides for 
MHC class II antigen presentation.   
LPS: Lipopolysaccharide; also known as lipoglycan or endotoxin. Large 
molecules composed of lipid and polyscaccharides that are the 
major component of the outer membrane of gram-negative bacteria. 
LPS acts as a ligand for TLR4.  
LTD/LTP: Long-term depression/potentiation. Activity-dependent reduction or 
increase in synaptic strength. Together LTD and LTP impact 
synaptic plasticity and therefore learning and memory.  
M0: Macrophage/microglial acquired de-activation state; also known as 
homeostatic state, M2c. Macrophage and microglial state thought to 
represent in vivo homeostatic state or acquired deactivation of 
inflammatory response. Induced in response to TGF-b, IL-10, or 
apoptosis. Still not clearly defined, but markers are thought to be 
similar to M2 markers. 
M1: Macrophage/microglia classical activation state. The classical 
macrophage or microglial activation state, induced by IFN-g or LPS. 
Characterized by secretion of pro-inflammatory cytokines and 
reactive oxygen species and antigen presentation.  
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M2: Macrophage/microglial alternative activation state; also known as 
M2a. Macrophage/Microglial alternative activation state induced by 
IL-4 and IL-13. Characterized by secretion of anti-inflammatory 
cytokines and growth factors. Involved in the repair process after a 
pro-inflammatory response, including extracellular matrix repair 
and phagocytosis of debris.  
MAL: MyD88-adapter-like protein; also known as Toll-Interleukin 1 
Receptor (TIR) domain-containing adapter protein. Adapter protein 
required in addition to MyD88 for TLR2 and TLR4 signaling.  
MAPK: Mitogen-activated protein kinase. Family of kinases involved in 
response to pro-inflammatory cytokines. MAPK signaling is 
activated in response to the MyD88-dependent pathway, TGF-b 
signaling, and TNF-a signaling. MAPK signaling leads to activation 
of the AP-1 transcription factors. Activation of MAPK can impact 
many cellular processes like apoptosis, cell cycle, inflammation, and 
neurotransmitter regulation.  
MCP-1: See CCL2.  
MHCI: Major histocompatibility complex class I. Class of molecules found 
on cell surface of all nucleated cells. MHC Class I molecules present 
non-self peptides from within the cell to T-cells. Activated microglia 
can display MHC class I proteins.  
MHCII:  Major histocompatibility complex class II. Class of molecules found 
on antigen-presenting cells. Antigen presentation involves 
phagocytosis and digestion of extracellular proteins which results in 
peptide fragments attached to the MHC II molecules. During 
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homeostasis, microglia do not express MHC proteins. Activated 
microglia can express MHCII proteins and participate in antigen 
presentation. 
MyD88: Myeloid differentiation primary response protein 88. Adapter 
protein that mediates signaling of the MyD88-dependent pathway in 
response to TLRs (All except TLR3) and IL-1b activation. Signaling 
of the MyD88-dependent pathway leads to activation of NF-kB and 
AP-1 transcription factors. 
NAc:  Nucleus accumbens. Brain region involved reward, motivation, and 
reinforcement. Further subdivided into the NAc core and shell. The 
NAc receives inputs from the PFC and amygdala and sends outputs 
ventral pallidum which projects to the PFC. The NAc is primarily 
composed of dopaminergic neurons.  
NADPH:  Nicotinamide adenine dinucleotide phosphate. NADPH oxidase 
generates superoxide anion by transferring electrons from NADPH 
and coupling them to oxygen. Superoxide anion is a reactive free-
radical that can undergo further reactions to produce reactive 
oxygen species.  
NF-kB: Nuclear factor kappa-light-chain-enhancer of activated B cells. 
Transcription factor containing 5 proteinsthat is activated in 
response to immune signaling including TLR signaling. 
Phosphorylation leads to activation and translocation to the nucleus 
where NF-kB transcribes cytokines and reactive oxygen species.  
NO: Nitric oxide. NO is a free radical synthesized from oxygen and 
NAPDH by NOS enzymes. NO diffuses easily and acts as a 
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paracrine and autocrine signaling molecule. NO is generated by 
immune cells as part of the immune response and can also activate 
immune signaling. NO can modulate neurotransmission and 
promote apopotosis.  
PBMC:  Peripheral blood mononuclear cell. Peripheral blood cells that have 
a round nucleus, including T-cells, B-cells, NK cells, and 
monocytes. PBMCs respond to immune stimuli in the blood and 
respond by producing cytokines.   
PFC: Prefrontal Cortex. Region of the frontal cortex that is responsible 
for executive functions like decision making, impulse inhibition, 
and planning. The PFC also integrates information from other brain 
regions, including those that regulate reward, anxiety, and memory.  
PAMP: Pathogen-associated molecular patterns. Molecules that are 
associated with pathogens and can be recognized by pattern 
recognition receptors to mount an immune response. PAMPs 
include components of bacteria and viruses. 
PRR: Pattern recognition receptor. Protein components of the innate 
immune system that recognize PAMPs and DAMPs. PRRs include 
Toll-like receptors (TLR), C-type lectin receptors (CLR), 
Nucleotide oliogmerisation receptors (NLR), and RIG-1 like 
receptors (RLR).  
ROS:  Reactive oxygen species. Chemically reactive species that contain 
oxygen, including peroxides, superoxide, hydroxyl radical, and 
singlet oxygen. Increased ROS levels can cause cellular damage and 
apoptosis.  
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Siglech: Sialic acid binding Ig-like lectin H. Member of the Siglec family: 
cell surface proteins that bind sialic acid and are primarily found on 
immune cells. Siglech is expressed on dendritic cells and microglia 
and is proposed to regulate microglial function under immune 
conditions. It also modulates the secretion of Type I interferons.  
SMAD:  Mothers against decapentaplegic homolog. Family of proteins that 
signal from TGF-b to the nucleus where they act as transcription 
factors. SMADs are broken into 3 classes, R-SMAD (SMAD1, 
SMAD2, SMAD3, SMAD5, and SMAD 8/9), co-SMADs 
(SMAD4), and I-SMADs (SMAD6, SMAD7).  
TGF-b:  Transforming growth factor beta. Cytokine that includes several 
isoforms (TGF-b 1-4). TGF-b proteins are synthesized as precursor 
molecules that can be activated by matrix metalloproteinases, pH, 
ROS, TGF-b, thrombospondin, and integrins. TGF-b complexes 
bind the TGF-b receptors leading to signaling through the SMAD 
pathway. TGF-b can also signal through a SMAD-independent 
apoptotic pathway.  
TLR2: Toll-like receptor 2. Cell surface toll-like receptor that responds to 
glycolipids and lipoproteins on bacterial peptidoglycans and signals 
through the MyD88-dependent pathway.  
TLR3: Toll-like receptor 3. Endosomal toll-like receptor that recognizes 
double stranded RNA and signals through the TRIF-dependent 
pathway. TLR3 is also activated in response to Poly I:C, a synthetic 
analog of double-stranded RNA.  
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TLR4: Toll-like receptor 4. Toll-like receptor that responds to 
lipopolysaccharide on gram negative bacteria. TLR4 can signal 
through both the MyD88-dependent and TRIF-dependent pathways. 
TLR4 can signal both from the cell membrane and from endosomes.  
TLR7: Toll-like receptor 7. Endosomal toll-like receptor that recognizes 
single-stranded RNA. Although TLR7 signals through the MyD88-
dependent pathway, it can activate both NF-kB and Type I 
interferons. 
TNFa: Tumor necrosis factor alpha. Pro-inflammatory cytokine that is 
released in response to TLR signaling and NF-kB activation. TNF 
can bind to 2 receptors, TNFR1 and TNFR2. TNF binding to 
receptors can lead to NF-kB activation, AP-1 activation, and 
apoptosis.  
TRAF3: TNF receptor-associated factor 3. TRAF3 is involved in signaling 
through the TRIF-dependent pathway.  
TRAF6: TNF receptor-associated factor 6. TRAF6 is involved in signaling 
through the MyD88-dependent pathway.  
TRIF: TIR-domain-containing adapter-inducing interferon-b, also known 
as TICAM1. TRIF is the adapter protein that mediates signaling 
from TLR3 and TLR4 leading to the activation of IRF3 and the 
production of type I interferons.  
TSPO: Translocator protein; also known as peripheral benzodiazepine 
receptor (PBR). Mitochondrial protein that is often using as a 
marker of microglial activation. Radioligands for TSPO are used for 
imaging studies as a way to measure microglial activation in vivo.  
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WGCNA: Weighted gene co-expression network analysis. Systems biology 
method for describing the correlation patterns among genes across 
gene expression data. WGCNA finds modules or clusters of highly 
correlated genes that can be related to external sample traits.  
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